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Background: Many nutrients have powerful immunomodulatory actions with the potential to alter 
susceptibility to COVID-19 infection, progression to symptoms, likelihood of severe disease and 
survival. The pandemic has fostered many nutrition-related theories, sometimes backed by a biased 
interpretation of evidence. 
Objectives: To provide a systematic review of the latest evidence on how malnutrition across all its 
forms (under- and over-nutrition and micronutrient status) may influence both susceptibility to, and 
progression and severity of, COVID-19.  
Methods: We synthesised information on 13 nutrition-related components and their potential 
interactions with COVID-19: overweight, obesity and diabetes; protein-energy malnutrition; 
anaemia; vitamins A, C, D, and E; poly-unsaturated fatty acids; iron; selenium; zinc; anti-oxidants, 
and nutritional support. For each section we provide: a) a landscape review of pertinent material; b) 
a systematic search of the literature in PubMed and EMBASE databases, including a systematic 
search of a wide range of pre-print servers; and c) a screen of six clinical trial registries. Two 
reviewers were assigned per section for data extraction. All original research was considered, 
without restriction to study design, and included if it covered: 1) SARS-CoV-2, MERS-CoV or SARS-
CoV viruses and 2) disease susceptibility or 3) disease progression, and 4) the nutritional component 
of interest. Searches took place between 16th May and 11th August, 2020. PROSPERO registration 
CRD42020186194. 
Results: Across the 13 searches, a total of 2732 articles from PubMed and EMBASE, 4164 articles 
from the pre-print servers, and 433 trials were returned. A total of 288 published articles and 278 
pre-print articles were taken to full text screening. In the final narrative synthesis, we cover 22 
published articles, 39 pre-print articles and 79 trials. The review highlights a range of mechanistic 
and observational evidence to highlight the role nutrition can play in susceptibility and progression 
of COVID-19. However, to date, there is limited evidence that high-dose supplements of 
micronutrients will either prevent severe disease or speed up recovery, although results of clinical 
trials are eagerly awaited. 
Conclusions: To date there is no conclusive evidence supporting adoption of novel nutritional 
therapies. However, given the known impacts of all forms of malnutrition on the immune system, 
public health strategies to reduce micronutrient deficiencies and undernutrition remain of critical 
importance. There is strong evidence that prevention of obesity, and its consequent type-2 diabetes, 
will reduce the risk of serious COVID-19 outcomes. 
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Could nutrition modulate COVID-19 susceptibility and severity of disease? 
A systematic review 
 
 
1. Introduction  
The astonishing spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, Box 1) 
since late 2019 has resulted in a global pandemic of the disease COVID-19. Alongside the worldwide 
effort to deliver a vaccine, there has been a surge of interest in the epidemiological factors that 
underlie susceptibility to COVID-19, and its progression, in an attempt to explore the most effective 
preventative and curative options1–4. Potential interactions between nutritional status and immune 
function have been widely documented5–7. As the pandemic unfolds, it exacerbates the risk factors 
for malnutrition in all its forms8,9. Disruption to agricultural production, market linkages and 
seasonal labour movements contribute to food price increases10,11, making nutritious food even 
more expensive for those most at risk of micronutrient deficiencies and undernutrition. Cancelled 
and delayed nutrition counselling, micronutrient distributions, vaccine rounds and school meal 
programmes accentuate the vulnerability12–14. Lockdown measures in many countries have increased 
physical and psychological barriers to healthy eating and exercising, creating an obesogenic 
environment for many15,16. 
Understanding the relationship between nutritional status and risk of COVID-19 is therefore of 
critical importance to generate evidence-based recommendations. There may be a potential for 
nutritional interventions to reduce an individual’s susceptibility to infection, progression to 
symptoms and likelihood of severe disease (including the use of high- or very-high-dose 
supplements enterally or intravenously as nutraceuticals).  
However, nutrition information has long been miscommunicated to the public17–19, and nutrition-
related myths on COVID-19 protection and treatment are widely prevalent in this pandemic20. To 
this end we have conducted a comprehensive systematic review of journal articles, pre-prints and 
clinical trial registries to provide a robust evidence base of what is currently known and what gaps 
remain.   
Box 1: Coronaviruses and COVID-19  
 
Coronaviruses consist of a small single-stranded RNA, belong to the Coronaviridae family. There are 
four sub-groups (α, β, γ and δ), of which the α- and β-coronaviruses are known to infect humans 
from zoonotic origins21,22. Coronavirus infection rates can vary seasonally due in part to the 
underlying epidemiology of susceptible host availability23. 
 
The pathogenicity of coronavirus infections in humans became apparent with the severe acute 
respiratory syndrome coronavirus (SARS-CoV) causing an outbreak of SARS in 2002-3, originating in 
Guangdong, China24. A decade later, the Middle East respiratory syndrome coronavirus (MERS-CoV) 
was first detected in 2012 in Saudi Arabia25. COVID-19, the disease caused by the severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2), originated in Wuhan, China in late 2019. It was 
declared a global pandemic by the World Health Organisation on 11 March 2020. SARS-CoV-2 is a β-
coronavirus and, as with SARS-CoV and MERS-CoV, can cause dysregulation of the pulmonary 
vasculature, microthromboembolisms, pneumonia and may progress to acute respiratory distress 
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syndrome (ARDS), multi-system organ failure and death26–28. SARS-CoV-2 invades type II alveolar 
epithelial cells, accessing cellular machinery through the binding of its spike protein to Angiotensin-
converting enzyme 2 (ACE2), which is highly expressed in the lungs and heart28. To date, SARS-CoV-2 
exhibits higher transmissibility but lower mortality than SARS-CoV and MERS-CoV29. 
 
2. Methods 
This review considers how malnutrition across all its forms (undernutrition, micronutrient 
deficiencies and overnutrition) may influence both susceptibility to, and progression of, COVID-19. 
We synthesised information on 13 nutrition-related components and their potential interactions 
with COVID-19: overweight, obesity and diabetes; protein-energy malnutrition; anaemia; vitamins A, 
C, D, and E; poly-unsaturated fatty acids; iron; selenium; zinc; anti-oxidants, and nutritional support. 
We published our strategy on the PROSPERO database, reference CRD42020186194. 
Search Strategy 
We adopted three key approaches for compiling information for each of the 13 sections listed 
above:  
a) A landscape review of pertinent material. This section is non-systematic, and covers a brief 
description of the nutrient/condition vis-à-vis infection and immunity, evidence of any role 
in viral infections, possible mechanisms, and possible utility in treatment. 
b) A systematic search of the literature in PubMed and EMBASE databases, and including a 
systematic search of a wide range of pre-print servers (listed in Supplementary Material 1).  
c) A screen of six clinical trial registries, listed in Supplementary Material 1.  
 
For the PubMed and EMBASE database searches a search string was designed to encompass terms 
related to 1) SARS-CoV-2, MERS-CoV or SARS-CoV viruses, 2) disease susceptibility, 3) disease 
progression and 4) the nutritional component of interest. The search string was then built combining 
the terms for 1 AND (2 OR 3) AND 4. The search string corresponding to components 1-3 was kept 
consistent between all sections, with component 4 being adapted to the relevant exposure of 
interest. The clinical trial registry and pre-print server searches were restricted to COVID-19. Full 
search string terms for the PubMed, EMBASE, pre-print server and clinical trial registry searches are 
provided in Supplementary Material 2. 
In the landscape reviews we summarised the insights learnt from other viral diseases where 
relevant, and included other coronaviruses (MERS-CoV and SARS-CoV) in the systematic searches. 
From the outset we acknowledge that COVID-19 is behaving differently to other viral diseases, and 
therefore cautiously extrapolate risk throughout the review.  
Inclusion and exclusion criteria 
We considered all populations of any sex, age, or nutritional status, with no specific geographic 
boundaries. We restricted the systematic searches to human populations and studies in English. All 
original research was considered, without restriction to study design. Systematic reviews were 
included to search bibliographies. We excluded comments, letters, opinions and non-systematic 
reviews. 
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Main outcomes for disease susceptibility were related to key concepts such as immunosuppression, 
inflammation, lymphocyte regulation, oxidative stress and all forms of immune dysfunction. Main 
outcomes for disease progression related to viral load, viral replication, viral mutation and 
transmission, worsening of respiratory tract and gastrointestinal infections, multiple organ failure, 
and other pathological features on disease progression to death. As the potential role of nutrition in 
disease susceptibility and progression is broad, we did not pre-specify the measures of effect to 
consider. Instead, we report the measures of effect that the authors have used in the eligible 
studies.  
Screening and selection 
A lead and co-author were assigned to each of the 13 nutrition-related sections of the review. The 
two researchers then performed the PubMed and EMBASE searches for their section. After abstract 
screening, full texts were retrieved for the potentially eligible studies. The lead author then reviewed 
these studies and used a standardised template to extract data on the eligible studies.  
A team of two researchers searched and abstract-screened all the pre-print servers listed in 
Appendix 1 for all 13 sections. They exported potentially eligible matches to the lead author of the 
relevant section for full screen.  One researcher searched all the clinical trial registries for the 13 
sections. Details of the potentially eligible clinical trials were sent to the lead author for review and 
data extraction. Searches took place between 16th May and 11th August, 2020. Full details of the 
search dates by section can be found in Supplementary Material 3.  
Due to the expected heterogeneity of study types, exposures and outcomes, we did not undertake a 
formal risk of bias assessment for each included study. 
Data synthesis 
We were guided by the Synthesis Without Meta-analysis (SWiM) reporting guidelines for systematic 
reviews30. Due to the heterogeneity of outcomes related to disease susceptibility and progression 
we did not attempt to transform results into a standardised metric. For each section of the review 
we summarised the effect sizes as reported by the authors in the included studies.  
3. Results 
Figure 1 provides the overall flow chart summary of all articles retrieved and included in the 
narrative synthesis. The detailed flow chart breakdowns per section are given in Supplementary 
Material 3. Across the 13 searches, a total of 2732 hits from PubMed and EMBASE were returned. 
After removal of 661 duplicates, 2071 were taken to title/abstract screen and 1783 were deemed 
ineligible at this stage. A total of 288 articles were taken to full text screen and 266 were further 
excluded. The remaining 22 articles were included in the narrative synthesis and further information 
captured in Supplementary Material 5.  
A total of 4164 hits from across the pre-print servers were returned. After removal of 178 duplicates, 
3986 were taken to title/abstract screen and 3708 were ineligible. 278 articles were taken to full text 
screen and 239 were excluded. The remaining 39 articles were included in the narrative synthesis 
and Supplementary Material 5. 
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From the clinical registry searches 433 trials were returned and 354 were ineligible. 79 trials were 
therefore included in the narrative synthesis and also detailed in Supplementary Material 4. 
 
4. Protein Energy Malnutrition 
Landscape review 
Protein-energy malnutrition (PEM), also called protein energy undernutrition or simply 
‘undernutrition’, is a state of nutritional insufficiency attributable to inadequate energy and/or 
protein intake, and is often associated with multiple micronutrient deficiencies31. According to the 
2020 Global Nutrition Report, an estimated 820 million people worldwide (11% of global population) 
are hungry or undernourished, and the majority are found in low-and-middle income countries 
(LMICs)32.  
Globally PEM affects at least 1 in 5 children under 5 years with the greatest burden in LMICs, 
predominantly those in sub-Saharan African and South Asia32. It manifests as stunting (weight-for-
age z-scores <-2, compared to the WHO Growth Reference Standards33), underweight (including low 
birth weight, weight-for-age z-scores <-2), and acute malnutrition (kwashiorkor or wasting, defined 
as weight-for-height/length <-2 z-scores). The severe form of the latter, severe acute malnutrition 
(SAM), is associated with up to 50% mortality among children admitted to hospital34. In 2019, 49.5 
million (7.3%) children aged under five years were wasted and 149 million (22%) were stunted 
globally32. 
Wasting and stunting often co-exist in children in LMICs and both are associated with increased 
mortality in childhood due to infectious diseases, particularly diarrhoea and pneumonia35. This 
susceptibility to infections is due to impaired immune function (including weakened gut-barrier 
function, humoral and cell mediated immunity) with consequent inadequate nutrient intake due to 
anorexia and malabsorption36. This further exacerbates immune suppression and impaired growth 
whilst energy and micronutrients are diverted to acute phase immune responses to combat multiple 
and often recurrent infections, leading to a chronic systemic inflammatory state and bacterial 
translocation37. Indeed, PEM is the primary cause of immune deficiency worldwide, and the vicious 
cycle of infection (clinical and sub-clinical) and PEM is well-described38,39. 
In high income countries PEM is common among hospitalised adults, particularly the elderly, where 
23-60% elderly patients in acute healthcare settings are malnourished40 and up to 50% of patients 
with concurrent morbidities are also affected41. The causes are commonly poor nutrient intake (for 
example, in the elderly due to poor oral health, depression, as a side effect of medication, or 
inadequate feeding support) and chronic underlying conditions that increase the metabolic demand 
due to inflammation, resulting in anorexia and increased muscle catabolism (cachexia), such as end 
stage renal failure42,43.  This leads to altered body composition and adverse functional and clinical 
outcomes. The Global Leadership Initiative on Malnutrition has developed internationally validated 
diagnostic criteria based on both phenotypic (weight loss, low body mass index, reduced muscle 
mass/sarcopenia) and etiologic criteria (reduced food intake or assimilation, and inflammation or 
disease burden, including major infections or trauma) to facilitate early identification and 
management of patients with PEM to avert deaths and adverse outcomes43. 
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In the current SARS-CoV-2 global pandemic, there is an urgent need to identify PEM-related factors 
that render individuals vulnerable to succumbing to this infection. As a staggering 11% of the 
population are likely to have impaired immunity due to PEM32, many populations particularly in 
LMICs are potentially at risk of developing disease during this pandemic, although the severity of the 
trajectory is yet to be fully determined. Furthermore, although COVID-19 primarily affects the 
respiratory tract, patients can also have gastrointestinal symptoms including diarrhoea, nausea, and 
vomiting and loss of smell that can have an impact on nutrient intake and assimilation44. Human 
enteric coronavirus causes moderate to severe villous atrophy in animal models with virus particles 
visible in enterocytes of large and small intestine45,46. Coronavirus-like particles have also been found 
in degenerating jejunal epithelial cells of adults in India with histological evidence of malabsorption 
due to environmental enteric dysfunction and among Aboriginal children with lactose malabsorption 
post gastroenteritis47,48. However, the exact mechanisms of COVID-19 induced gastrointestinal 
symptoms of nausea, vomiting and loss of taste remain elusive49. 
Although there is no current published data on the impact of PEM on the susceptibility and disease 
progression of SARS-CoV-2 infection in children, extrapolation from other RNA viral infections 
suggests that undernourished children are likely to have more severe respiratory and 
gastrointestinal disease. RNA viruses, including influenza A and B, and human metapneumovirus, are 
important pathogens causing pneumonia in children aged under 5 years globally50. PEM has been 
associated with influenza-related severe acute respiratory illness in under-5s in South Africa 
(adjusted odds ratio [aOR] 2.4; 95% CI, 1.1–5.6)51. In previous pandemics of influenza A (H1N1) such 
as the one in Guatemala in 2009 where 5 of the 11 deaths among hospitalised patients occurred in 
under 5’s, PEM was thought to have been a key contributing factor52. Children between 6 months 
and 5 years were thus identified as a priority group for vaccination52. However, to date children 
appear to be at lower risk of suffering severe episodes of COVID-19 than adults53. 
Systematic review  
Our systematic search involved terms related to PEM in both children and adults and RNA viruses. 
The systematic screen of PubMed and EMBASE yielded 120 papers after removing duplicates; 23 
were taken to full text screen and all were excluded as they did not examine the influence of PEM on 
coronavirus susceptibility or disease course.  
A further search of the pre-print servers identified 3 studies that were included. Li et al. conducted a 
cross-sectional study and recruited 182 elderly hospitalised COVID-19 patients ≥65 years, in one 
centre in Wuhan, China54. The authors found that 53% were classified as malnourished using a mini 
nutrition assessment (based on recall of dietary intake) and 28% were at risk of malnutrition. There 
were no statistically significant differences in the triceps skin-fold thickness and mid-arm 
circumference between those who were non-malnourished, at risk of malnutrition or malnourished. 
However, diabetes mellitus (OR 2.12; 95% CI 1.92–3.21), low calf circumference (OR 2.42; 95% CI 
2.29–3.53), and low albumin (OR 2.98; 95% CI 2.43–5.19) were independent risk factors for 
malnutrition. Their recommendation was for nutritional support to be enhanced for COVID-19 
elderly patients with diabetes, low albumin and low calf circumference due to their increased risk of 
becoming malnourished. A retrospective study that included 141 COVID-19 patients in the analysis, 
explored the risk of adverse clinical outcomes among elderly patients (>65y) by nutritional status 
(using validated nutrition risk screening tools for adults including Nutrition Risk Screening 2002 (NRS-
2002), Malnutrition Universal Screening Tool (MUST), Mini Nutrition Assessment Shortcut (MNA-sf), 
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and Nutrition Risk Index (NRI)) in one hospital in China55. They found that patients at risk of PEM had 
significantly longer hospital stay, poor appetite, more severe COVID-19 disease and greater weight 
loss than patients not at nutritional risk using NRS 2002, MNA-sf, and NRI-2002. They recommended 
routine screening of elderly COVID-19 patients for nutrition risk coupled with nutrition interventions 
to improve clinical outcomes. Caccialanza et al.’s protocol is on a pragmatic trial in Italy for early 
nutritional supplementation with high-calorie dense diets combined with intravenous infusion of 
multivitamin, multimineral trace elements solutions for non-critically ill patients hospitalized for 
COVID-19 disease56. This was based on their observations of the drastic reduction in food intake due 
to severe inflammation among these patients at admission that predisposes them to poor 
respiratory outcomes. The nutritional interventions will be modified based on the clinical and 
nutritional status of patients during admission to include parenteral nutrition. The analysis of the 
effectiveness of this package of nutrition interventions is likely to be complex but is keenly awaited.  
Clinical trials  
In the current pandemic, a similar pattern is being played out to what we have seen in previous 
pandemics. Patients with PEM, especially amongst the elderly and those presenting comorbidities, 
have been among those with the highest mortality57. Indeed a cross-sectional study in Wuhan, China 
with 182 COVID-19 patients aged ≥65y in a single centre found that diabetes (OR 2.12; 95% CI 1.92–
3.21), low calf circumference (OR 2.42; 95% CI 2.29–3.53), and low albumin (OR 2.98; 95% CI 2.43–
5.19) were independent risk factors for PEM54. Prolonged ICU admission causes or worsens existing 
PEM with associated sarcopenia (loss of skeletal muscle mass and function), exacerbated by the 
inflammation associated with the infection58. Identification and management of PEM is now a key 
component of managing patients with COVID-19 in Europe to avert adverse outcomes. There are no 
clinical trial data to guide the design of optimal nutrition management strategies in the context of 
COVID-19. The European Society for Clinical Nutrition and Metabolism has published nutrition 
rehabilitation guidelines primarily based on consensus and expert opinion using a combination of 
enteral and parenteral nutrition if oral intake not adequate58 (see also Section 16).  
The clinical trials registry search identified 3 on-going studies in the US, Spain and France related to 
PEM, none of which are in children (Supplementary Material 4). All of these are observational 
studies. The US study (NCT04350073) seeks to undertake a detailed evaluation of the longitudinal 
energy expenditure and metabolic effects in COVID-19 adult patients, admitted to a single intensive 
care unit (ICU) with respiratory failure, using indirect calorimetry, cardiac assessment, body 
composition, and muscle and ultrasound measures. This is to guide the metabolic and nutritional 
care of these high-risk patients, optimise their care and ultimately improve outcomes. In Spain, the 
study (NCT04346212) seeks to assess the prevalence of oropharyngeal dysphagia among COVID-19 
adult patients post discharge from one ICU and to describe their associated nutritional status, 
requirements for nutritional supplements and adaptations, in order to design strategies to optimise 
their care and clinical outcomes. The study in France (NCT04386460) seeks to explore the associated 
risks of dental health/isolation/ anorexia with malnutrition among elderly patients and evaluate the 
impact of dentists referring these at-risk patients to physicians on malnutrition prevention. The 
results of these studies are eagerly awaited as they will be key to informing the design of targeted 
nutritional interventions to both prevent and manage PEM in the context of COVID-19. 
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Obesity is a recognised risk factor for type 2 diabetes mellitus (DM), and both have been associated 
with an increased burden of respiratory tract infections (RTIs)59. A systematic analysis found a U-
shaped relationship between body size and risk of RTIs60 and DM has also been found to increase 
susceptibility to, as well as severity of, respiratory infections in general61. It is therefore not 
understood if they independently contribute to this increased morbidity and mortality risk62.  
 
Obesity is causally related to, and potentiates, cardiovascular and metabolic derangements such as 
hyperglycaemia and DM63. This reduces the protective cardiorespiratory reserve and potentiates the 
immune dysregulation that appears, at least in part, to mediate the progression to critical illness and 
organ failure in a proportion of patients with severe respiratory infections including COVID-1963,64. 
 
Several cellular mechanisms that may increase the susceptibility of DM patients to respiratory 
infections have also been described, including greater affinity of SARS-COV-2 for cell binding and 
entry, reduced viral clearance65, inhibited lymphocyte proliferative response to different kinds of 
stimuli66, as well as impaired monocyte/macrophage and neutrophil functions67.  
 
Systematic review  
 
The systematic literature search yielded a total of 1331 articles; 947 were taken to title and abstract 
screen after 384 duplicates were removed. 115 articles were considered for full-text screening and  
6 papers met the inclusion criteria for obesity and 12 for diabetes. The pre-print server search for 
obesity and diabetes yielded a total of 154 articles. 34 were considered for full-text screening and 29 
of these met the inclusion criteria. Since included studies were numerous, and largely confirmed the 
same key messages of increased risk of severe disease progression, we did not extract all studies to 
Supplementary Material 5 but do refer to all included studies in the following narrative synthesis.  
 
Obesity 
Obesity is a frequent finding in hospitalised COVID-19 patients with the prevalence varying between 
studies: 10% in China68, 41.7%69 and 47.5%70 in the US and 75.8% in France71. A study compared 44 
ICU COVID-19 patients in France with a historical control group of 39 consecutive acute respiratory 
distress syndrome patients admitted to the ICU just before the COVID-19 crisis and found obesity to 
be the most frequent comorbidity among patients (n=32, 73% vs n=11, 28% in controls; p < 0.001)72.  
 
Obesity is generally associated with poor COVID-19 outcomes and this has been confirmed in all 
studies included in this systematic review.  The contributory mechanisms, as has been suggested by 
Zhang et al.73, are aggravated inflammatory response, enhanced cardiac injury and increased 
coagulation activity. Their study which included 13 young patients who died of COVID‐19 and 40 
matched survivors found a higher body mass index among deceased individuals (OR = 1.35; 95% CI= 
1.08‐1.70)73. Another study has suggested that increased ACE2 expression in the bronchial 
epithelium of obese individuals may contribute to poor outcome74.  
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Obesity has been associated with higher risk of severe COVID-19 disease in many populations and 
across age brackets. A study by Cai et al. found that patients with a BMI >28kg/m2 had significantly 
higher odds of developing severe disease (aOR 3.40, 95% CI 1.40-2.86)68. Klang et al., in a study of 
3406 patients, found poor outcomes in different age groups (young: <50y and old: 50y). For the 
younger population, BMI above 40 kg/m2 was independently associated with mortality (aOR 5.1, 
95% CI: 2.3–11.1). For the older population, BMI above 40 kg/m2 was also independently associated 
with mortality but to a lesser extent (aOR 1.6, 95% CI 1.2 – 2.3)75. In a cohort of 46 pregnant women, 
15 had severe COVID-19 with the majority being either overweight or obese (80%)76. Another study 
also found that obesity (BMI >30 kg/m2) was associated with increased risk of ICU admission or 
death (RR = 1.58, p = 0.002) whereas being underweight was not (RR = 1.04, p = 0.892)77. 
 
Obese patients were more likely to require invasive mechanical ventilation, with severe obesity (BMI 
≥35 kg/m2) found to be associated with ICU admission (aOR 5.39; 95% CI:1.13-25.64)70. Similar 
findings of adverse outcomes were found in other studies71,78. Hur et al. found that obese patients 
with COVID-19 had a decreased chance of extubation compared with non-obese patients79 [Hazard 
Ratio for extubation: 0.53 (95% CI: 0.32-0.90) for patients with a BMI of 30 to 39.99 and 0.40 (95% 
CI, 0.19-0.82) for those with a BMI of ≥40]. Palaiodimos et al. also found that severe obesity i.e. BMI 
≥ 35 kg/m2 compared with those with a BMI 25-34 kg/m2, was independently associated with higher 




Diabetes is a common comorbidity among COVID-19 patients and has been associated with poor 
outcomes in all included studies with the exception of Cariou et al. (see below). The frequency of 
diabetes among hospitalised patients was investigated in many studies, ranging from 3.8% in Iran81, 
5.5%-35.7% in various studies from China2,82–90, 19.9% in the UK biobank91, and 33.8% in the USA69.  
 
Hyperglycaemia in those with and without a history of diabetes may indicate a poor prognosis in 
COVID-1992. A study by Guo et al. suggests diabetes should be considered as a risk factor for a rapid 
progression and poor prognosis of COVID-1993. The utility of diabetes screening after admission has 
been suggested by Wang et al. who found high HbA1c level at admission to be associated with 
inflammation, hypercoagulability, and low SaO2 in COVID-19 patients94. This severe inflammatory 
response was also reported by other studies93,95. The mechanism, though not completely 
understood, may be through metabolic derangement such as that leading to ketosis and 
ketoacidosis. A study found that ketosis and ketoacidosis disproportionately affected diabetic 
patients compared with those without diabetes90. 
 
Patients with diabetes are found to be more likely to develop severe or critical disease conditions 
with more complications, and had higher incidence rates of antibiotic therapy, non-invasive and 
invasive mechanical ventilation, and death (11.1% vs. 4.1%)96. Chen et al. found that diabetes and 
other factors such as increasing age, male sex and hypertension delay viral clearance thereby leading 
to a poor prognosis97. These risk factors are similar to those found in other studies98–100. COVID-19 
patients with diabetes were more likely to develop severe or critical disease with more 
complications at presentation, and had higher incidence rates of antibiotic therapy, non-invasive and 
invasive mechanical ventilation and death (11.1% vs. 4.1%)101. In another study by Wu et al., the 
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prevalence of diabetes among those with COVID-19-related acute respiratory distress syndrome 
(ARDS) was significantly higher than in those without ARDS (difference, 13.9%; 95% CI, 3.6%-
24.2%)102. Bode et al. found in patients with diabetes and/or hyperglycaemia compared with those 
without, a longer median length of stay in hospital (5.7 vs 4.3 days, P <0.001) and higher mortality 
rate (28.8% vs 6.2%, p < 0.001)103. This mortality rate was similar to that found in another study 
(27.7%)94. Shi et al. found a higher proportion of intensive care unit admission (17.6% vs. 7.8%, p 
<0.01) and more fatal cases (20.3% vs. 10.5%, p <0.017) were identified in COVID-19 patients with 
diabetes than in the matched patients104. A study by Chang et al. found that patients with diabetes 
were more likely to progress to severe disease compared to those without [OR: 64.1 (4.6–895.5)]105. 
The findings were similar to those of Huang et al (OR: 4.3; 95% CI, 1.1-17.7)106. In Iran, Rastad et al. 
found diabetes alone or in association with other comorbidities was associated with increased risk of 
death [OR 1.69 (1.05–2.74) and 1.62 (95% CI 1.14–2.30) respectively]107. In a cohort of 28 diabetic 
patients, half required ICU admission108. 
 
A study by Li et al. suggests that COVID-19 patients with newly diagnosed diabetes have a higher 
mortality risk of all-cause mortality [multivariable-adjusted HR: 9.42 (95% CI 2.18-40.7)] but this was 
not statistically significant compared with patients with normal glucose (1.00), hyperglycaemia [3.29 
(95% CI: 0.65-16.6)] and known diabetes [4.63 (95% CI 1.02-21.0)]109. Increased mortality for patients 
with diabetes and COVID-19 has been linked to older age (aOR 1.09 [95% CI 1.04, 1.15] per year 
increase), elevated C-reactive protein (aOR 1.12 [95% CI 1.00, 1.24]) and insulin usage (aOR 3.58 
[95% CI 1.37, 9.35])110.  The latter finding on insulin use is in contrast to findings by another study 
which showed that patients with hyperglycaemia already treated with insulin infusion at admission 
had a lower risk of severe disease than patients without insulin infusion111. Metformin use, however, 
was associated with better outcomes in diabetics compared with those not receiving it112. These 
findings were complemented by Zhu et al. who found that well-controlled blood glucose (glycaemic 
variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to 
individuals with poorly-controlled blood glucose (upper limit of glycaemic variability exceeding 10.0 
mmol/L) (adjusted HR: 0.14) during hospitalization113. 
 
Only one study did not find diabetes to be associated with poor COVID-19 outcomes. Cariou et al. 
found that diabetes, HbA1c, diabetic complications and glucose-lowering therapies were not 
associated with disease severity (tracheal intubation for mechanical ventilation and/or death) within 
7 days of admission114.  
 
Clinical trials  
 
Searches of clinical trials databases revealed 13 planned or ongoing studies related to 
overweight/obesity or diabetes and COVID-19 (Supplementary Material 4). Of these nine were 
observational studies and four RCTs (two in the USA, one in Israel and one in Italy). Three of the RCTs 
evaluate the efficacy of the use of dipeptidyl peptidase 4 (DPP4) inhibitors (oral hypoglycemic 
agents: Linagliptin and Sitagliptin respectively) whilst another uses an antiviral nucleotide analogue 
(AT-527) on COVID-19 outcomes. All three studies using oral hypoglycemic agents evaluate their 
efficacy, compared with standard care, on clinical outcomes defined as lung disease in two studies 
and changes in glucose levels in one. The study using AT-527 seeks to assess its effect on progression 
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to respiratory insufficiency, compared with a matching placebo, in moderate COVID-19 patients 




Anaemia is a condition where an individual’s haemoglobin concentration falls below the accepted 
lower threshold specific for their age, sex and pregnancy status. Anaemia remains highly prevalent 
worldwide, especially in low income countries, and particularly in South Asia and sub-Saharan Africa. 
The most common cause of anaemia worldwide is iron deficiency, which is caused by inadequate 
nutritional iron intake, impaired iron absorption, increased iron utilisation (for example during 
pregnancy or during rapid child growth), and blood losses (for example, menstrual blood losses, 
gastrointestinal bleeding, and blood donation). Anaemia is thus most common in preschool children, 
women of reproductive age, and during pregnancy115. 
Beyond iron deficiency, there are many other causes of anaemia. During inflammation, iron may be 
withheld from the plasma through elevated hepcidin concentrations (functional iron deficiency); 
coupled with impairments on erythropoiesis and reduced red cell survival, this can result in anaemia 
of inflammation, which is common in patients with medical illnesses (such as cancer, infection and 
autoimmune conditions)116. Functional iron deficiency may also be an important component of the 
overall burden of anaemia in low income countries where exposure to endemic infections is intense. 
Other acquired causes of anaemia include haemolytic anaemias. These include autoimmune 
haemolytic anaemias, caused by autoimmune destruction of red blood cells (usually provoked by 
viral infections, some bacterial infections, underlying lymphoproliferative disorders, and 
medications)117. Other causes of haemolytic anaemia include microangiopathic haemolysis (which 
can be due to many causes including congenital, caused by infections, autoimmune conditions, 
cancer, pregnancy complications, and mediations). Bone marrow failure (aplastic anaemia, or 
replacement of the bone marrow by malignancy) can also cause anaemia. In the tropics a major 
cause of childhood anaemia is malaria, malaria anaemia has elements of haemolysis, marrow failure 
and functional iron deficiency. Other important causes of anaemia include genetic disorders of 
haemoglobin including alpha thalassaemia, beta thalassaemia and sickle cell disease.  
Like all infections, acute viral infection can promote an innate immune response, elevation in 
hepcidin, and hence functional iron deficiency and anaemia of inflammation. Viral infections can also 
cause bone marrow failure. For example, Parvovirus B19 infection is frequently asymptomatic, or 
may cause a mild febrile illness with a rash (‘slapped cheek disease’). However, in 
immunocompromised individuals, and in individuals with chronic erythroid overactivity (e.g. 
haemolytic disease, sickle cell disease) it can cause cessation of erythropoiesis resulting in a 
transient aplastic crisis with severe anaemia. Parvovirus B19 during pregnancy can infect the fetus, 
causing failure of fetal erythropoiesis and severe fetal anaemia, which can result in hydrops fetalis 
and fetal death118. 
Systematic Review 
From the PubMed and EMBASE database searches, after deduplication 407 articles were assessed at 
the title/abstract stage. Of those that mentioned anaemia we only considered those addressing 
potential nutritional causes of anaemia for formal data extraction, due to the scope of this review. 
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However, several other types of anaemia featured in the initial screen, which we briefly summarise 
here. For example, two articles described the management of pernicious anaemia in the case of 
disrupted B12 treatment119,120. Two case series have provided preliminary information on beta 
thalassaemia major. A small series of 11 patients with beta thalassaemia in Italy infected with 
COVID-19 all experienced mild to moderate disease and all survived, even despite the presence of 
comorbidities associated with iron overload121. A nationwide study in Iran identified a lower 
incidence of diagnosed COVID-19 among patients with thalassaemia compared with the general 
population (8.7 per 10000 in the thalassaemia population compared with 11.0 per 10000 in the 
general population), although patients with thalassaemia may have been sheltering. Patients with 
thalassaemia experienced a higher mortality rate (26.6%) compared with the general population 
(6.3%); patients who did not survive had higher risks of comorbidities including diabetes, 
hypertension, and heart disease, although splenectomy was not a risk factor for mortality in this 
group122.  A case report identified combined autoimmune anaemia (destruction of red blood cells by 
autoantibodies) and thrombocytopenia (destruction of platelets by autoantibodies) (collectively 
termed “Evan’s syndrome”) in a patient with COVID-19123. A case series from Belgian and French 
hospitals identified the onset of acquired warm and cold autoimmune haemolytic anaemia 
associated with a positive direct antiglobulin test in seven patients; four of the patients had a 
previous or new diagnosis of an indolent B cell malignancy, and viral infection may have triggered 
the onset of haemolysis124. These cases were each successfully treated using therapies including 
intravenous immunoglobulin, steroid and even rituximab, and all patients across these case series 
survived. There have been further case reports describing the association between autoimmune 
haemolytic anaemia and COVID-19125,126.   
Whilst haemoglobin measurement has not been included in the core-outcome dataset proposed by 
WHO127, several studies suggest anaemia may be a clinical feature of COVID-19. For example, initial 
reports from Wuhan describing clinical features of COVID-19 pneumonia identified anaemia in up to 
50% of patients whom mostly appeared to have severe disease44. A subsequent report from Wuhan 
identified anaemia in 15% of patients with COVID-19, with anaemia more common among non-
survivors2. Similar haemoglobin concentrations have been reported in other COVID-19 cohorts128 
and several studies include anaemia as a covariate in descriptive statistics. As in other medical 
conditions, anaemia appears to be associated with poorer prognosis, perhaps as a biomarker for 
more severe inflammation129,130.  
After the title and abstract review nine articles were taken to full screen. Six articles did not address 
nutritional causes of anaemia. One paper by Cavezzi et al. was a review on the possible 
pathophysiological pathways by which SARS-CoV-2 may cause both haemoglobin dysfunction and 
hypoxia (through haemolysis and forming complexes with haem) and tissue iron overload (through 
mimicking the action of hepcidin)131.  
Ultimately, we found two eligible studies for formal inclusion (Supplementary Material 5). The first 
was a case report of a patient testing positive for COVID-19 alongside several co-morbidities 
including severe iron-deficiency anaemia132. He was successfully treated with antiviral treatment 
alongside recombinant human Erythropoietin (rhEPO), leading the authors to propose further 
testing of the effectiveness of rhEPO in anaemic COVID-19 patients. The second study was a 
retrospective analysis of 259 patients hospitalised with COVID-19 in Austria133. The authors 
distinguished between those patients presenting with anaemia of inflammation at admission and 
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those with iron-deficiency anaemia (IDA). Compared to patients with no iron deficiency, having IDA 
was associated with a longer hospital stay, but was not associated with increased mortality, risk of 
ICU admission, nor of mechanical ventilator use. However, when considering purely anaemic versus 
non-anaemic patients, the anaemic patients had a higher risk of death (OR 3.729 (95%CI 1.739–
7.995). Of these anaemic patients, the majority (68.8%) had anaemia of inflammation, which the 
authors describe could be linked to co-morbidities, or to the advanced inflammation associated with 
COVID-19, or both. Collectively, these limited data indicate anaemia is an adverse prognostic 
indicator in severe COVID-19. 
From the pre-print server screen, of the 122 articles returned 4 were taken to full screen review and 
none were eligible. 
Clinical trials  
 
The search of clinical trial registries did not identify any ongoing clinical studies specifically 





Approximately 2% of human genes encode proteins that interact with iron, and around 6.5% of 
enzymes depend on iron134. Viruses co-opt host cellular processes to replicate, so it is unsurprising 
that viral replication utilizes proteins that are iron-dependent135, such as ribonucleotide reductase 
(the key enzyme involved in nucleotide biosynthesis). Consequently, viral pathogenesis could be 
influenced by cellular iron status. However, several features of host responses to viral infection 
could also be affected by iron, for example macrophage polarisation and lymphocyte proliferation, 
potentially influencing either disease susceptibility or course.    
 
Iron deficiency is the most prevalent micronutrient deficiency worldwide, most prominently causing 
anaemia. The major burden of iron deficiency is borne by young children and women of 
reproductive age - groups at lower risk of COVID-19 mortality136 - and pregnant women (for whom 
patterns of COVID-19 hospitalisation risk appear similar to the general population137)138. Functional 
iron deficiency, where iron is present but sequestered and unavailable in circulation, occurs during 
many chronic conditions, including obesity139 – a known COVID-19 risk factor136. 
 
Effects of iron status on infection susceptibility are not fully defined, and likely vary according to age, 
setting (e.g. malarial or non-malarial) and type of infection140,141, meaning caution should be 
employed in making extrapolations to viral infections in general and specifically to COVID-19. Iron 
deficiency protects against certain microbial infections including malaria142, and iron 
supplementation exacerbates malaria risk in children in malaria-endemic areas in the absence of 
malaria control measures143,144. Excess iron increases siderophilic bacterial infection risk145, and 
elevated iron indices predict mortality during HIV-1 infection, even after adjustment for CD4 count 
and inflammation146. Non-malarial infections, including gastrointestinal and respiratory infections, 
are also reported in several trials of childhood iron supplementation144. One large intervention trial 
in Pakistan reported increased signs of respiratory infection in children administered iron147, 
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although other smaller trials have reported contrasting effects of iron supplementation on incidence 
of respiratory tract infections in children140,148–150. However, high quality evidence on interactions 
between iron status or interventions and specific respiratory viral infections in humans is lacking. 
 
Although precedents from other human viral infections are limited, iron could in principle affect 
several aspects of the host-SARS-CoV2 interaction:  
 
• As discussed above, viral replication, in general terms, co-opts several iron-dependent host 
cellular processes135.  
• Impaired lung function and hypoxia are key features of severe COVID-19 disease, and iron 
deficiency exaggerates the pulmonary response to hypoxic stress151,152. 
• Iron levels may influence macrophage polarisation and cytokine production153, potentially 
influencing COVID-19-related inflammatory phenotypes.  
 
In addition, a rare mutation of Tfrc (encoding the transferrin receptor) that disables cellular iron 
uptake causes severe combined immunodeficiency in children154. Nutritional iron deficiency or pre-
existing functional iron deficiency have also been linked to immune impairment155. Moreover, during 
many infections, interleukin-6 (IL-6)-mediated stimulation of the iron regulatory hormone hepcidin, 
as part of the hepatic acute phase response, causes macrophage iron sequestration and acute 
reduction in serum iron concentration141. Common respiratory infections and fevers associate with 
hepcidin upregulation in African children156. A key feature of COVID-19 severe/critical disease is 
excessive production of inflammatory cytokines, notably IL-6, and accordingly, raised hepcidin has 
been reported in hospitalised COVID-19 patients157,158. Consistent with involvement of hepcidin 
activity, extreme hypoferraemia has been reported in several studies in severe COVID-19 patients, 
with serum iron concentration shown to be highly predictive of disease severity157,159–161. A further 
retrospective analysis (also described in Section 6 on anaemia) also reported perturbed markers of 
iron homeostasis in hospitalised COVID-19 patients, with functional iron deficiency classified in 
approximately 80% of patients at admission133. Whether or not this functional iron deficiency limits 
the development of the adaptive response (analogous to the effect of the Tfrc mutation154) in the 
context of SARS-CoV-2 infection remains to be determined. 
 
Systematic review  
Besides “iron”, our systematic search involved terms, related to common biomarkers of iron status 
and iron handling – including “ferritin”, “transferrin”, “Tsat” [transferrin saturation] and “hepcidin” 
(Supplementary Material 2). The systematic screen of PubMed and EMBASE returned 110 papers 
after removing duplicates; 45 were taken to full text screen, all of which were excluded as none 
examined the influence of iron deficiency or interventions on coronavirus susceptibility or disease 
course.  
 
A further 10 distinct studies were identified through the pre-print server screen; again, all were 
excluded for the same reasons. The combined screen of PubMed/EMBASE and pre-print servers did 
identify 32 original studies or meta-analyses reporting effects of coronavirus infection on iron-
related markers, most prominently the iron storage protein ferritin. However, in the context of 
typically extreme COVID-19 associated inflammation, serum ferritin is not useful as a marker of iron 
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status, yet it does show relevance as an indicator of disease severity and could potentially reflect 
iron dysregulation besides inflammation (see Box 2).   
 
Clinical trials  
 
The clinical trial screen returned 134 trials. Amongst these 124 were identified owing to inclusion of 
ferritin concentration amongst clinical outcomes.  No clinical trials pertaining to iron 
supplementation, or investigations of baseline iron status on COVID-19 susceptibility or progression 
were identified. However, three clinical trials were identified aimed at targeting iron during COVID-
19 infection (Supplementary Material 4): each proposes to examine the effect of deferoxamine 
(Desferal®) on COVID-19 disease course and mortality, an approach discussed in a recent review162.  
The rationale was not described in two of the three trials; in the third, a rationale of reducing iron-
induced lung toxicity was proposed. Iron chelation can reduce replication of viruses including HIV-1 
in vitro162, yet its effect on viral pathogenesis in vivo is less clear. Given the emerging importance of 
iron in immune function and the uncharacterised role of iron in the SARS-CoV2 life cycle, outcomes 
of trials of iron sequestration in the context of COVID-19 are awaited with interest. 
 
Box 2: Ferritin and COVID-19  
 
Ferritin was included as a systematic review search term since low serum ferritin is frequently used 
in diagnosis of iron deficiency163,164.  The initial screen returned 22 papers, 9 preprints and 124 
clinical trials mentioning ferritin, none of which related to iron status assessment. Instead, elevated 
ferritin (hyperferritinaemia) was consistently reported in COVID-19 patients, with levels highest in 
critical disease (see meta-analyses165,166).  While serum ferritin is upregulated in response to 
increased iron, it is also induced during inflammation by IL-1β and TNF-α, often correlating with 
inflammatory markers such as C reactive protein (CRP); as such, inflammation is a well-known 
confounder of ferritin-based iron status assessment163,167.  Given that severe COVID-19 disease is 
characterised by hyperinflammation, reminiscent of other syndromes with macrophage activation-
related hyperferritineamia167,168, serum ferritin levels will not reflect iron levels in the majority of  
COVID-19 patients. However, it does show potential as a prognostic biomarker given its association 
with COVID-19 disease severity165,166. Whether or not ferritin plays an active role in disease 
pathogenesis, or merely reflects the degree of inflammation and macrophage activation warrants 
further attention. 
 




Vitamin A has an established role in supporting immune function and protecting against viral 
infections. Evidence from animal studies shows clear effects of serum retinol level on mucosal 
immune function and intestinal lymphocyte action, and protection against viral infections of the 
respiratory and intestinal tracts169–173.   
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The effectiveness of viral vaccines is compromised by low serum vitamin A through the suppression 
of immunoglobulin G1 (IgG1)172,174 and inflammatory responses173. Vitamin A also modulates other 
immune components through its action on dendritic and natural killer cells175. It is essential in 
maintaining epithelial tissue integrity176, which is severely damaged in viral infections such as 
measles177. Recent systematic reviews conclude that vitamin A supplementation in children is 
associated with a reduction in all-cause mortality, and with reductions in the incidence of measles 
and diarrhoea, but there is little evidence to support a beneficial effect on respiratory 
infections178,179.  
 
Serious COVID-19 caused by SARS-CoV-2 infection has some similar manifestations to measles 
including fever, cough and pneumonia (though it is important to note that the severe lung pathology 
of COVID-19 has a distinct pathophysiology from other viral pneumonias)180. People with underlying 
chronic diseases and impaired immunity are also at high risk for both COVID-19181,182 and measles183.  
 
Vitamin A is recommended by the World Health Organization as part of the standard treatment 
package for all children with acute measles184. The COVID-19 pandemic has likely increased measles 
mortality – more than 20 countries have suspended measles vaccination and vitamin A 
supplementation campaigns as healthcare workers focus attention on COVID-19 leading to a surge in 
measles infections and mortality particularly in low income settings such as the DR Congo where 
measles has killed more than 6500 children and is still spreading185. Vitamin A is recommended 
mainly to reduce mortality186 and  risk of complications from pneumonia, croup and ocular 
problems187 by correcting the low or depleted retinol levels resulting from measles infection. The 
treatment regimen consists of the administration of high dose vitamin A on two consecutive days. 
Children with evidence of deficiency (ocular symptoms) receive a repeated dose at 2 to 4 weeks184. A 
Cochrane systematic review of eight trials188 and another systematic review of six trials189 showed no 
overall reduction in mortality with vitamin A treatment of measles. However, when stratified by 
vitamin A treatment dose, administering two doses (on consecutive days) reduced measles mortality 
significantly in both meta-analyses with RR=0.38 (95% CI 0.18-0.81)188 and RR=0.21 (95% CI 0.07-
0.66)189, and therefore forms the basis for the recommended regimen of vitamin A treatment of 
measles. 
 
A recent non-randomised study observed a reduction in mortality among 330 Ebola virus patients 
who received vitamin A supplementation compared to 94 patients who, due to supply problems, did 





The systematic search of PubMed and EMBASE databases yielded 44 articles. After removal of 
duplicates (n=5) and those not meeting inclusion criteria (n=36), 3 systematic review articles were 
considered for full text extraction to examine reference lists for potentially eligible articles. No 
papers were included from examining reference lists. Our preprint search on vitamin A and COVID-
19 yielded one potential paper which did not meet the inclusion criteria. 
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Two small sized randomized clinical trials involving vitamin A in the treatment of COVID-19 patients 
were identified from the clinical trials registries search. One of the trials, targeting 30 hospitalised 
patients (15 in the intervention arm) involves the use of an oral nutrient supplement (anti-
inflammatory/antioxidant nutrients and vitamins) as supportive care for COVID-19 and includes 
2840 IU vitamin A among other nutrients in the supplement for 14 days (NCT04323228). The reason 
for using anti-inflammatory or anti-oxidant nutrients in COVID-19 patients in this trial is to modulate 
the cytokine storm associated with the disease on the lungs. The other trial, targeting 80 
hospitalised (non-ICU) patients (NCT04360980) uses an unspecified amount of vitamin A as part of a 
combination of nutrients given to the control group or standard of care (n=40).  
 
 




Vitamin C (ascorbic acid), synthesised by all mammals except humans and guinea pigs, supports 
diverse aspects of immune function by strengthening epithelial barriers, enhancing the function of 
adaptive and innate immune cells, promoting cell migration to infection sites, and participating in 
macrophage microbial killing191. 
 
Unfortunately, vitamin C has a particularly chequered history in relation to viral infections. Double 
Nobel Laureate Linus Pauling blighted the end of his career by promoting mega-doses of vitamin C as 
a cure for common colds192 and cancers193 despite an absence of any robust evidence. Even today it 
is difficult to interpret the scientific and allied literature without encountering partisan opinions, and 
there remains a widespread popular view that vitamin C is effective. Pauling’s favoured mechanism 
of action was through its anti-oxidant effects. His belief in, and self-medication with, mega-doses of 
vitamin C runs contrary to the fact that there is a renal threshold leading to diminished retention 
and tissue saturation at oral intakes above 200mg/d194,195. Intravenous infusion of large doses of 
vitamin C can elevate leukocyte levels much further, but the putative mechanism of action against 
cancers (as yet unproven in humans) is proposed to be through its pro-oxidant effects of generating 
hydrogen peroxide at large doses196. This is pertinent to the on-going therapeutic trials in COVID-19 
patients listed below. 
 
Regarding the common cold, the most recent Cochrane review197 summarised 24 trials with 10,708 
participants and found no evidence in the general population that regular consumption of vitamin C 
at 200mg/d or above reduced the incidence of colds (RR = 0.97 (95%CI 0.94 – 1.00)). In contrast, five 
trials with 598 marathon runners, skiers and soldiers on subarctic exercises yielded a combined RR of 
0.48 (95%CI 0.35 – 0.64). The possibility that free radicals generated by extreme exercise are 
quenched by vitamin C provides a plausible explanation for this heterogeneity of results. Thirty-one 
trials covering 9745 episodes showed that taking regular vitamin C shortened the duration of 
symptoms in adults by 8% (95%CI 3 – 12%) and in children by 14% (95%CI 7 – 21%). Seven trials of 
therapeutic use of vitamin C administered at the start of an infection in 3249 episodes revealed no 
evidence of altered duration or severity. A single additional RCT in 1444 Korean soldiers has been 
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published since the meta-analysis and reported a marginally significant reduction in incidence of 
colds among soldiers receiving 6000mg/d vitamin C orally (RR 0.80, 95%CI 0.64 – 0.99)198. 
 
A Cochrane meta-analysis of the potential effect of vitamin C on the prevention and treatment of 
pneumonia has been updated very recently199. The results from 7 studies (5 RCTs and 2 quasi-RCTs) 
involving 2774 participants (children, adults, army personnel) receiving doses ranging from 125 to 
2000 mg/d vitamin C were judged to provide very low-quality evidence with respect to both 
prevention and treatment; hence no conclusions can be securely drawn. 
 
For critically-ill patients the prior evidence for efficacy of low- to moderate-dose vitamin C (alone or 
as a cocktail with other anti-oxidants) is weak. A recent systematic review and meta-analysis of 11 
RCTs found no evidence of benefit for mortality (9 trials) or any secondary outcomes200. There was a 
non-significant tendency towards mortality reduction in subgroup analysis confined to intravenous 
administration of high-dose vitamin C200. The meta-analysis was dominated by a large and robust 
multi-centre trial of 1223 ICU patients with half randomised to anti-oxidants including 1500mg/d 
enteral vitamin C (with or without glutamine) which reported no effect on survival (primary 
outcome) or on any secondary outcomes201.  
 
The evidence from prior trials of high-dose intravenous vitamin C (HDIVC) in pneumonia and ARDS-
type conditions is also of low quality and was either not summarised, summarised poorly, or in a 
biased manner in most trial registrations. One reason for the high interest in intravenous vitamin C 
can be traced to a single-centre uncontrolled observational study of 94 sepsis patients that reported 
a 5-fold reduction in mortality when vitamin C and thiamine were combined with hydrocortisone202. 
A follow-up multi-centre RCT of the same regimen in sepsis patients (the VITAMINS Study) has very 
recently reported no benefit in any outcome203. The CITRIS-ALI Trial in 7 US ICUs randomised 167 
patients with sepsis or ARDS to 200mg/kg/d intravenous vitamin C or placebo for 4 days. There was 
no difference in the primary outcome of Sequential Organ Failure Assessment score or in the 
secondary outcomes of CRP or thrombomodulin204. In un-prespecified exploratory analysis not 
adjusted for multiple testing there was some evidence of enhanced survival to 28 days. 
 
Systematic review  
From a total of 54 papers returned, 4 papers were identified for full screen. Most papers were 
commentaries or non-systematic reviews. In no case was there any substantive new data on clinical 
outcomes. Two papers used a systems biology bioinformatic approach to explore mechanisms 
through which vitamin C might be active205,206. 
 
The search of preprint servers yielded 13 relevant papers all of which were accessed for full review; 
most were commentaries or editorials. Two systematic reviews concluded that the evidence that 
vitamin C was likely to benefit COVID patients was weak or absent207,208. 
 
Clinical trials  
The search of clinical trials registers in June 2020 yielded 27 entries involving vitamin C. Three were 
observational studies, and 8 used vitamin C as a placebo (reportedly because vitamin C tablets are a 
similar size and appearance to the hydroxychloroquine tablets used in all these trials). Of the 
remaining 16 trials where vitamin C was, or was part of, the active compound under test, 2 did not 
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clearly state dose or mode of administration. Four trials involved dietary supplements of vitamin C 
combined with other micronutrients, herbal remedies or in one case methylene blue and n-acetyl 
cysteine. These trials target 1220 participants at various stages of SARS-CoV-2 infection; usually in 
mild disease or testing the prophylactic value in healthcare workers. Based upon prior trials of HDIVC 
in patients with pneumonia, sepsis and cancers, 10 trials involve the intravenous administration of 
vitamin C.  
 
The 10 currently-registered trials of HDIVC for COVID involve a target of 2,758 adult patients 
hospitalised with significant-to-critical COVID disease. They range from Phase 1 to 4. Three studies 
involve single-day bolus treatments with 10-20g vitamin C (for a 70kg individual). The remaining 
studies use doses ranging from 14 to 66g per day over 3-8 days with total doses amounting to 
between 56 and 327g of vitamin C (again for a 70kg individual). The rationale for these mega-doses 
is mixed, with claims of both anti-oxidant and pro-oxidant mechanisms, sometimes within the same 
rationale statements. Note that these doses are between 150 and 730 times higher than the 
recommended daily intake, and 7 to 33 times higher than the US Institute of Medicine’s Tolerable 
Upper Limits for vitamin C209. These should be viewed as pharmaceutical trials having no reference 
to vitamin C’s normal physiological functions. Based upon the paucity of prior evidence the 
investment in such trials is questionable. 
 




The wide-spread distribution of the vitamin D receptor (VDR) and vitamin D-metabolising enzymes in 
cells and tissues, including those of the immune system, is evidence of a wide-role for vitamin D in 
health. The role of vitamin D in the immune system has been reviewed recently210,211, including in 
relation to COVID-19212–215, and spans aspects of the immune system including the maintenance of 
barrier defences, innate immune response and an immunoregulatory role in antigen presentation 
and the adaptive immune responses210,216,217. As part of the innate immune response, antimicrobial 
peptides play an important role in the first line of defence against infections, including in respiratory 
infections218.  Vitamin D is required for the production of anti-microbial peptides such as 
cathelicidins in macrophages and in the epithelial cells of the airways217 and in an RCT, vitamin D 
supplementation was shown to increase levels of antimicrobial activity in airway surface liquid219. 
Vitamin D can also reduce the production of pro-inflammatory Th1-type cytokines210,212 that are 
implicated in the cytokine storm associated with more serious COVID-19 clinical outcomes such as 
acute respiratory distress syndrome and multiple-organ failure212,220,221. The binding site for SARS-
CoV-2 is ACE2222. Studies have shown that higher levels of ACE2 can reduce acute lung injury from 
infection and that vitamin D can modulate the expression of enzymes balancing the expression of 
ACE2 and ACE (reviewed in223–225) providing a mechanism for a potential role for vitamin D in the 
prevention and progression of COVID-19. 25OHD concentration may decrease as part of the acute 
phase response so data from observational studies in acutely ill patients should be interpreted with 
a degree of caution226–228. 
 
Vitamin D deficiency (VDD) is prevalent across all continents, not only those at more extreme 
latitudes229–232 and certain groups are at particular risk including the elderly (especially those in care 
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homes), ethnic minorities (living at higher latitudes) and the obese. There is a strong overlap 
between groups at risk of COVID-19 morbidity and VDD (ethnic minorities, obese, institutionalised 
elderly). Groups identified at higher risk of serious illness with COVID-19233 are also at risk for VDD, 
not only from low circulating 25OHD per se, but also lower circulating vitamin D binding protein 
(DBP), e.g. in patients with renal or hepatic disease234. 
 
Human data from both observational studies and intervention trials support a role for vitamin D in 
the prevention of respiratory infections. Meta-analyses of observational data have found 
associations between low vitamin D status and both risk of acute respiratory infection235,236 and 
severity of symptoms236. A meta-analysis237,238 of individual participant data found a reduced risk of 
acute respiratory infection (aOR (95% CI): 0.88 (0.81 – 0.96)), particularly in individuals receiving 
regular (weekly or daily) vitamin D supplementation and in those with baseline 25OHD < 25 nmol/L 
(0.30 (0.17 – 0.53). More recent trials of respiratory infection prevention in children and adults have 
reported both a beneficial239–241 and no effect242–245 of vitamin D supplementation. The findings from 
a recently published large trial (n 5110) in New Zealand found no effect of a bolus dose of vitamin D 
on the incidence of acute respiratory infection246. The results of another large trial in 25,871 men 
(≥50 y) and women (≥55 y) of vitamin D and/or omega-3 fatty acids found no reduction in all-cause 
mortality whilst results for respiratory conditions are yet to be published247,248 
 
Genetic polymorphisms within the genes for DBP, vitamin D-metabolising enzymes and the VDR may 
affect vitamin D transport, metabolism and action. Polymorphisms within the DBP have a small 
effect on DBP and 25OHD concentration249 and metabolism250 as well as response to 
supplementation251,252. VDR polymorphisms may impact the risk and progression of disease although 
results are mixed253,254. A recent meta-analysis in relation to enveloped-virus infection (a group that 
includes coronaviruses) found significant associations between certain VDR polymorphisms and 
susceptibility to respiratory syncytial virus255. 
 
Systematic review 
From a total of 59 papers returned from Pubmed and Embase searches, 9 were taken to full text 
screen and two papers224,256 were identified for full screen. D’Avolio et al. found that mean 25OHD 
concentration measured a median 3 days after a COVID-19 PCR test was lower in 27 PCR-positive 
patients compared with 80 PCR-negative patients (28 vs 62 nmol/L; P=0.004)256.  In an ecological 
analysis, Ilie et al. observed an inverse correlation between both COVID-19 case numbers and 
mortality figures against published population mean 25OHD concentrations (both r  = -4; p=0.05) 
across 20 European countries224. 
 
Screening of pre-print servers revealed a total of 38 manuscripts after exclusion of those previously 
identified from the Pubmed/Embase search. Of these, six were taken to full review.  
 
Manuscripts described observational studies and investigated 25OHD concentration in COVID-19 
positive cases. Three studies had fewer than 20 participants with both COVID-19 and vitamin D test 
results, and no control group; 2 reports measured 25OHD concentration in hospital in-patients: 
Cunat et al. reported 13/17 intensive care unit patients had 25OHD concentration less than 31 
nmol/L257 whilst Lau et al. found that 11/13 ICU patients had 25OHD < 75 nmol/L compared to 4/7 
in-patients, although there was no significant difference in mean 25OHD concentration between 
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groups258. A third report from Indonesia in 10 hospitalized COVID-19-positive patients, found that 
9/10 had a 25OHD concentration less than 50 nmol/L and 4/10 less than 25 nmol/L259.  
 
A larger Belgian study described lower 25OHD concentrations and greater prevalence of VDD 
(defined as < 50 nmol/L) in a group of hospitalized COVID-19 patients (n 186) compared with a group 
of 2717 patients of similar age distribution sampled a year earlier (47 nmol/L and 54 nmol/L, 
p=0.0016; 59% vs 45%, p=0.0005). However, when stratified by sex, the significant difference in 
25OHD concentration and VDD only remained in males260. In a study of 499 hospitalised patients or 
health care workers in the USA (Chicago) with a COVID-19 test result and vitamin D status 
measurement (in the past year) there was no difference between COVID-19 positive and negative 
cases (p=0.11)261. An expanded analysis that sought to categorize the vitamin D status of an 
individual based on (1) their vitamin D status test result and (2) vitamin D treatment regimen in the 
previous 2 years found that participants who were predicted ‘vitamin D deficient’ had an increased 
risk (relative risk  = 1.77, p<0.02) of testing positive for COVID-19 compared with participants with 
predicted vitamin D status of ‘likely sufficient’261.  In a different approach, Haustie et al. used 
baseline UK Biobank data from 348,598 participants collected 10 to 14 years ago of whom 449 had a 
positive COVID-19 test in between March and April 2020. After inclusion of other factors such as 
season, ethnicity and other health conditions there was no significant association between 25OHD 
and COVID-19 infection (OR = 1.00; 95% CI = 0.998 - 1.01)262. 
 
Two additional studies were identified from reference screening. A study from the Philippines found 
that in 212 COVID-19 hospitalized patients, vitamin D status was associated with clinical outcomes 
such that for each standard deviation increase in 25OHD concentration, the odds of having a mild 
clinical outcome rather than a severe or critical outcome were 7.94 and 19.61, respectively  (CI not 
reported)263. A study of 780 COVID-19 positive hospital patients found that after correction for age, 
sex and comorbidity the odds ratio of death was 10.2 p<0.0001 (95% CI not reported) in cases with 
VDD (defined as < 50 nmol/L) compared with ‘normal’ vitamin D status (defined as 75 nmol/L)264. 
However, this study has since been discredited265. 
 
Clinical trials 
Searches of clinical trials databases revealed 21 planned or ongoing studies related to vitamin D and 
COVID-19. Of these four were observational studies. The remaining 17 focussed on treatment 
(including disease progression) (n 12), prevention (n 2) or both prevention and treatment (n 2). Of 
the four prevention studies, vitamin D is registered as the main intervention for one trial, whilst two 
use vitamin D as an adjuvant with hydroxycholoroquine and one as a placebo. Of the remaining 13 
trials, four use vitamin D in all groups, two as an adjuvant to the main treatment and seven either 
vitamin D3 (between 25 µg daily to single, bolus dose of 10 mg), vitamin D2 (1.25 mg twice weekly) 
or 25OHD (0.266 mg daily) as the primary intervention (one in combination with zinc). Study size 
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11. Vitamin E 
 
Landscape review  
 
Vitamin E is the collective term for 4 tocopherols and 4 tocotrienols266. Human dietary requirements 
are based on α-tocopherol, but there is increasing evidence of biological functions for the related 
compounds, including in relation to immunity267.  Vegetable oils and nuts are rich sources of vitamin 
E and hence human deficiency is rare; thus the interest in vitamin E and immunity is frequently 
related to the question of whether supplementary vitamin E might improve immunity in at-risk 
subgroups such as smokers or the elderly. 
 
The main biological role of vitamin E is as an anti-oxidant that quenches oxidative cascades 
especially of membrane poly-unsaturated fatty acids (PUFAs) in which it is highly soluble and hence 
penetrant266. Animal, human and cell culture studies have examined the role of supplemental 
vitamin E on a wide range of innate and adaptive immune cells. Numerous possible mechanisms of 
action are postulated (maintenance of cell membrane integrity, increased (and decreased) cell 
proliferation, increased IL-2 and decreased IL-6 production, enhanced immunoglobulin production, 
etc) but few confirmatory studies are available266,267. 
 
Due to their dual and overlapping roles in antioxidant pathways there are close parallels between 
selenium and vitamin E with regard to immune function; roles that have been best studied in regard 
to viral infections. In the section on selenium, we describe the work by Beck and her team 
demonstrating that the virulence of coxsackie B3 and influenza H3N2 viruses is enhanced in 
selenium deficient hosts resulting from systematic viral mutations (see section 13). Beck’s team have 
used the same mouse protocol with vitamin E deficient mice and demonstrated that the viral 
mutation and enhanced pathogenicity is recapitulated with either or both selenium and vitamin E 
deficiency268–271, an effect that is enhanced in iron-loaded animals due to the increased oxidant 
stress. 
 
The evidence for interactions between vitamin E status or supplementation and viral infections in 
humans is sparse and there are no available meta-analyses as a consequence. A recent (non-
systematic) review has tabulated summary outputs from 8 studies of human infections of which 5 
relate to respiratory infections266. Several of the studies involved post-hoc sub-group analysis of 
smokers and hence have questionable validity and poor generalisability272,273. The best study was a 
2x2 factorial design of multivitamin-mineral or vitamin E supplementation in free-living adults >60 
years old274. In 652 participants with 1024 respiratory infections there was no benefit of either 
regime in reducing incidence, and some evidence that vitamin E made the infections more serious274. 
 
Systematic review  
 
Results from the systematic literature review for vitamin E are highlighted in Supplementary 
Material 3. From a total of 39 papers returned, 9 duplicates were removed and 30 titles and 
abstracts screened. Six review papers were considered for full text screen and to check reference 
lists for possible papers. None had substantive novel relevant information. 
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The search of preprint servers yielded four papers of which two were accessed for full review; these 
were both general reviews and lacked substantive new information in relation to coronaviruses or 
severe ARDS207,208.  
 
Clinical trials  
 
The search of clinical trials registers yielded a single entry (NCT04323228) involving a very small 
study (n=30) in Saudi Arabia with vitamin E administered to 15 patients as part of a broad 
antioxidant cocktail.  
 
12. Poly-unsaturated fatty acids (PUFAs) 
Landscape review  
Long-chain poly-unsaturated fatty acids (LC PUFAs) are classified into two series (ω-3 or ω-6) 
according to the position of their double bonds. Both series have extensive immunomodulatory 
activity with ω -3 PUFAs tending to be anti-inflammatory and ω-6 PUFAs tending to be pro-
inflammatory. ω -3 fatty acids are abundant in fish oils and ω-6 in vegetable oils. The ω-3 and ω-6 
synthetic pathways compete for the same elongase, desaturase and ω-oxidation enzymes and hence 
the ratio of ω-3 to ω-6 series can be especially crucial. Comprehensive reviews of the 
immunomodulatory effects of PUFAs are available elsewhere275–280. 
In brief, LC PUFAs exert immunomodulatory effects through a number of generic mechanisms. 
Eicosapentaenoic acid (EPA; ω-3) and arachidonic acid (ARA; ω-6) are precursors of eicosanoids; ARA 
generates inflammatory-type eicosanoids and EPA-derived eicosanoids tend to be anti-
inflammatory277,279; a property that may be crucial to COVID-19 disease (see below)276. When 
incorporated into cell membranes LC PUFAs can beneficially modulate the activity of T-cells and 
other components of cellular immunity279. They also modulate cytokine responses; with ω-3 fatty 
acids tending to enhance IL-10 and suppress IL-6 production as well as inhibiting NF(κB)279. More 
recently PUFAs have been shown to play a crucial role in the production and action of specialised 
pro-resolution mediators (SPMs) that play a crucial role in ending the inflammatory cycle and 
thereby avoiding an excessive inflammatory response and cytokine storm. EPA and DHA 
(docosahexaenoic acid; ω-3) are precursors for resolvins and DHA is the precursor for protectins and 
maresins276. 
Despite the wealth of biochemical evidence for key roles of ω-3 PUFAs in anti-inflammatory 
pathways the evidence of clear roles in human health is less robust. Meta-analyses with a range of 
health outcomes have failed to provide evidence for efficacy and in those where efficacy seems 
secure it is usually only achieved at high doses. 
There have been several meta-analyses of the effects of ω-3 fatty acids from fish oils on critically ill 
patients. Due to differences in selection criteria and outcome measures the outcomes are varied. In 
2018, Koekkoek et al.281 reviewed 24 RCTs of fish-oil containing enteral  nutrition involving 3574 
patients. There was no significant benefit on the primary outcome of 28d, ICU or hospital mortality. 
However, fish-oil administration significantly reduced length of stay (LOS) in ICU and duration of 
ventilation. In a pre-planned subgroup analysis there was a reduction in 28d mortality (OR 0.69, 
95%CI 0.54-0.89), ICU LOS (-3.71 days, 95%CI -5.40 - -2.02) and duration of ventilation (-3.61 days, 
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95%CI -5.91 - -1.32) in patients with acute respiratory distress syndrome (ARDS). In 2019, Langlois et 
al.282 conducted a meta-analysis of the RCTs of ω-3 PUFA administration on gas exchange (PaO2-to-
FiO2) and clinical outcomes in 12 trials involving 1280 ARDS patients. There was a significant early 
increase in PaO2-to-FiO2 that diminished but remained significant at days 4-7. There were non-
significant trends towards reduced ICU LOS and duration of ventilation but not improvement in 
mortality, length of stay in hospital or infectious complications. Also in 2019, Dushianthan et al.283 
meta-analysed 10 RCTs of enteral ω-3 supplementation in a total of 1015 ARDS patients. There was 
no benefit to all-cause mortality (OR 0.79, 95%CI 0.59 – 1.07) or any of the secondary outcomes. All 
of these meta-analyses encountered studies with high risk of bias and poor-quality evidence. 
Systematic review  
From a total of 37 papers returned, 5 were taken to full screen, and none yielded relevant 
information not already considered.  
The search of pre-print servers yielded one paper284 that extensively reviews the role of 
inflammation and the cytokine storm in lung damage but cites no supportive evidence for a 
modulating role of PUFAs other than that already reviewed above.  
Clinical trials  
Notwithstanding this rather weak evidence of benefit in critically-ill patients including those 
requiring ventilation there have been calls for clinical trials of intravenous high-dose fish-oil lipid 
emulsions (FOLE) in hospitalized COVID-19 patients285,286. The first of these recommends use in 
patients at special risk of hyperinflammatory outcomes (e.g. the obese)285. In the second call, 
Torrinhas et al. emphasise the need to tailor dosage to body weight, recommend its use in all 
patients and that it should be combined with aspirin286. A very comprehensive summary of the 
putative benefits of high-dose fish oil has recently been published276. Despite these calls for 
intravenous FOLE trials, none have yet been registered. 
The search of trial registers yielded three trials that had PUFA in the active intervention arm (see 
Supplementary Material 4). The two trials in hospitalized patients in the USA are testing 
eicosapentaenoic acid (EPA). One of the trials combines the EPA with docosahexaenoic acid (DHA) 
and gamma linolenic acid (GLA) plus additional antioxidant micronutrients. The third trial, in Latin 
American countries, will test whether icosapent ethyl (IPE) will prevent occurrence of COVID in at-
risk health providers. Severity of disease will also be compared against placebo. 
 
13. Selenium 
Landscape review  
There is very strong evidence that selenium, through its role as a cofactor in the two key anti-oxidant 
pathways in humans (reduction of glutathione and thioredoxin), plays a key role in host-virus 
interactions. An excellent and comprehensive recent review is available which covers both the host 
and (putative) viral aspects of selenoprotein actions287.  
The selenium content of staple cereals is strongly determined by the selenium content of soils 
which, prior to the use of selenium-enriched fertilisers or dietary supplements, caused regional 
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disease outbreaks of which the iconic example is Keshan Disease; a multi-factorial syndrome whose 
aetiology includes an interaction between selenium deficiency and coxsackievirus B (see below)288. 
Selenium is incorporated into the 21st amino acid, selenocysteine (where it replaces the sulphur of 
cysteine287). Gene mapping has identified 25 human selenoproteins of which 5 are glutathione 
reductases and 3 are thioredoxin reductases critical to the regeneration of anti-oxidant potential287. 
Activity of these enzymes is reduced in selenium deficiency. Whilst acknowledging that host-viral 
interactions can be modulated by both pro-oxidant and anti-oxidant factors, it is clear that anti-
oxidants are key players. In this respect there are overlaps between the actions of selenium and 
vitamins C and E summarised elsewhere in this review. 
The example of Keshan Disease provides a fascinating example of human, viral, dietary and 
environmental interactions with strong resonance with the emergence of SARS-CoV-2. Named after 
the Keshan region of China notable for selenium deficient soils, Keshan is a serious multisystem 
disorder affecting children and women of reproductive age269. A key feature is a congestive 
cardiomyopathy that has been linked to coxsackievirus B and can be modelled in mice. Inspired by 
prior studies in China289, Beck and colleagues passaged a benign variant of coxsackievirus B3 through 
selenium deficient and selenium replete mice290,291. The viral genome mutated in the deficient 
animals undergoing 6 nucleotide changes292, leading to myopathy and death290,291. Most critically, 
when the virus from the deficient mice was then passaged through healthy selenium-replete mice it 
retained its pathogenicity and caused the cardiomyopathy290,291. Although SARS-CoV-2 appears to be 
mutating slowly these studies contain a general warning that circulating viruses may be more likely 
to mutate to give highly-pathogenic strains with pandemic potential in nutritionally deficient 
populations.  
A meta-analyses of almost 2 million participants in 41 randomised trials has confirmed that selenium 
supplementation is highly protective against Keshan disease (OR 0.14; CI 0.012-0.016)293. 
Programmes of selenium enhancement in crops and direct supplementation of the population have 
largely eliminated Keshan disease from the Keshan district, though it remains prevalent in 
neighbouring regions including Tibet and North Korea.  
Beck and her team extended these studies to include the influenza A (H3N2) virus strain268,294. Using 
a similar experimental model they showed viral stability in selenium replete mice and high rates of 
mutation with downstream pathology in selenium deficient mice268,294. As with coxsackievirus the 
mutated strains retained their pathogenicity when re-passaged through healthy well-nourished 
mice10. Mechanisms by which selenium deficiency affect the host response to the virus were also 
described295–297. There has been little substantive new research activity in the field of selenium and 
viral infections by Beck’s group or others for the past decade. 
Systematic review  
From a total of 12 papers returned, 4 were taken to full text screen and 2 papers were identified for 
full screen. One of these listed selenium as part of a COVID-19 treatment protocol but listed no 
results. Zhang and Liu report a general systematic review of nutrition and coronaviruses but 
contained no new information not already summarized above298.  
The search of pre-print servers yielded four papers of which two were excluded. Of the remaining 
papers one was a systematic review299 and the other screened 12 organoselenium structural 
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analogues of the antioxidant drug ebselen for inhibition of the SARS-CoV-2 papain-like protease 
critical to viral replication300. Four possible drug targets were identified. 
Clinical trials  
Prior non-COVID-19 trials have investigated the impact of selenium supplementation in critically-ill 
patients in ICU (for a range of conditions not including ARDS). No fewer than nine meta-analyses 
have been performed with slightly different inclusion and grading criteria301–309. These analyses 
mostly agree that intravenous sodium selenite might yield a significant improvement in short-term 
mortality (meta-analysed ORs between 0.82 and 0.98), but in the latest Cochrane analysis the 
evidence was judged to be of very low quality due to potential to bias302. There was no effect on 
longer-term (28 or 90 day) mortality. Surprisingly, in the light of the robust animal data, there have 
been almost no trials of selenium and influenza or other respiratory infections. A randomised trial in 
25 geriatric centres in France reported a tendency toward slightly fewer respiratory infections in 
patients receiving zinc and selenium, and better responses to the A/Beijing/32/92(H3N2) component 
of a multivalent vaccine310. A smaller study of a selenium-containing micronutrient supplement in 
English nursing homes found no effect on antibody titres after influenza vaccination311. In a small 
randomised trial, Ivory et al.312 reported no effect on mucosal influenza antibody responses to 
vaccination and both positive and negative effects on cellular immunity. Another small study 
reported that marginally deficient adults given selenium supplements had faster elimination of 
vaccine strains of poliovirus and fewer mutations in viral product extracted from faeces313. 
The search of trial registers yielded two listed trials. In one of these small doses of selenium are 
included in the control arm. The other was a very small Phase 4 trial in which low dose selenium 
forms part of an antioxidant cocktail administered to both arms. There were no listed trials of 
intravenous selenium, suggesting that the null or very marginal results from previous trials in ICU 
patients have discouraged further endeavours. 
 
14. Zinc 
Landscape review  
Zinc is an essential trace element crucial for growth, development and the maintenance of immune 
function314. It is the second most abundant trace metal in the human body after iron, and an 
essential component of protein structure and function314. The global prevalence of zinc deficiency is 
estimated to range from 17-20%, with the vast majority occurring in low- and middle-income 
countries in Africa and Asia315. Zinc deficiency is also common in sub-groups of the population, 
including the elderly, vegans/vegetarians, and individuals with chronic disease such as liver cirrhosis 
or inflammatory bowel disease314,316,317.  
Zinc is required for a wide variety of immune functions318 and those deficient in zinc, particularly 
children, are prone to increased diarrhoeal and respiratory infections. Zinc supplementation has 
been shown to significantly reduce the frequency and severity of both infections in children319, 
although such findings are not universal (e.g. Howie et al.320) and a recent systematic review and 
meta-analysis found no evidence that adjunctive zinc treatment improves recovery from pneumonia 
in children in low- and middle-income countries321. Similar to vitamin C, zinc supplementation has 
also been suggested as a potential remedy for the treatment of the common cold (rhinovirus 
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infection); a meta-analysis of 3 trials reporting on 199 patients supports a faster recovery time322 
although the small sample size (N=199) of included studies warrants caution.  
At the molecular level, zinc is an essential component of protein structure and function and is a 
structural constituent of ~750 zinc-finger transcription factors, enabling gene transcription314,323. It is 
also a catalytic component of approximately 2000 enzymes324. The role of zinc homeostasis in 
antibacterial immune responses is well-documented; binding and sequestering extracellular zinc 
(and calcium) can prevent bacterial and fungal overgrowth325 while toxic endosomal zinc 
accumulation can inhibit intracellular Mycobacterium growth in macrophages326. For viral infections, 
however, these mechanisms are less well described although a number of new hypotheses are now 
being suggested327.  
The SARS-CoV-2 pandemic has resulted in a global search for suitable antiviral and 
immunomodulatory candidates. Attracting global attention at the start of the pandemic was the 
potential use of oral chloroquine (CQ) and hydroxychloroquine (HQ), prescription drugs normally 
used for the treatment of malaria. Emerging trial evidence, however, does not support the use of 
either CQ or HQ as a treatment option for the disease328–330. Of relevance to the current review is the 
finding that CQ has characteristics of a zinc ionophore and specifically targets extracellular zinc to 
intracellular lysosomes331. This has led to an interest in zinc as a potential target for anti-viral 
therapies, most notably in combination with CQ/HQ in clinical trials for the prevention or treatment 
of SARS-CoV-2332. 
Systematic review  
 
From a total of 69 papers returned (after removal of eight duplicates), six were taken to full text 
screen. On full screen five papers were rejected as ineligible and one review paper, although 
ineligible for this review as it included no new data presented, highlighted the potential synergistic 
action of zinc and CQ in patients with SARS-CoV-2333.  
A review of preprint listings returned 10 potentially relevant papers. Five of these were duplicates 
(already identified via PubMed or EMBASE). Four were found to be review articles, with no novel 
data specific to COVID-19 disease susceptibility or progression. Only a single paper was eligible for 
inclusion, a retrospective observational study comparing hospital outcomes (New York, USA) among 
patients who received HQ and azithromycin plus zinc versus HQ and azithromycin alone334. Using 
data from 932 patients admitted over a one-month period (March-April 2020) the authors found 
that addition of zinc sulphate did not impact the length of hospitalization, duration of ventilation, or 
ICU duration. In univariate analyses, zinc sulphate increased the frequency of patients being 
discharged home, and decreased the need for ventilation, admission to the ICU, and mortality or 
transfer to hospice for patients who were never admitted to the ICU. After adjusting for the time at 
which zinc sulphate was added to the protocol, an increased frequency of being discharged home 
(OR 1.53, 95% CI 1.12-2.09), and a reduction in mortality or transfer to hospice remained significant 
(OR 0.449, 95% CI 0.271-0.744). These data provide initial in vivo evidence that zinc sulphate may 
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Clinical trials  
 
A screen of registered trials revealed 16 studies of potential relevance. On review, three were 
removed; one was an observational case-control study and in a further two studies zinc was not 
included in any of the experimental arms. Of the remaining 13 trials, only a single trial (USA, n=520) 
is designed to fully assess the impact of zinc, in a four-arm trial of outpatients who test positive for 
SARS-CoV-2 and comparing vitamin C (8000mg/d) vs zinc (50mg/d) vs vitamin C + zinc (doses as 
before) vs standard of care (NCT04342728). In a further treatment trial among SARS-CoV-2 patients 
in Senegal (n=384), zinc (20mg/d) is being used as the control arm in a trial of HQ plus azithromycin 
(two arms with differing dosing regimens) (PACTR202005622389003). In four trials, zinc (at doses 
ranging from 15 to 250mg/d) is being administered in combination with other antiviral drugs 
including HQ, HC and azithromycin, HC and doxycycline or favipiravir. In the remaining seven trials, 
zinc is being provided in combination with single or multiple other micronutrients, including vitamin 
C, and vitamin B12 and, therefore, the potential therapeutic benefits of zinc as a single 
micronutrient cannot be established.  
15. Antioxidants 
Landscape review  
During severe COVID-19, the SARS-CoV2 virus can trigger a strong host immune response. This can 
then result in the production of high levels of free radicals by both macrophages and neutrophils and 
the induction of severe oxidative stress335. Oxidative stress causes protein and lipid oxidation which 
then further activates and amplifies the immune response creating a self-amplifying loop which can 
result in extensive tissue damage336.  
Oxidative stress is currently thought to be a major cause of the pathophysiology of severe COVID-19 
infections and has previously been implicated as a mediator in acute respiratory distress 
syndrome337. The level of oxidative stress may indeed determine the intensity of the organ damage 
seen during severe COVID-19 specifically to endothelial, pulmonary, cardiac and immune cells338. In 
addition, increased levels of oxidative stress pre-exist in individuals with co-morbidities such as 
obesity, diabetes and cardiovascular disease, and may play a role in increasing the risk of severe 
COVID-19 in these groups339. 
Antioxidants decrease oxidative stress and can be broadly divided into four groups: (1) Endogenous 
antioxidants which include molecules (e.g. glutathione, uric acid and transferrin), vitamins (such as 
Vitamin A, C, and E) and enzymatic co-factors (e.g. selenium and zinc) synthesized by the human 
body; (2) Dietary antioxidant molecules and vitamins found in food (e.g. fruit, vegetables, green tea, 
olive oil and red wine); (3) Nutritional supplement antioxidants which include supplements that 
contain increased doses of dietary antioxidants (e.g. vitamin C or quercetin tablets), molecules from 
medicinal plants (e.g. molecules found in traditional Chinese medicine), and (4) Synthetic molecules 
or drugs with known antioxidant activities (e.g. N-acetyl cysteine and metformin).  
There is an abundance of epidemiological and in vitro evidence to suggest that levels of endogenous 
antioxidants and increased consumption of dietary antioxidants may decrease inflammation and 
oxidative stress213, particularly in patients with cardiovascular disease340.  
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However, there is a lack of clinical evidence that consuming antioxidants from dietary sources or 
giving acute doses of naturally occurring antioxidants has direct long-term clinical benefits in the 
treatment of chronic conditions or acute viral infections341.  Some relevant evidence exists for the 
clinical utility of a synthetic antioxidant, N-acetyl cysteine, which is also an FDA-approved drug for 
the treatment of paracetamol toxicity. N-acetyl cysteine has been shown to have some modest 
benefit in ARDS342 and there is limited evidence that it improves clinical outcomes in several viral 
diseases including HIV343, hepatitis A344, H1N1 influenza345, dengue346–348, and rotavirus infection349. 
Systematic review  
From a total of 212 papers returned, 44 were taken to full text screen. Nineteen papers were 
commentaries or non-systematic reviews. In no case was there any new data related to antioxidants 
as a clinical therapy for COVID-19. Note that information on COVID-19 and vitamins A, C and E as 
well as selenium and zinc have been reviewed in separate sections of this manuscript and those 
papers were not included here.  
The search of preprint servers yielded six relevant papers all of which were accessed for full review. 
All were commentaries or editorials. None contained any new data on antioxidants as a treatment or 
preventative therapy for COVID-19.  
Clinical trials  
The search of clinical trials registers yielded eight entries involving antioxidants (that were not 
vitamins A, C or E) (Supplementary Material 4). Of the eight trials, three involved dietary 
supplements containing a mixture of antioxidants and other molecules. The remaining five are 
testing the following molecules: Reservatrol, Silymarin, Quercetin, N-acetyl cysteine and melatonin.  
These trials target participants at various stages of SARS-CoV2 infection.  
 
16. Nutritional Support 
Landscape Review 
Evidence on best practice for nutritional support for patients with COVID-19 is currently lacking350. In 
those infected, 80% have a mild condition (not requiring hospitalisation) whilst 20% require 
inpatient care and 5% will require intensive care351,352. In the 80% with mild disease there is a 
growing body of evidence that the course of illness may take several weeks and in some cases many 
months for recovery and have multiple complications along the way353. 
In those admitted to hospital, nutritional support guidelines and advice are generally based on 
evidence drawn from treatment of viral pneumonia, sepsis and ARDS. Specific evidence in relation to 
COVID-19 is not available as yet, but a pragmatic approach and “doing what we know, and doing it 
well” has been adopted in most settings. There is a huge wealth of literature on nutritional support 
in critically ill patients354, which is beyond the scope of this review, but we will briefly discuss 
consensus on best practice. 
Nutritional support during an acute illness has long been recognised as an important component to 
care355. In an acute, severe illness there is a high risk of catabolism and the resulting malnutrition 
and sarcopenia can impact both on mortality and morbidity354,356. 
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Recommended nutritional support varies in mild, severe and critical disease but there are 
overarching considerations which can be divided into patient factors, healthcare staffing factors and 
system factors357. Patient factors overlap in all disease states. There may be the need for special 
nutritional intervention in mild disease especially in those with pre-existing conditions such as 
diabetes, heart failure and other cardiac or chronic diseases. These may be exacerbated by an acute 
viral illness, especially if diarrhoea, vomiting or anorexia are present. A study from a rehabilitation 
centre in Italy, focused on patients once they were past the acute phase of their illness, found 45% 
of COVID-19 infected patients were at risk of malnutrition358. At the peak of cases, when healthcare 
systems have the potential to be overrun, the staffing shortages and other demands would make 
this easy to neglect to the detriment of the patients.  
Patients with severe disease are usually admitted to hospital. There is consensus that all patients 
admitted with COVID-19 should have their nutritional status assessed56,359. There are a number of 
important and practical considerations that affect nutritional care: 
• Risk of hypoxia on removal of oxygen delivery device (mask or non-invasive ventilation) to 
eat and drink. 
• Ability to remove oxygen delivery device independently to eat and drink. 
• Ease of access to food and drink. 
• Air leakage with non-invasive ventilation (NIV) mask due to nasogastric (NG) tube. 
 
These factors, along with isolation of COVID-19 patients in single rooms, limited visits by healthcare 
workers due to the need to conserve PPE and reduce risk of transmission, and limited visits by family 
or friends, mean there is a real danger of malnutrition and dehydration359.  
A solution to this is the adoption of an early nutritional supplementation program as detailed in the 
study by Caccialanza et al56. In this feeding protocol all patients were screened at admission using a 
simplified nutritional risk score and due to a high number of patients being unable to meet their 
nutritional needs on a normal diet, all patients were started on whey proteins (20g/day) and 
multivitamins, multiminerals and trace elements supplement. Those at nutritional risk were then 
commenced on 2-3 bottles of Oral Nutritional Supplements (ONS) and escalated to parenteral 
nutrition (PN) should they be unable to tolerate oral intake. 
Another solution adopted in the UK is the “Every Contact Counts” model, where patients are offered 
food and drink at every encounter with health professionals359.  
Both the consensus statement by nursing practitioners in China and the ESPEN expert statement 
agree on the following steps58,360: 
• Early screening for risk of malnutrition 
• Individualized nutritional plans 
• Oral Nutritional Supplements to be used 
• Parenteral nutrition should be initiated within 3 days should enteral nutrition (EN) not meet 
nutritional requirements 
• Ongoing monitoring of nutritional status 
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ESPEN give the following additional details: 
• Aim for 30 kcal/kg/day to meet energy needs (may need to be adjusted in certain 
populations) 
• 1g/protein/day (may need to be adjusted in certain populations) 
• Fat: carbohydrate ratio in non-ventilated patients 30:70 
 
Whichever approach is taken, prevention of inpatient malnutrition and its associated complications 
must be considered an essential component to clinical care and requires monitoring throughout the 
illness. 
The ESPEN guidelines on nutritional support of patients admitted to ICU and the document 
specifying treatment in those with COVID-19 are thorough and comprehensive58,354. These guidelines 
as well as the guidelines from the American Society for Enteral and Parenteral Nutrition are based 





Energy Expenditure calculated 
by either: 
1) Indirect calorimetry 
2) VO2 
3) VCO 








Feeding commenced within 48 hours of 
admission 
  Day 3-7 / acute phase late period  
Hypocaloric intake: < 70% of EE 
 
  Day 7 onwards / late phase rehabilitation 
or chronic phase: 
100% EE 
 




Minimal: 150g/day Upper limit: 5mg/kg/day 
Lipids 
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propofol 
Upper limit: 1.5mg/kg/day 
 
COVID-19 patients in ICU have a few special considerations relating to treatment and nutrition. For 
example, many patients required proning during the course of their ventilation and there is 
consensus in all guidelines on EN feeding being safe to continue as long as awareness of 
complications with NG placement and specified steps to minimize this were taken. Depending on the 
severity of lung injury and its availability, there can be many patients requiring extracorporeal 
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membrane oxygenation (ECMO) and there was consensus in all guidelines that EN feeding can be 
started at trophic or hypocaloric levels. Use of PN differed, with American guidelines advocating 
early implementation and European and Chinese guidelines taking a more cautious case-by-case 
approach. Finally nutritional support may well be needed post ICU discharge with high rates of 
dysphagia being reported358,361.  
Systematic review  
Our systematic search yielded 17 papers for full review, none of which met the criteria for inclusion. 
Of the pre-prints, 15 were reviewed and none met the full criteria. 
Clinical trials  
Sixteen clinical trials were identified through our search and two were relevant to nutritional 
support (Supplementary Material 4). One has not yet started recruitment and aims to describe 
nutritional consequences of COVID-19 in patients discharged from hospital (based in France). The 
other aims to validate the use of a nutrition scoring tool “NUTRIC” in Chinese ICU patients diagnosed 
with COVID-19, results pending.  
 
17. Discussion  
 
As the pandemic continues to evolve at rapid pace, so does our understanding of the epidemiology 
and underlying mechanisms of the SARS-CoV-2 virus. However, despite the wealth of literature being 
published, the evidence directly linking nutritional status to the risk and progression of COVID-19 is 
still sparse. In Figure 2 we summarise the key themes emerging from our landscape and systematic 
reviews. 
 
Nutritional status has the potential to influence susceptibility to the risk of COVID-19 through its 
integral role in immune function. For example, above we have covered some of the ways 
micronutrients support mucosal immune function (vitamin A), epithelial tissue integrity (vitamins A, 
C and D), enhancing the function of certain adaptive and innate immune cells (vitamins A, C, D, E, 
iron, zinc and PUFAs) and potential pro-oxidant effects (vitamin C). Undernutrition, overweight, 
obesity and type-II diabetes are all associated with impaired immunity, through independent 
(though as yet not clearly defined) mechanisms as well as through the effects of concurrent 
micronutrient deficiencies. The various presentations of overnutrition have been the most 
frequently documented nutrition-related co-morbidities amongst patients admitted to hospital with 
COVID-19 to date. However, many markers of micronutrient deficiency are not routinely measured 
on hospital admission. Furthermore, at the time of writing, the pandemic is still penetrating LMICs, 
where the burden of undernutrition is higher. We therefore anticipate further evidence on the 
potential impact of undernutrition on COVID-19 susceptibility to be generated soon.  
 
The influence of nutrition on immune function can also affect the progression of viral infections, 
with implications for the length, severity and final outcomes of disease episodes. From our 
landscape reviews we only have limited insight from other viral diseases as to how nutritional 
supplementation may potentially influence outcomes. For example, although there is strong 
evidence of an association between vitamin A supplementation and reduced outbreaks of measles, 
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there is insufficient evidence regarding the association with Ebola outcomes. For vitamin C there is 
some positive, but inconsistent, evidence regarding supplementation and the prevention of 
pneumonia, but very limited evidence describing an effect of supplementation on overall mortality 
reduction. For vitamin D we have mixed evidence describing the influence of supplementation on 
both the risk and severity of acute respiratory infections. For the minerals, we have documented 
evidence of an association between iron deficiency and increased risk of impaired lung function in 
hypoxic conditions, and literature describing the association between zinc supplementation and 
reduction of diarrhoea and respiratory infections. It is important to note, however, that not all 
evidence of nutritional supplementation points to positive, or null, outcomes. For example, we have 
described how there is some evidence linking vitamin E supplementation to the worsening of 
respiratory infections. Furthermore, some studies have found evidence of associations between iron 
supplementation or elevated iron status with increased risk of malaria, bacterial infections, HIV-1 
progression, and certain respiratory infections.  
 
However, when it comes to COVID-19 explicitly, our ability to draw conclusions between nutritional 
status and disease progression is limited by the current lack of high-quality data. We have 
documented some observational studies describing an association between lower vitamin D status 
and increased COVID-19 infection. We noted that a single observational study suggested treatment 
with zinc sulphate showed signs of reduction in mortality and increased discharge from hospital to 
home in patients treated with hydroxychloroquine and azithromycin. However, more recent findings 
from the Recovery trial find no beneficial effect of HQ in the absence of zinc362. We also summarised 
some observational studies that described how patients presenting with malnutrition on hospital 
admission (both under- and over-nutrition) have increased risk of mortality from COVID-19. With 
studies on undernutrition in particular, it is not easy to distinguish between the effect of pre-existing 
undernutrition on immune function and increased disease severity, and the subsequent nutritional 
impact of prolonged inflammatory states and intensive care admission through impaired appetite 
and dysregulated metabolism.  
 
The literature has, however, highlighted some hypotheses regarding mechanisms through which 
nutrition could modulate disease severity and progression. Particularly relevant to COVID-19 is the 
role anti-oxidants may play in reducing the impact of the cytokine storm during the acute phase of 
the infection. This has to be carefully balanced against not overly dampening the immune response 
during other phases of the illness, as described in detail in Iddir et al.213. Of the micronutrients 
covered in our review, vitamins A, C, E, and certain dietary polyphenols have potentially important 
roles in quenching free radicals through their anti-oxidant properties, alongside zinc and selenium in 
their coenzyme roles. Synthetic anti-oxidants can be produced and are being tested for effectiveness 
in mitigating the damage from the cytokine storm, and it is not yet clear to what extent dietary 
components will play a synergistic role. 
 
Micronutrients may help slow down processes vital for viral replication. For example, we have 
described how vitamin D may influence the expression of ACE2, implicated in SARS-CoV-2 binding. 
Animal studies have shown, tentatively, how deficiencies in selenium and vitamin E may increase 
viral replication as well as enhancing virulence and mutation rates.  
 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
35 
 
To date, the role of nutritional support in the clinical management of severe COVID-19 cases is based 
on knowledge from successful protocols used in other viral infections and, more generally, in 
recovery from intensive care. There are, however, some new treatment regimens being tested. 
Treatments comprising combinations of various antioxidants are currently being investigated in the 
early stages of intervention trials. It is not be possible to separate out the effects of individual 
micronutrients in these treatments. Higher doses of vitamins A, C, and D are also being trialled, 
some intra-venously, but there is limited prior evidence to suggest they will be successful and many 
trials do not seem to take account of normal physiological thresholds. For the minerals, the potential 
role of iron chelation in reducing iron-induced lung toxicity is being considered. Zinc features mainly 
as an adjunct therapy alongside chloroquine and hydroxychloroquine interventions, although 
interest is growing in its potential as an intervention in its own right. Nutritional supplementation 
will require careful consideration of the extent to which the suggested micronutrients can be 
utilised, especially during acute inflammation and the related states of anaemia of inflammation. It is 
likely a period of stabilisation to bring down inflammation will be essential before any positive 
effects from micronutrient supplementation can be seen156,363.  
 
In this review we have focussed on the direct relationship between nutritional status and risk of 
infection and progression of COVID-19. This is an important but incomplete part of the vicious cycle 
of nutritional status, immune response and infection. Beyond the scope of this review, but integral 
to the overall picture, are the impacts the pandemic has on livelihoods and health, that are 
inextricably linked to nutritional status and therefore overall morbidity and mortality. We know from 
the Ebola outbreak in West Africa during 2013-16 that disruption to the health system brought 
about excess mortality equal to, if not greater than, direct deaths from the infection itself364. The 
disruption from COVID-19 to food systems, the economy and health infrastructure means that 
nutritional status of the most vulnerable will be enormously impacted. Headey et al. summarise 
recent estimates from modelling, suggesting that an additional 140 million people are expected to 
fall into extreme poverty due to the pandemic in 2020 alone, with a doubling of people facing food 
insecurity (estimated at 265 million)8. An estimated 14.3% increase in wasting prevalence in children 
under 5 will equate to an additional 6.7 million children wasted compared to estimates without 
COVID-198. Furthermore, the increase in numbers of people facing acute nutritional vulnerability will 
be compounded by the reduction in health services offered to the population during the pandemic. 
Roberton et al. modelled scenarios estimating impacts of different levels of disruption to availability 
of health workers and supplies, and on demand and access to health services. Even in the best case 
scenario they estimated the additional prevalence of acute malnutrition and reduced coverage of 
health services would result in an additional quarter of a million child deaths in the next 6 months365.  
 
Many consortia have highlighted the urgency of tackling the immense impact of the pandemic on 
nutrition and health outlined above. Recommendations point both to nutrition-specific strategies, 
such as prevention and treatment of wasting, vitamin A supplementation, and breast-feeding 
support;366 and to nutrition-sensitive strategies, such as strengthening the food-supply chain, 
providing safety net programmes, implementing community-led sanitation initiatives, improving 
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Strengths and limitations of the review 
 
Our review provides a synthesis of information to complement other existing comprehensive 
reviews207,213. However, to our knowledge ours is the most detailed systematic search to date, 
bringing together 13 separate systematic reviews. Our inclusion of material from pre-print servers 
and trial registries adds to the breadth of information we have been able to include. 
 
The pandemic is evolving rapidly and new evidence has likely surfaced since our search dates. Whilst 
the collation of 13 reviews in this article provided breadth, we were unable to ensure all searches 
took place exactly synchronously. We did not perform a risk of bias assessment of the included 
literature, and it is important to note that pre-prints are not peer-reviewed. Our inclusion criteria of 
literature written in English may have missed some pertinent information in other journals. We 
necessarily had to limit our scope to the most important nutrition-related conditions and 
micronutrients of interest. However, this is incomplete, and other potentially relevant areas of 
interest include the role of macronutrient intake, gut microbiota, dietary fibre, B vitamins, other 
minerals, phytochemicals, and carotenoids. These are covered in other narrative reviews210,213. 
Furthermore, we were unable to comprehensively cover all the additional factors that can influence 
the relationship between nutrition, immunity and disease progression. Interpretation of the 
included literature is necessarily restricted to the context of the original studies, and a wide range of 
factors (some measured, many not measured) preclude extrapolation to the wider population. Such 
considerations should include genetic polymorphisms and their frequency and impact in different 
populations, haemoglobinopathies, the environment (e.g. soil type, latitude), age, sex, access to 
healthcare, and other underlying economic and political factors determining nutritional 
vulnerability. Finally, there is always a degree of uncertainty and risk when extrapolating from one 
infection to another, especially when age profiles of the affected population vary. We find that much 
of the previous literature on micronutrient deficiencies and viral infection focus on the younger 




Our review of the current literature highlights a range of mechanistic and observational evidence to 
highlight the role nutrition can play in susceptibility and progression of COVID-19. Prior knowledge 
of interactions between nutrition and other viral diseases can help inform hypotheses relevant to 
COVID-19. However, the literature taken from other viral diseases is far from consistent, and studies 
taken in isolation can be a source of rumours and ill-advised quick-fixes surrounding COVID-19 
prevention and cure. There is limited evidence to date that high-dose supplements of micronutrients 
will either prevent disease or speed up treatment. Attempting to ensure people have an adequate 
dietary intake is critical. However, we believe the focus should be on ways to promote a balanced 
diet and reduce the infective burden rather than reliance on high-dose supplementation, until more 
concrete evidence from clinical trials suggests otherwise. Whilst the quantity of literature on these 
topics is increasing daily, this does not necessarily correspond to an increase in high-quality 
evidence. Reviews such as ours will continually need updating to allow for a balanced view of the 
available data in order to counter unjustified nutrition-related claims. To date there is no evidence 
supporting adoption of novel nutritional therapies, although results of clinical trials are eagerly 
awaited. Given the known impacts of all forms of malnutrition on the immune system, public health 
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strategies to reduce micronutrient deficiencies, undernutrition and over-nutrition remain of critical 
importance, drawing on the numerous lessons learnt from other viral diseases. 
 
Funding acknowledgements: ZA and PS are supported by the Wellcome Trust Our Planet Our Health 
Programme (FACE-Africa grant number: 216021/Z/19/Z). MJ is supported by Wellcome Trust grant 
(ref 216451/Z/19/Z). HD, AEA and MT are supported by UK Medical Research Council (MRC Human 
Immunology Unit core funding to H.D., award no. MC_UU_12010/10). SEM is supported by The 
Wellcome Trust (ref 220225/Z/20/Z) and the Medical Research Council (UK) (ref MR/P012019/1). 
AMP, CC and MJS are jointly funded by the UK Medical Research Council and the Department for 
International Development (DFID) under the MRC/DFID Concordat agreement (MRC Programme 
MC-A760-5QX00). KSJ is supported by the National Institute for Health Research (NIHR) Cambridge 
Biomedical Research Centre (IS-BRC-1215- 20014). The NIHR Cambridge Biomedical Research Centre 
is a partnership between Cambridge University Hospitals NHS Foundation Trust and the University of 
Cambridge, funded by the NIHR. The views expressed are those of the authors and not necessarily 
those of the NHS, the NIHR or the Department of Health and Social Care. All other authors received 
no specific funding for this work. 
 




1 Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19 Epidemiology 
Based on Current Evidence. J Clin Med 2020; 9: 967. 
2 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with 
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62. 
3 Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses 2020; 12: 135. 
4 Bousquet J, Anto JM, Iaccarino G, et al. Is diet partly responsible for differences in COVID-19 
death rates between and within countries? Clin Transl Allergy 2020; 10: 16. 
5 Keusch GT. The History of Nutrition: Malnutrition, Infection and Immunity. J Nutr 2003; 133: 
336S-340S. 
6 Bhaskaram P. Micronutrient Malnutrition, Infection and Immunity: an overview.pdf. Nutr Rev 
2002; 60: S40–5. 
7 Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: an overview. 
Am J Clin Nutr 1997; 66: 464S-477S. 
8 Headey D, Heidkamp R, Osendarp S, et al. Impacts of COVID-19 on childhood malnutrition 
and nutrition-related mortality. Lancet 2020; 396: 519–21. 
9 Akseer N, Kandru G, Keats EC, Bhutta ZA. COVID-19 pandemic and mitigation strategies: 
implications for maternal and child health and nutrition. Am J Clin Nutr 2020; 112: 251–6. 
10 Torero M. Without food, there can be no exit from the pandemic. Nature 2020; 580: 588–9. 
11 International Panel of Experts on Sustainable Food Systems. International Panel of Experts on 
Sustainable Food Systems. (2020). COVID-19 and the crisis in food systems: Symptoms, 
causes, and potential solutions. 2020 http://www.ipes-food.org/_img/upload/files/COVID-
19_CommuniqueEN.pdf (accessed June 9, 2020). 
12 Headey D, Ruel M. The COVID-19 nutrition crisis: What to expect and how to protect. IFPRI 
Blog Ser. 2020. https://www.ifpri.org/blog/covid-19-nutrition-crisis-what-expect-and-how-
protect. 
13 Pérez-Escamilla R, Cunningham K, Moran VH. COVID-19, food and nutrition insecurity and the 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
38 
 
wellbeing of children, pregnant and lactating women: A complex syndemic. Matern Child Nutr 
2020; : e13036. 
14 Dunn CG, Kenney E, Fleischhacker SE, Bleich SN. Feeding Low-Income Children during the 
Covid-19 Pandemic. N Engl J Med 2020; 382: e40. 
15 Di Renzo L, Gualtieri P, Pivari F, et al. Eating habits and lifestyle changes during COVID-19 
lockdown: an Italian survey. J Transl Med 2020; 18: 229. 
16 Muscogiuri G, Barrea L, Savastano S, Colao A. Nutritional recommendations for CoVID-19 
quarantine. Eur J Clin Nutr 2020; 74: 850–1. 
17 Kininmonth AR, Jamil N, Almatrouk N, Evans CEL. Quality assessment of nutrition coverage in 
the media: a 6-week survey of five popular UK newspapers. BMJ Open 2017; 7: e014633. 
18 Rowe SB. Communicating Science-Based Food and Nutrition Information. J Nutr 2002; 132: 
2481S-2482S. 
19 Goldberg JP, Sliwa SA. Communicating actionable nutrition messages: challenges and 
opportunities. Proc Nutr Soc 2011; 70: 26–37. 
20 Mian A, Khan S. Coronavirus: the spread of misinformation. BMC Med 2020; 18: 89. 
21 Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, 
and characteristics of human coronaviruses. J Adv Res 2020; 24: 91–8. 
22 Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 
17: 181–92. 
23 Nickbakhsh S, Nickbakhsh S, Ho A, et al. Epidemiology of Seasonal Coronaviruses: Establishing 
the Context for the Emergence of Coronavirus Disease 2019. J Infect Dis 2020; 222: 17–25. 
24 Zhong N, Zheng B, Li Y, et al. Epidemiology and cause of severe acute respiratory syndrome 
(SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003; 362: 1353–
8. 
25 Cotten M, Watson SJ, Zumla AI, et al. Spread, circulation, and evolution of the Middle East 
respiratory syndrome coronavirus. MBio 2014; 5. DOI:10.1128/mBio.01062-13. 
26 Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family Cluster of Middle 
East Respiratory Syndrome Coronavirus Infections. N Engl J Med 2013; 368: 2487–94. 
27 Liu C, Wu C, Zheng X, et al. Clinical features and multidisciplinary treatment outcome of 
COVID-19 pneumonia: A report of three cases. J Formos Med Assoc 2020; published online 
April 16. DOI:10.1016/j.jfma.2020.04.008. 
28 Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 
2020; 17: 259–60. 
29 Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: 
Lessons learned from SARS and MERS epidemic. Asian Pacific J allergy Immunol 2020; 38: 1–
9. 
30 Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in 
systematic reviews: reporting guideline. BMJ 2020; 368: l6890. 
31 Waterlow JC. Protein Energy Malnutrition. London: Edward Arnold, 1992. 
32 Global Nutrition Report Stakeholder Group. 2020 Global Nutrition Report: Action on equity to 
end malnutrition. Bristol, UK, 2020 https://globalnutritionreport.org/reports/20%0A-global-
nutrition-report/executive-summary/%0A. 
33 WHO Multicentre Growth Reference Study. WHO Child Growth Standards: Length/height-for-
age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: 
Methods and development. Geneva, 2006. 
34 Bhutta ZA, Berkley JA, Bandsma RHJ, Kerac M, Trehan I, Briend A. Severe childhood 
malnutrition. Nat Rev Dis Prim 2017; 3: 17067. 
35 Schoenbuchner SM, Dolan C, Mwangome M, et al. The relationship between wasting and 
stunting: a retrospective cohort analysis of longitudinal data in Gambian children from 1976 
to 2016. Am J Clin Nutr 2019; 110: 498–507. 
36 Rytter MJH, Kolte L, Briend A, Friis H, Christensen VB. The Immune System in Children with 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
39 
 
Malnutrition—A Systematic Review. PLoS One 2014; 9: e105017. 
37 Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of 
Malnutrition. Trends Immunol 2016; 37: 386–98. 
38 Katona P, Katona-Apte J. The interaction between nutrition and infection. Clin Infect Dis 
2008; 46: 1582–8. 
39 Jones KD, Thitiri J, Ngari M, Berkley JA. Childhood malnutrition: toward an understanding of 
infections, inflammation, and antimicrobials. Food Nutr Bull 2014; 35: S64-70. 
40 Agarwal E, Miller M, Yaxley A, Isenring E. Malnutrition in the elderly: a narrative review. 
Maturitas 2013; 76: 296–302. 
41 Felder S, Lechtenboehmer C, Bally M, et al. Association of nutritional risk and adverse 
medical outcomes across different medical inpatient populations. Nutrition 2015; 31: 1385–
93. 
42 Mehta S. Nutritional status and COVID-19: an opportunity for lasting change? Clin Med 
(Northfield Il) 2020; 20: 270–3. 
43 Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition – 
A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia 
Muscle 2019; 10: 207–17. 
44 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 
novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 
2020; 395: 507–13. 
45 Han MG, Cheon D-S, Zhang X, Saif LJ. Cross-Protection against a Human Enteric Coronavirus 
and a Virulent Bovine Enteric Coronavirus in Gnotobiotic Calves. J Virol 2006; 80: 12350–6. 
46 Papatsiros VG, Stylianaki I, Papakonstantinou G, Papaioannou N, Christodoulopoulos G. Case 
Report of Transmissible Gastroenteritis Coronavirus Infection Associated with Small Intestine 
and Brain Lesions in Piglets. Viral Immunol 2019; 32: 63–7. 
47 Baker SJ, Mathan M, Mathan VI, Jesudoss S, Swaminathan SP. Chronic enterocyte infection 
with coronavirus. Dig Dis Sci 1982; 27: 1039–43. 
48 Edgeley GR, Davidson GP, Goodwin DA, Ringenbergs ML, Erlich J, Robb TA. Lactose 
malabsorption in Central Australian Aboriginal children hospitalized with acute enteritis. J 
Gastroenterol Hepatol 1988; 3: 63–9. 
49 Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral 
Transmission. Gastroenterology 2020; 158: 1518–9. 
50 Atkinson M, Yanney M, Stephenson T, Smyth A. Effective treatment strategies for paediatric 
community-acquired pneumonia. Expert Opin Pharmacother 2007; 8: 1091–101. 
51 Tempia S, Walaza S, Moyes J, et al. Risk Factors for Influenza-Associated Severe Acute 
Respiratory Illness Hospitalization in South Africa, 2012-2015. Open forum Infect Dis 2017; 4: 
ofw262. 
52 Reyes L, Arvelo W, Estevez A, et al. Population-based surveillance for 2009 pandemic 
influenza A (H1N1) virus in Guatemala, 2009. Influenza Other Respi Viruses 2010; 4: 129–40. 
53 Swann O V., Holden KA, Turtle L, et al. Clinical characteristics of children and young people 
admitted to hospital with covid-19 in United Kingdom: Prospective multicentre observational 
cohort study. BMJ 2020; 370: 5. 
54 Li T, Zhang Y, Gong C, et al. Prevalence of malnutrition and analysis of related factors in 
elderly patients with COVID-19 in Wuhan, China. Eur J Clin Nutr 2020; 74: 871–5. 
55 Liu G, Zhang S, Mao Z, Wang W, Hu H. Clinical significance of nutritional risk screening for 
older adult patients with COVID-19. Eur J Clin Nutr 2020; 74: 876–83. 
56 Caccialanza R, Laviano A, Lobascio F, et al. Early nutritional supplementation in non-critically 
ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and 
feasibility of a shared pragmatic protocol. Nutrition 2020; 74: 110835. 
57 Li X, Wang L, Yan S, et al. Clinical characteristics of 25 death cases with COVID-19: A 
retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
40 
 
Dis 2020; 94: 128–32. 
58 Barazzoni R, Bischoff SC, Breda J, et al. ESPEN expert statements and practical guidance for 
nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr 2020; 39: 1631–8. 
59 Maccioni L, Weber S, Elgizouli M, et al. Obesity and risk of respiratory tract infections: Results 
of an infection-diary based cohort study. BMC Public Health 2018; 18: 1–13. 
60 Phung DT, Wang Z, Rutherford S, Huang C, Chu C. Body mass index and risk of pneumonia: A 
systematic review and meta-analysis. Obes Rev 2013; 14: 839–57. 
61 Barber TM. COVID-19 and diabetes mellitus: implications for prognosis and clinical 
management. Expert Rev Endocrinol Metab 2020; 15: 227–36. 
62 Leitner DR, Frühbeck G, Yumuk V, et al. Obesity and type 2 diabetes: Two diseases with a 
need for combined treatment strategies - EASO can lead the way. Obes Facts 2017; 10: 483–
92. 
63 Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection. 
Circulation 2020; 142: 4–6. 
64 Petrakis D, Margină D, Tsarouhas K, et al. Obesity ‑ a risk factor for increased COVID‑19 
prevalence, severity and lethality (Review). Mol Med Rep 2020; 22: 9–19. 
65 Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J 
Physiol Endocrinol Metab 2020; 318: E736–41. 
66 Wösten-Van Asperen RM, Lutter R, Specht PA, et al. Acute respiratory distress syndrome 
leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an 
angiotensin II receptor antagonist. J Pathol 2011; 225: 618–27. 
67 Rao S, Lau A, So H-C. Exploring Diseases/Traits and Blood Proteins Causally Related to 
Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization 
Analysis Highlights Tentative Relevance of Diabetes-Related Traits. Diabetes Care 2020. 
DOI:10.2337/dc20-0643. 
68 Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 Severity in a Designated Hospital in 
Shenzhen, China. Diabetes Care 2020. DOI:10.2337/dc20-0576. 
69 Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and 
Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 
2020. DOI:10.1001/jama.2020.6775. 
70 Kalligeros M, Shehadeh F, Mylona EK, et al. Association of Obesity with Disease Severity 
Among Patients with Coronavirus Disease 2019. Obesity 2020; 28: 1200–4. 
71 Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute 
Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation. 
Obesity 2020; 28: 1195–9. 
72 Lemyze M, Courageux N, Maladobry T, et al. Implications of Obesity for the Management of 
Severe Coronavirus Disease 2019 Pneumonia. Crit Care Med 2020; 48: e761–7. 
73 Zhang F, Xiong Y, Wei Y, et al. Obesity predisposes to the risk of higher mortality in young 
COVID‐19 patients. J Med Virol 2020; 92: 2536–42. 
74 Higham A, Singh D. Increased ACE2 Expression in the Bronchial Epithelium of COPD Patients 
who are Overweight. Obesity 2020. DOI:10.1002/oby.22907. 
75 Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Morbid Obesity as an 
Independent Risk Factor for COVID‐19 Mortality in Hospitalized Patients Younger than 50. 
Obesity 2020. DOI:10.1002/oby.22913. 
76 Lokken EM, Walker CL, Delaney S, et al. Clinical characteristics of 46 pregnant women with a 
severe acute respiratory syndrome coronavirus 2 infection in Washington State. Am J Obstet 
Gynecol 2020; published online May 19. DOI:10.1016/j.ajog.2020.05.031. 
77 Hajifathalian K, Kumar S, Newberry C, et al. Obesity is Associated with Worse Outcomes in 
COVID‐19: Analysis of Early Data from New York City. Obesity 2020; 28: 1606–12. 
78 Busetto L, Bettini S, Fabris R, et al. Obesity and COVID‐19: An Italian Snapshot. Obesity 2020; 
28: 1600–5. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
41 
 
79 Hur K, Price CPE, Gray EL, et al. Factors Associated With Intubation and Prolonged Intubation 
in Hospitalized Patients With COVID-19. Otolaryngol Neck Surg 2020; 163: 170–8. 
80 Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J. Severe obesity, increasing age 
and male sex are independently associated with worse in-hospital outcomes, and higher in-
hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metab Clin 
Exp 2020; 108. 
81 Nikpouraghdam M, Jalali Farahani A, Alishiri G, et al. Epidemiological characteristics of 
coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol 2020; 
127: 104378. 
82 Zheng Y, Xiong C, Liu Y, et al. Epidemiological and clinical characteristics analysis of COVID-19 
in the surrounding areas of Wuhan, Hubei Province in 2020. Pharmacol Res 2020; 157: 
104821. 
83 Lian J, Jin X, Hao S, et al. Analysis of Epidemiological and Clinical Features in Older Patients 
With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. Clin Infect Dis 2020; 71: 740–7. 
84 Guan W-J, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 
in China: a nationwide analysis. Eur Respir J 2020; 55: 2000547. 
85 Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID‐19 patients in 
northeast Chongqing. J Med Virol 2020; 92: 797–806. 
86 Chen Q, Zheng Z, Zhang C, et al. Clinical characteristics of 145 patients with corona virus 
disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection 2020; 48: 543–51. 
87 Zhang J-J, Dong X, Cao Y-Y, et al. Clinical characteristics of 140 patients infected with SARS-
CoV-2 in Wuhan, China. Allergy 2020; 75: 1730–1741. 
88 Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and 
prognostic factors based on 4-week follow-up. J Infect 2020; 80: 639–45. 
89 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus 
in Wuhan, China. Lancet 2020; 395: 497–506. 
90 Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and 
ketoacidosis. Diabetes Obes Metab 2020; 22: 1935–41. 
91 Atkins JL, Masoli JAH, Delgado J, et al. Preexisting Comorbidities Predicting COVID-19 and 
Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci 2020; published 
online July 20. DOI:10.1093/gerona/glaa183. 
92 Zhang Y, Li H, Zhang J, et al. The clinical characteristics and outcomes of patients with 
diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single‐centre, 
retrospective, observational study in Wuhan. Diabetes, Obes Metab 2020; 22: 1443–54. 
93 Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of 
COVID-19. Diabetes Metab Res Rev 2020; 36: e3319. 
94 Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, 
hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract 2020; 164: 
108214. 
95 Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe 
covid-19 with diabetes. BMJ Open Diabetes Res Care 2020; 8: e001343. 
96 Zhang Y, Cui Y, Shen M, et al. Association of diabetes mellitus with disease severity and 
prognosis in COVID-19: A retrospective cohort study. Diabetes Res Clin Pract 2020; 165: 
108227. 
97 Chen X, Hu W, Ling J, et al. Hypertension and Diabetes Delay the Viral Clearance in COVID-19 
Patients. medRxiv 2020; published online Jan. DOI:10.1101/2020.03.22.20040774. 
98 Ebinger JE, Achamallah N, Ji H, et al. Pre-existing traits associated with Covid-19 illness 
severity. PLoS One 2020; 15: e0236240. 
99 Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-
19: results from UK Biobank. medRxiv 2020; published online May. 
DOI:10.1101/2020.04.28.20083295. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
42 
 
100 Hu L, Chen S, Fu Y, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 
Hospitalized Patients in Wuhan, China. Clin Infect Dis 2020. DOI:10.1093/cid/ciaa539. 
101 Zhang Y, Cui Y, Shen M, et al. Comorbid Diabetes Mellitus was Associated with Poorer 
Prognosis in Patients with COVID-19: A Retrospective Cohort Study. medRxiv 2020; published 
online Jan. DOI:10.1101/2020.03.24.20042358. 
102 Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome 
and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA 
Intern Med 2020; 180: 934. 
103 Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-
19 Patients Hospitalized in the United States. J Diabetes Sci Technol 2020; 14: 813–21. 
104 Shi Q, Zhang X, Jiang F, et al. Clinical Characteristics and Risk Factors for Mortality of COVID-
19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes 
Care 2020; 43: 1382–91. 
105 Chang MC, Park Y-K, Kim B-O, Park D. Risk factors for disease progression in COVID-19 
patients. BMC Infect Dis 2020; 20: 445. 
106 Huang R, Zhu L, Xue L, et al. Clinical findings of patients with coronavirus disease 2019 in 
Jiangsu province, China: A retrospective, multi-center study. PLoS Negl Trop Dis 2020; 14: 
e0008280. 
107 Rastad H, Karim H, Ejtahed H-S, et al. Risk and predictors of in-hospital mortality from COVID-
19 in patients with diabetes and cardiovascular disease. Diabetol Metab Syndr 2020; 12: 57. 
108 Wang F, Yang Y, Dong K, et al. CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES 
AND COVID-19 IN WUHAN, CHINA. Endocr Pract 2020; 26: 668–74. 
109 Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of 
mortality than known diabetes in hospitalized patients with COVID-19. Diabetes, Obes Metab 
2020. DOI:10.1111/dom.14099. 
110 Chen Y, Yang D, Cheng B, et al. Clinical Characteristics and Outcomes of Patients With 
Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 
2020; 43: 1399–407. 
111 Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in Patients With Hyperglycemia 
Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care 2020; 43: 1408–
15. 
112 Luo P, Qiu L, Liu Y, et al. Metformin Treatment Was Associated with Decreased Mortality in 
COVID-19 Patients with Diabetes in a Retrospective Analysis. Am J Trop Med Hyg 2020; 103: 
69–72. 
113 Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients 
with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020; 31: 1068–77. 
114 Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients 
with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020; 63: 1500–15. 
115 Pasricha S-R, Drakesmith H, Black J, Hipgrave D, Biggs B-A. Control of iron deficiency anemia 
in low- and middle-income countries. Blood 2013; 121: 2607–17. 
116 Ganz T. Anemia of Inflammation. N Engl J Med 2019; 381: 1148–57. 
117 Hill A, Hill QA. Autoimmune hemolytic anemia. Hematol Am Soc Hematol Educ Progr 2018; 
2018: 382–9. 
118 Landry ML. Parvovirus B19. Microbiol Spectr 2016; 4. DOI:10.1128/microbiolspec.DMIH2-
0008-2015. 
119 Takhar A. Pernicious anaemia: switch to oral B12 supplementation to reduce risk of covid-19 
transmission. BMJ 2020; 369: m2383. 
120 Warren J. Pernicious anaemia: self-administration of hydroxocobalamin in the covid-19 crisis. 
BMJ 2020; 369: m2380. 
121 Motta I, Migone De Amicis M, Pinto VM, et al. SARS-CoV-2 infection in beta thalassemia: 
Preliminary data from the Italian experience. Am J Hematol 2020; published online April 20. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 




122 Karimi M, Haghpanah S, Azarkeivan A, et al. Prevalence and Mortality due to Outbreak of 
Novel Coronavirus Disease (COVID-19) in β-Thalassemias: The Nationwide Iranian Experience. 
Br J Haematol 2020; published online June 2. DOI:10.1111/bjh.16911. 
123 Li M, Nguyen CB, Yeung Z, Sanchez K, Rosen D, Bushan S. Evans syndrome in a patient with 
COVID‐19. Br J Haematol 2020; 190. DOI:10.1111/bjh.16846. 
124 Lazarian G, Quinquenel A, Bellal M, et al. Autoimmune haemolytic anaemia associated with 
COVID‐19 infection. Br J Haematol 2020; 190: 29–31. 
125 Lopez C, Kim J, Pandey A, Huang T, DeLoughery TG. Simultaneous onset of COVID‐19 and 
autoimmune haemolytic anaemia. Br J Haematol 2020; 190: 31–2. 
126 Capes A, Bailly S, Hantson P, Gerard L, Laterre P-F. COVID-19 infection associated with 
autoimmune hemolytic anemia. Ann Hematol 2020; 99: 1679–80. 
127 WHO Working Group on the Clinical Characterisation and Management of COVID-19 
infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet 
Infect Dis 2020; published online June 12. DOI:10.1016/S1473-3099(20)30483-7. 
128 Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N 
Engl J Med 2020; 382: 1708–20. 
129 Mei Y, Weinberg SE, Zhao L, et al. Risk stratification of hospitalized COVID-19 patients 
through comparative studies of laboratory results with influenza. EClinicalMedicine 2020; 26: 
100475. 
130 Mendy A, Apewokin S, Wells AA, Morrow AL. Factors Associated with Hospitalization and 
Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients. medRxiv 
2020. DOI:10.1101/2020.06.25.20137323. 
131 Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond 
inflammation. A narrative review. Clin Pract 2020; 10: 1271. 
132 Hadadi A, Mortezazadeh M, Kolahdouzan K, Alavian G. Does recombinant human 
erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic 
effects? J Med Virol 2020; 92: 915–8. 
133 Bellmann-Weiler R, Lanser L, Barket R, et al. Prevalence and Predictive Value of Anemia and 
Dysregulated Iron Homeostasis in Patients with COVID-19 Infection. J Clin Med 2020; 9: 2429. 
134 Andreini C, Putignano V, Rosato A, Banci L. The human iron-proteome. Metallomics 2018; 10: 
1223–31. 
135 Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol 2008; 6: 
541–52. 
136 Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death 
using OpenSAFELY. Nature 2020; 584: 430–6. 
137 Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women 
admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based 
cohort study. BMJ 2020; 369: m2107. 
138 WHO. The global prevalence of anaemia in 2011. Geneva, Switzerland, 2015 
https://www.who.int/nutrition/publications/micronutrients/global_prevalence_anaemia_20
11/en/. 
139 Zhao L, Zhang X, Shen Y, Fang X, Wang Y, Wang F. Obesity and iron deficiency: a quantitative 
meta-analysis. Obes Rev 2015; 16: 1081–93. 
140 Oppenheimer SJ. Iron and Its Relation to Immunity and Infectious Disease. J Nutr 2001; 131: 
616S-635S. 
141 Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012; 338: 768–72. 
142 Gwamaka M, Kurtis JD, Sorensen BE, et al. Iron deficiency protects against severe 
Plasmodium falciparum malaria and death in young children. Clin Infect Dis 2012; 54: 1137–
44. 
143 Neuberger A, Okebe J, Yahav D, Paul M. Oral iron supplements for children in malaria-
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
44 
 
endemic areas. Cochrane database Syst Rev 2016; 2: CD006589. 
144 Pasricha S-R, Armitage AE, Prentice AM, Drakesmith H. Reducing anaemia in low income 
countries: control of infection is essential. BMJ 2018; 362: k3165. 
145 Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol 
2015; 15: 500–10. 
146 McDermid JM, van der Loeff MFS, Jaye A, et al. Mortality in HIV infection is independently 
predicted by host iron status and SLC11A1 and HP genotypes, with new evidence of a gene-
nutrient interaction. Am J Clin Nutr 2009; 90: 225–33. 
147 Soofi S, Cousens S, Iqbal SP, et al. Effect of provision of daily zinc and iron with several 
micronutrients on growth and morbidity among young children in Pakistan: a cluster-
randomised trial. Lancet 2013; 382: 29–40. 
148 de Silva A, Atukorala S, Weerasinghe I, Ahluwalia N. Iron supplementation improves iron 
status and reduces morbidity in children with or without upper respiratory tract infections: a 
randomized controlled study in Colombo, Sri Lanka. Am J Clin Nutr 2003; 77: 234–41. 
149 Jayaweera JAAS, Reyes M, Joseph A. Childhood iron deficiency anemia leads to recurrent 
respiratory tract infections and gastroenteritis. Sci Rep 2019; 9: 12637. 
150 Richard SA, Zavaleta N, Caulfield LE, Black RE, Witzig RS, Shankar AH. Zinc and iron 
supplementation and malaria, diarrhea, and respiratory infections in children in the Peruvian 
Amazon. Am J Trop Med Hyg 2006; 75: 126–32. 
151 Frise MC, Cheng H-Y, Nickol AH, et al. Clinical iron deficiency disturbs normal human 
responses to hypoxia. J Clin Invest 2016; 126: 2139–50. 
152 Sonnweber T, Pizzini A, Tancevski I, Löffler-Ragg J, Weiss G. Anaemia, iron homeostasis and 
pulmonary hypertension: a review. Intern Emerg Med 2020; 15: 573–85. 
153 Cronin SJF, Woolf CJ, Weiss G, Penninger JM. The Role of Iron Regulation in 
Immunometabolism and Immune-Related Disease. Front Mol Biosci 2019; 6: 116. 
154 Jabara HH, Boyden SE, Chou J, et al. A missense mutation in TFRC, encoding transferrin 
receptor 1, causes combined immunodeficiency. Nat Genet 2016; 48: 74–8. 
155 Savy M, Edmond K, Fine PEM, et al. Landscape analysis of interactions between nutrition and 
vaccine responses in children. J Nutr 2009; 139: 2154S-218S. 
156 Prentice AM, Bah A, Jallow MW, et al. Respiratory infections drive hepcidin-mediated 
blockade of iron absorption leading to iron deficiency anemia in African children. Sci Adv 
2019; 5: eaav9020. 
157 Hippchen T, Altamura S, Muckenthaler MU, Merle U. Hypoferremia predicts hospitalization 
and oxygen demand in COVID-19 patients. medRxiv 2020; published online June 26. 
DOI:10.1101/2020.06.26.20140525. 
158 Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-
19. Nature 2020; 583: 437–40. 
159 Shah A, Frost JN, Aaron L, Donovan K, Drakesmith H, Collaborators. Systemic hypoferremia 
and severity of hypoxemic respiratory failure in COVID-19. Crit Care 2020; 24: 320. 
160 Bolondi G, Russo E, Gamberini E, et al. Iron metabolism and lymphocyte characterisation 
during Covid-19 infection in ICU patients: an observational cohort study. World J Emerg Surg 
2020; 15: 41. 
161 Zhao K, Huang J, Dai D, Feng Y, Liu L, Nie S. Serum Iron Level as a Potential Predictor of 
Coronavirus Disease 2019 Severity and Mortality: A Retrospective Study. Open Forum Infect 
Dis 2020; 7. DOI:10.1093/ofid/ofaa250. 
162 Liu W, Zhang S, Nekhai S, Liu S. Depriving Iron Supply to the Virus Represents a Promising 
Adjuvant Therapeutic Against Viral Survival. Curr Clin Microbiol Reports 2020; 7: 13–9. 
163 Namaste SM, Rohner F, Huang J, et al. Adjusting ferritin concentrations for inflammation: 
Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) 
project. Am J Clin Nutr 2017; 106: 359S-371S. 
164 Daru J, Colman K, Stanworth SJ, De La Salle B, Wood EM, Pasricha S-R. Serum ferritin as an 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
45 
 
indicator of iron status: what do we need to know? Am J Clin Nutr 2017; 106: 1634S-1639S. 
165 Moutchia J, Pokharel P, Kerri A, et al. Clinical Laboratory Parameters Associated with Severe 
or Critical Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-
analysis. medRxiv 2020; published online April 29. DOI:10.1101/2020.04.24.20078782. 
166 Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of 
COVID-19: A meta-analysis. Int J Infect Dis 2020; 96: 467–74. 
167 Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol 2017; 29: 401–9. 
168 Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for 
monocytes and macrophages. Nat Rev Immunol 2020; 20: 355–62. 
169 Langel SN, Paim FC, Alhamo MA, Lager KM, Vlasova AN, Saif LJ. Oral vitamin A 
supplementation of porcine epidemic diarrhea virus infected gilts enhances IgA and 
lactogenic immune protection of nursing piglets. Vet Res 2019; 50: 101. 
170 Chen X, Tu C, Qin T, Zhu L, Yin Y, Yang Q. Retinoic acid facilitates inactivated transmissible 
gastroenteritis virus induction of CD8+ T-cell migration to the porcine gut. Sci Rep 2016; 6: 
24152. 
171 West CE, Sijtsma SR, Kouwenhoven B, Rombout JHWM, van der Zijpp AJ. Epithelia-Damaging 
Virus Infections Affect Vitamin A Status in Chickens. J Nutr 1992; 122: 333–9. 
172 Jee J, Hoet AE, Azevedo MP, et al. Effects of dietary vitamin A content on antibody responses 
of feedlot calves inoculated intramuscularly with an inactivated bovine coronavirus vaccine. 
Am J Vet Res 2013; 74: 1353–62. 
173 McGill JL, Kelly SM, Guerra-Maupome M, et al. Vitamin A deficiency impairs the immune 
response to intranasal vaccination and RSV infection in neonatal calves. Sci Rep 2019; 9: 
15157. 
174 Rahman MM, Mahalanabis D, Hossain S, et al. Simultaneous vitamin A administration at 
routine immunization contact enhances antibody response to diphtheria vaccine in infants 
younger than six months. J Nutr 1999; 129: 2192–5. 
175 Klebanoff CA, Spencer SP, Torabi-Parizi P, et al. Retinoic acid controls the homeostasis of pre-
cDC-derived splenic and intestinal dendritic cells. J Exp Med 2013; 210: 1961–76. 
176 Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A vitamin. J Exp 
Med 1925; 42: 753–77. 
177 Coutsoudis A, Broughton M, Coovadia HM. Vitamin A supplementation reduces measles 
morbidity in young African children: a randomized, placebo-controlled, double-blind trial. Am 
J Clin Nutr 1991; 54: 890–5. 
178 Tam E, Keats EC, Rind F, Das JK, Bhutta AZA. Micronutrient Supplementation and Fortification 
Interventions on Health and Development Outcomes among Children Under-Five in Low- and 
Middle-Income Countries: A Systematic Review and Meta-Analysis. Nutrients 2020; 12. 
DOI:10.3390/nu12020289. 
179 Imdad A, Mayo-Wilson E, Herzer K, Bhutta ZA. Vitamin A supplementation for preventing 
morbidity and mortality in children from six months to five years of age. Cochrane database 
Syst Rev 2017; 3: CD008524. 
180 Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J. A systematic review of 
pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of 
disease progression. Mod Pathol 2020; : 1–11. 
181 Adhikari SP, Meng S, Wu Y-J, et al. Epidemiology, causes, clinical manifestation and diagnosis, 
prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a 
scoping review. Infect Dis poverty 2020; 9: 29. 
182 Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel 
Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382: 1199–207. 
183 Laksono BM, de Vries RD, McQuaid S, Duprex WP, de Swart RL. Measles virus host invasion 
and pathogenesis. Viruses. 2016; 8. DOI:10.3390/v8080210. 
184 WHO. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
46 
 
Childhood Illnesses. 2013 
http://www.who.int/maternal_child_adolescent/documents/9241546700/en/. 
185 Roberts L. Why measles deaths are surging — and coronavirus could make it worse. Nat 2020 
5807804 2020; published online April 7. 
186 Bester JC. Measles and Measles Vaccination: A Review. JAMA Pediatr 2016; 170: 1209–15. 
187 Alves Graber EM, Andrade FJ, Bost W, Gibbs MA. An Update and Review of Measles for 
Emergency Physicians. J Emerg Med 2020; 58: 610–5. 
188 Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. Cochrane 
database Syst Rev 2005; 2005: CD001479. 
189 Sudfeld CR, Navar AM, Halsey NA. Effectiveness of measles vaccination and vitamin A 
treatment. Int J Epidemiol 2010; 39 Suppl 1: i48-55. 
190 Aluisio AR, Perera SM, Yam D, et al. Vitamin A Supplementation Was Associated with 
Reduced Mortality in Patients with Ebola Virus Disease during the West African Outbreak. J 
Nutr 2019; 149: 1757–65. 
191 Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients 2017; 9. 
DOI:10.3390/nu9111211. 
192 Pauling L. The significance of the evidence about ascorbic acid and the common cold. Proc 
Natl Acad Sci U S A 1971; 68: 2678–81. 
193 Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: 
Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 1976; 73: 
3685–9. 
194 Jacob RA, Sotoudeh G. Vitamin C function and status in chronic disease. Nutr Clin Care 2002; 
5: 66–74. 
195 Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and 
intravenous use. Ann Intern Med 2004; 140: 533–7. 
196 Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively 
generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl 
Acad Sci U S A 2007; 104: 8749–54. 
197 Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane 
database Syst Rev 2013; : CD000980. 
198 Kim TK, Lim HR, Byun JS. Vitamin C supplementation reduces the odds of developing a 
common cold in Republic of Korea Army recruits: randomised controlled trial. BMJ Mil Heal 
2020; published online March 5. DOI:10.1136/bmjmilitary-2019-001384. 
199 Padhani ZA, Moazzam Z, Ashraf A, et al. Vitamin C supplementation for prevention and 
treatment of pneumonia. Cochrane database Syst Rev 2020; 4: CD013134. 
200 Langlois PL, Manzanares W, Adhikari NKJ, et al. Vitamin C Administration to the Critically Ill: A 
Systematic Review and Meta-Analysis. JPEN J Parenter Enteral Nutr 2019; 43: 335–46. 
201 Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and 
antioxidants in critically ill patients. N Engl J Med 2013; 368: 1489–97. 
202 Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and 
Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After 
Study. Chest 2017; 151: 1229–38. 
203 Fujii T, Luethi N, Young PJ, et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs 
Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With 
Septic Shock: The VITAMINS Randomized Clinical Trial. JAMA 2020; 323. 
DOI:10.1001/jama.2019.22176. 
204 Fowler AA, Truwit JD, Hite RD, et al. Effect of Vitamin C Infusion on Organ Failure and 
Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute 
Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA 2019; 322: 1261–70. 
205 Li R, Guo C, Li Y, Qin Z, Huang W. Therapeutic targets and signaling mechanisms of vitamin C 
activity against sepsis: a bioinformatics study. Brief Bioinform 2020; published online May 11. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 




206 Chen L, Hu C, Hood M, et al. A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic 
Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus 
Infections: A Perspective from System Biology Analysis. Nutrients 2020; 12: 1193. 
207 Jayawardena R, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing 
immunity in viral infections, with special emphasis on COVID-19: A review. Diabetes Metab 
Syndr Clin Res Rev 2020; 14: 367–82. 
208 Rozga M, Cheng FW, Moloney L, Handu D. Effects of Micronutrients or Conditional Amino 
Acids on COVID-19-Related Outcomes: An Evidence Analysis Center Scoping Review. J Acad 
Nutr Diet 2020; published online May. DOI:10.1016/j.jand.2020.05.015. 
209 Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and 
Carotenoids. Washington, D.C.: National Academies Press, 2000 DOI:10.17226/9810. 
210 Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System–
Working in Harmony to Reduce the Risk of Infection. Nutrients 2020; 12: 236. 
211 Sassi F, Tamone C, D’Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. 
Nutrients 2018; 10: 1656. 
212 Grant WB, Lahore H, McDonnell SL, et al. Evidence that Vitamin D Supplementation Could 
Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients 2020; 12: 988. 
213 Iddir M, Brito A, Dingeo G, et al. Strengthening the Immune System and Reducing 
Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the 
COVID-19 Crisis. Nutrients 2020; 12: 1562. 
214 Lanham-New SA, Webb AR, Cashman KD, et al. Vitamin D and SARS-CoV-2 virus/COVID-19 
disease. BMJ Nutr Prev Heal 2020; 3: 106–10. 
215 Zabetakis I, Lordan R, Norton C, Tsoupras A. COVID-19: The Inflammation Link and the Role of 
Nutrition in Potential Mitigation. Nutrients 2020; 12. DOI:10.3390/nu12051466. 
216 Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc 2012; 71: 50–61. 
217 Greiller LC, Martineau RA. Modulation of the Immune Response to Respiratory Viruses by 
Vitamin D. Nutr. . 2015; 7. DOI:10.3390/nu7064240. 
218 Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in 
epithelia of the human lung where it has broad antimicrobial activity at the airway surface. 
Proc Natl Acad Sci U S A 1998; 95: 9541–6. 
219 Vargas Buonfiglio LG, Cano M, Pezzulo AA, et al. Effect of vitamin D(3) on the antimicrobial 
activity of human airway surface liquid: preliminary results of a randomised placebo-
controlled double-blind trial. BMJ open Respir Res 2017; 4: e000211–e000211. 
220 Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J 
Infect 2020; 80: 607–13. 
221 Daneshkhah A, Agrawal V, Eshein A, Subramanian H, Roy HK, Backman V. The Possible Role of 
Vitamin D in Suppressing Cytokine Storm and Associated Mortality in COVID-19 Patients. 
medRxiv 2020; published online Jan. DOI:10.1101/2020.04.08.20058578. 
222 Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 
and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181: 271-
280.e8. 
223 Ghafouri-Fard S, Noroozi R, Omrani MD, et al. Angiotensin converting enzyme: A review on 
expression profile and its association with human disorders with special focus on SARS-CoV-2 
infection. Vascul Pharmacol 2020; 130: 106680. 
224 Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 
2019 infection and  mortality. Aging Clin Exp Res 2020; : 1–4. 
225 Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and 
controversies with renin angiotensin system blockers. Diabetes Metab Syndr Clin Res Rev 
2020; 14: 283–7. 
226 Silva MC, Furlanetto TW. Does serum 25-hydroxyvitamin D decrease during acute-phase 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
48 
 
response? A systematic  review. Nutr Res 2015; 35: 91–6. 
227 Ghashut RA, Talwar D, Kinsella J, Duncan A, McMillan DC. The effect of the systemic 
inflammatory response on plasma vitamin 25 (OH) D concentrations adjusted for albumin. 
PLoS One 2014; 9: e92614–e92614. 
228 Williams AM, Ladva CN, Leon JS, et al. Changes in micronutrient and inflammation serum 
biomarker concentrations after a norovirus human challenge. Am J Clin Nutr 2019; 110: 
1456–64. 
229 van Schoor N, Lips P. Global Overview of Vitamin D Status. Endocrinol Metab Clin North Am 
2017; 46: 845–70. 
230 Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and 
Middle East countries and strategies to  prevent vitamin D deficiency: a position statement of 
the European Calcified Tissue Society. Eur J Endocrinol 2019; 180: P23–54. 
231 Cashman KD, Dowling KG, Škrabáková Z, et al. Vitamin D deficiency in Europe: pandemic? Am 
J Clin Nutr 2016; 103: 1033–44. 
232 Cashman KD, Sheehy T, O’Neill CM. Is vitamin D deficiency a public health concern for low 
middle income countries? A  systematic literature review. Eur J Nutr 2019; 58: 433–53. 
233 Centers for Disease Control and Prevention. People Who Are at Higher Risk for Severe Illness 
| Coronavirus | COVID-19 | CDC. Coronavirus Dis. 2019. 2020. 
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-
risk.html (accessed June 21, 2020). 
234 Bikle DD, Schwartz J. Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different 
Physiological and Pathophysiological Conditions. Front Endocrinol (Lausanne) 2019; 10: 317. 
235 Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory 
infection: Systematic review of clinical studies. J Steroid Biochem Mol Biol 2013; 136: 321–9. 
236 Pham H, Rahman A, Majidi A, Waterhouse M, Neale RE. Acute Respiratory Tract Infection and 
25-Hydroxyvitamin D Concentration: A Systematic Review and Meta-Analysis. Int J Environ 
Res Public Health 2019; 16: 3020. 
237 Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute 
respiratory tract infections: systematic review and meta-analysis of individual participant 
data. BMJ 2017; 356: i6583. 
238 Martineau AR, Jolliffe DA, Greenberg L, et al. Vitamin D supplementation to prevent acute 
respiratory infections: individual participant data meta-analysis. 2019; 23: 2. 
239 Arihiro S, Nakashima A, Matsuoka M, et al. Randomized Trial of Vitamin D Supplementation 
to Prevent Seasonal Influenza and  Upper Respiratory Infection in Patients With Inflammatory 
Bowel Disease. Inflamm Bowel Dis 2019; 25: 1088–95. 
240 Loeb M, Dang AD, Thiem VD, et al. Effect of Vitamin D supplementation to reduce respiratory 
infections in children and  adolescents in Vietnam: A randomized controlled trial. Influenza 
Other Respi Viruses 2019; 13: 176–83. 
241 Ginde AA, Blatchford P, Breese K, et al. High-Dose Monthly Vitamin D for Prevention of Acute 
Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial. J Am 
Geriatr Soc 2017; 65: 496–503. 
242 Hueniken K, Aglipay M, Birken CS, et al. Effect of High-Dose Vitamin D Supplementation on 
Upper Respiratory Tract Infection  Symptom Severity in Healthy Children. Pediatr Infect Dis J 
2019; 38: 564–8. 
243 Shimizu Y, Ito Y, Yui K, Egawa K, Orimo H. Intake of 25-Hydroxyvitamin D3 Reduces Duration 
and Severity of Upper Respiratory  Tract Infection: A Randomized, Double-Blind, Placebo-
Controlled, Parallel Group Comparison Study. J Nutr Health Aging 2018; 22: 491–500. 
244 Zhou J, Du J, Huang L, Wang Y, Shi Y, Lin H. Preventive Effects of Vitamin D on Seasonal 
Influenza A in Infants: A Multicenter,  Randomized, Open, Controlled Clinical Trial. Pediatr 
Infect Dis J 2018; 37: 749–54. 
245 Aglipay M, Birken CS, Parkin PC, et al. Effect of High-Dose vs Standard-Dose Wintertime 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
49 
 
Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy 
Children. JAMA 2017; 318: 245–54. 
246 Scragg R. The Vitamin D Assessment (ViDA) study – Design and main findings. J Steroid 
Biochem Mol Biol 2020; 198: 105562. 
247 Gold DR, Litonjua AA, Carey VJ, et al. Lung VITAL: Rationale, design, and baseline 
characteristics of an ancillary study  evaluating the effects of vitamin D and/or marine omega-
3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma 
control, pneumonia and lung f. Contemp Clin Trials 2016; 47: 185–95. 
248 Manson JE, Bassuk SS, Buring JE. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) 
and updated meta-analyses of relevant vitamin D trials. J Steroid Biochem Mol Biol 2020; 198: 
105522. 
249 Chun RF, Shieh A, Gottlieb C, et al. Vitamin D Binding Protein and the Biological Activity of 
Vitamin D. Front Endocrinol (Lausanne) 2019; 10: 718. 
250 Jones KS, Assar S, Harnpanich D, et al. 25(OH)D2 Half-Life Is Shorter Than 25(OH)D3 Half-Life 
and Is Influenced by DBP Concentration and Genotype. J Clin Endocrinol Metab 2014; 99: 
3373–81. 
251 Slow S, Pearson JP, Florkowski CM, et al. Effect of genetic factors on the response to vitamin 
D(3) supplementation in the  VIDARIS randomized controlled trial. Nutrition 2020; 75–76: 
110761. 
252 Al-Daghri NM, Mohammed AK, Bukhari I, et al. Efficacy of vitamin D supplementation 
according to vitamin D-binding protein  polymorphisms. Nutrition 2019; 63–64: 148–54. 
253 Jolliffe DA, Greiller CL, Mein CA, et al. Vitamin D receptor genotype influences risk of upper 
respiratory infection. Br J Nutr 2018; 120: 891–900. 
254 Mansy W, Ibrahim NH, Al-Gawhary S, et al. Vitamin D status and vitamin D receptor gene 
polymorphism in Saudi children with  acute lower respiratory tract infection. Mol Biol Rep 
2019; 46: 1955–62. 
255 Laplana M, Royo JL, Fibla J. Vitamin D Receptor polymorphisms and risk of enveloped virus 
infection: A  meta-analysis. Gene 2018; 678: 384–94. 
256 D’Avolio A, Avataneo V, Manca A, et al. 25-Hydroxyvitamin D Concentrations Are Lower in 
Patients with Positive PCR for  SARS-CoV-2. Nutrients 2020; 12. DOI:10.3390/nu12051359. 
257 Cuñat T, Ojeda A, Calvo A. Vitamin D deficiency in critically ill patients diagnosed with COVID -
19. Are we doing enough? A retrospective analysis of 226 patients. Res Sq 2020; published 
online May. DOI:10.21203/rs.3.rs-30390/v1. 
258 Lau FH, Majumder R, Torabi R, et al. Vitamin D Insufficiency is Prevalent in Severe COVID-19. 
medRxiv 2020; published online May. DOI:10.1101/2020.04.24.20075838. 
259 Pinzon RT, Angela A, Pradana AW. Vitamin D Deficiency Among Patients with COVID-19 : Case 
Series and Recent Literature Review. Res Sq 2020; published online May. 
DOI:10.21203/rs.3.rs-29473/v1. 
260 De Smet D, De Smet K, Herroelen P, Gryspeerdt S, Martens GA. Vitamin D deficiency as risk 
factor for severe COVID-19: a convergence of two pandemics. medRxiv 2020; published 
online May. DOI:10.1101/2020.05.01.20079376. 
261 Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Deficiency 
and Treatment with COVID-19 Incidence. medRxiv 2020; published online May. 
DOI:10.1101/2020.05.08.20095893. 
262 Hastie CE, Mackay DF, Ho F, et al. Vitamin D concentrations and COVID-19 infection in UK 
Biobank. Diabetes Metab Syndr Clin Res Rev 2020; 14: 561–5. 
263 Alipio MM. Vitamin D supplementation could possibly improve clinical outcomes of patients 
infected with Coronavirus-2019 (COVID-19). SSRN 2020. DOI:102139/ssrn3571484 2020. 
264 Raharusun P, Priambada S, Budiarti C, Agung E, Budi C. Patterns of COVID-19 Mortality and 
Vitamin D: An Indonesian Study. SSRN Electron J 2020. DOI:10.2139/ssrn.3585561. 
265 Henrina J, Lim MA, Pranata R. COVID-19 and misinformation: how an infodemic fuelled the 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
50 
 
prominence of vitamin D. Br J Nutr 2020; : 1–2. 
266 Lee GY, Han SN. The Role of Vitamin E in Immunity. Nutrients 2018; 10: 1614. 
267 Lewis ED, Meydani SN, Wu D. Regulatory role of vitamin E in the immune system and 
inflammation. IUBMB Life 2019; 71: 487–94. 
268 Nelson HK, Shi Q, Van Dael P, et al. Host nutritional selenium status as a driving force for 
influenza virus mutations. FASEB J 2001; 15: 1846–8. 
269 Beck MA, Handy J, Levander OA. Host nutritional status: the neglected virulence factor. 
Trends Microbiol 2004; 12: 417–23. 
270 Beck MA, Kolbeck PC, Rohr LH, Shi Q, Morris VC, Levander OA. Vitamin E deficiency intensifies 
the myocardial injury of coxsackievirus B3 infection of mice. J Nutr 1994; 124: 345–58. 
271 Levander OA, Ager AL, Beck MA. Vitamin E and selenium: contrasting and interacting 
nutritional determinants of host resistance to parasitic and viral infections. Proc Nutr Soc 
1995; 54: 475–87. 
272 Hemila¨ H, Virtamo J, Albanes D, Kaprio J. Vitamin E and Beta-Carotene Supplementation and 
Hospital-Treated Pneumonia Incidence in Male Smokers. Chest 2004; 125: 557–65. 
273 Hemilä H. Vitamin E administration may decrease the incidence of pneumonia in elderly 
males. Clin Interv Aging 2016; 11: 1379–85. 
274 Graat JM, Schouten EG, Kok FJ. Effect of Daily Vitamin E and Multivitamin-Mineral 
Supplementation on Acute Respiratory Tract Infections in Elderly Persons. JAMA 2002; 288: 
715. 
275 Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001; 36. 
DOI:10.1007/s11745-001-0812-7. 
276 Torrinhas RS, Calder PC, Lemos GO, Waitzberg DL. Parenteral fish oil: An adjuvant 
pharmacotherapy for coronavirus disease 2019? Nutrition 2020; 81: 110900. 
277 Calder PC. n -3 Fatty acids, inflammation and immunity: new mechanisms to explain old 
actions. Proc Nutr Soc 2013; 72: 326–36. 
278 Calder PC. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fat Acids 
2007; 77. DOI:10.1016/j.plefa.2007.10.015. 
279 Wu D, Lewis ED, Pae M, Meydani SN. Nutritional Modulation of Immune Function: Analysis of 
Evidence, Mechanisms, and Clinical Relevance. Front Immunol 2019; 9. 
DOI:10.3389/fimmu.2018.03160. 
280 Fritsche K. Fatty Acids as Modulators of the Immune Response. Annu Rev Nutr 2006; 26: 45–
73. 
281 (Kristine) Koekkoek W, Panteleon V, van Zanten AR. Current evidence on ω-3 fatty acids in 
enteral nutrition in the critically ill: A systematic review and meta-analysis. Nutrition 2019; 
59: 56–68. 
282 Langlois PL, D’Aragon F, Hardy G, Manzanares W. Omega-3 polyunsaturated fatty acids in 
critically ill patients with acute respiratory distress syndrome: A systematic review and meta-
analysis. Nutrition 2019; 61: 84–92. 
283 Dushianthan A, Cusack R, Burgess VA, Grocott MPW, Calder PC. Immunonutrition for acute 
respiratory distress syndrome (ARDS) in adults. Cochrane database Syst Rev 2019; 1: 
CD012041. 
284 Messina G, Polito R, Monda V, et al. Functional Role of Dietary Intervention to Improve the 
Outcome of COVID-19: A Hypothesis of Work. Int J Mol Sci 2020; 21: 3104. 
285 Bistrian BR. Parenteral Fish‐Oil Emulsions in Critically Ill COVID‐19 Emulsions. J Parenter Enter 
Nutr 2020; 44: 1168–1168. 
286 Torrinhas RS, Calder PC, Waitzberg DL. Response to Bistrian BR. Parenteral Fish‐Oil Emulsions 
in Critically Ill COVID‐19 Emulsions. J Parenter Enter Nutr 2020; 44: 1169–70. 
287 Guillin OM, Vindry C, Ohlmann T, Chavatte L. Selenium, Selenoproteins and Viral Infection. 
Nutrients 2019; 11. DOI:10.3390/nu11092101. 
288 Beck MA, Levander OA, Handy J. Selenium Deficiency and Viral Infection. J Nutr 2003; 133: 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 




289 Bai J. The combined effect of selenium deficiency and viral infection on the myocardium of 
mice (preliminary study). Acta Acad Med Sin 1980; 2: 29–31. 
290 Beck MA, Kolbeck PC, Rohr LH, Shi Q, Morris VC, Levander OA. Benign human enterovirus 
becomes virulent in selenium-deficient mice. J Med Virol 1994; 43: 166–70. 
291 Beck MA, Kolbeck PC, Shi Q, Rohr LH, Morris VC, Levander OA. Increased virulence of a 
human enterovirus (coxsackievirus B3) in selenium-deficient mice. J Infect Dis 1994; 170: 
351–7. 
292 Beck MA, Shi Q, Morris VC, Levander OA. Rapid genomic evolution of a non-virulent 
coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. 
Nat Med 1995; 1: 433–6. 
293 Zhou H, Wang T, Li Q, Li D. Prevention of Keshan Disease by Selenium Supplementation: a 
Systematic Review and Meta-analysis. Biol Trace Elem Res 2018; 186: 98–105. 
294 Beck MA, Nelson HK, Shi Q, et al. Selenium deficiency increases the pathology of an influenza 
virus infection. FASEB J 2001; 15: 1481–3. 
295 Jaspers I, Zhang W, Brighton LE, Carson JL, Styblo M, Beck MA. Selenium deficiency alters 
epithelial cell morphology and responses to influenza. Free Radic Biol Med 2007; 42: 1826–
37. 
296 Sheridan PA, Zhong N, Carlson BA, Perella CM, Hatfield DL, Beck MA. Decreased 
selenoprotein expression alters the immune response during influenza virus infection in mice. 
J Nutr 2007; 137: 1466–71. 
297 Stýblo M, Walton FS, Harmon AW, Sheridan PA, Beck MA. Activation of superoxide dismutase 
in selenium-deficient mice infected with influenza virus. J Trace Elem Med Biol 2007; 21: 52–
62. 
298 Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J 
Med Virol 2020; 92: 479–90. 
299 Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal Nutritional Status for a Well-
Functioning Immune System Is an Important Factor to Protect against Viral Infections. 
Nutrients 2020; 12: 1181. 
300 Weglarz-Tomczak E, Tomczak JM, Giurg M, Burda-Grabowska M, Brul S. Discovery of potent 
inhibitors of PLproCoV2 by screening libraries of selenium-containing compounds. bioRxiv 
2020. DOI:10.1101/2020.05.20.107052. 
301 Alhazzani W, Jacobi J, Sindi A, et al. The Effect of Selenium Therapy on Mortality in Patients 
With Sepsis Syndrome. Crit Care Med 2013; 41: 1555–64. 
302 Allingstrup M, Afshari A. Selenium supplementation for critically ill adults. Cochrane database 
Syst Rev 2015; 2015: CD003703. 
303 Huang T-S, Shyu Y-C, Chen H-Y, et al. Effect of Parenteral Selenium Supplementation in 
Critically Ill Patients: A Systematic Review and Meta-Analysis. PLoS One 2013; 8: e54431. 
304 Kong Z, Wang F, Ji S, Deng X, Xia Z. Selenium supplementation for sepsis: a meta-analysis of 
randomized controlled trials. Am J Emerg Med 2013; 31: 1170–5. 
305 Landucci F, Mancinelli P, De Gaudio AR, Virgili G. Selenium supplementation in critically ill 
patients: A systematic review and meta-analysis. J Crit Care 2014; 29: 150–6. 
306 Li S, Tang T, Guo P, et al. A meta-analysis of randomized controlled trials: Efficacy of selenium 
treatment for sepsis. Medicine (Baltimore) 2019; 98: e14733. 
307 Manzanares W, Dhaliwal R, Jiang X, Murch L, Heyland DK. Antioxidant micronutrients in the 
critically ill: a systematic review and meta-analysis. Crit Care 2012; 16: R66. 
308 Manzanares W, Lemieux M, Elke G, Langlois PL, Bloos F, Heyland DK. High-dose intravenous 
selenium does not improve clinical outcomes in the critically ill: a systematic review and 
meta-analysis. Crit Care 2016; 20: 356. 
309 Zhao Y, Yang M, Mao Z, et al. The clinical outcomes of selenium supplementation on critically 
ill patients: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019; 98: 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 




310 Girodon F, Galan P, Monget A-L, et al. Impact of Trace Elements and Vitamin 
Supplementation on Immunity and Infections in Institutionalized Elderly Patients. Arch Intern 
Med 1999; 159: 748. 
311 Allsup SJ, Shenkin A, Gosney MA, et al. Can a Short Period of Micronutrient Supplementation 
in Older Institutionalized People Improve Response to Influenza Vaccine? A Randomized, 
Controlled Trial. J Am Geriatr Soc 2004; 52: 20–4. 
312 Ivory K, Prieto E, Spinks C, et al. Selenium supplementation has beneficial and detrimental 
effects on immunity to influenza vaccine in older adults. Clin Nutr 2017; 36: 407–15. 
313 Broome CS, McArdle F, Kyle JA, et al. An increase in selenium intake improves immune 
function and poliovirus handling in adults with marginal selenium status. Am J Clin Nutr 2004; 
80: 154–62. 
314 Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The Role of Zinc in Antiviral Immunity. Adv Nutr 
2019; 10: 696–710. 
315 Wessells KR, Brown KH. Estimating the global prevalence of zinc deficiency: results based on 
zinc availability in national food supplies and the prevalence of stunting. PLoS One 2012; 7: 
e50568. 
316 Himoto T, Masaki T. Associations between Zinc Deficiency and Metabolic Abnormalities in 
Patients with Chronic Liver Disease. Nutrients 2018; 10: 88. 
317 Siva S, Rubin DT, Gulotta G, Wroblewski K, Pekow J. Zinc Deficiency is Associated with Poor 
Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23: 
152–7. 
318 Overbeck S, Rink L, Haase H. Modulating the immune response by oral zinc supplementation: 
a single approach for multiple diseases. Arch Immunol Ther Exp (Warsz) 2008; 56: 15–30. 
319 Aggarwal R, Sentz J, Miller MA. Role of zinc administration in prevention of childhood 
diarrhea and respiratory illnesses: a meta-analysis. Pediatrics 2007; 119: 1120–30. 
320 Howie S, Bottomley C, Chimah O, et al. Zinc as an adjunct therapy in the management of 
severe pneumonia among Gambian children: randomized controlled trial. J Glob Health 2018; 
8: 010418. 
321 Brown N, Kukka AJ, Mårtensson A. Efficacy of zinc as adjunctive pneumonia treatment in 
children aged 2 to 60 months in low-income and middle-income countries: A systematic 
review and meta-analysis. BMJ Paediatr Open 2020; 4. DOI:10.1136/bmjpo-2020-000662. 
322 Hemilä H, Fitzgerald JT, Petrus EJ, Prasad A. Zinc Acetate Lozenges May Improve the Recovery 
Rate of Common Cold Patients: An Individual Patient Data Meta-Analysis. Open Forum Infect 
Dis 2017; 4. DOI:10.1093/ofid/ofx059. 
323 Lambert SA, Jolma A, Campitelli LF, et al. The Human Transcription Factors. Cell 2018; 172: 
650–65. 
324 Andreini C, Bertini I. A bioinformatics view of zinc enzymes. J Inorg Biochem 2012; 111: 150–
6. 
325 Becker KW, Skaar EP. Metal limitation and toxicity at the interface between host and 
pathogen. FEMS Microbiol Rev 2014; 38: 1235–49. 
326 Botella H, Peyron P, Levillain F, et al. Mycobacterial p(1)-type ATPases mediate resistance to 
zinc poisoning in human macrophages. Cell Host Microbe 2011; 10: 248–59. 
327 Mayor-Ibarguren A, Busca-Arenzana C, Robles-Marhuenda Á. A Hypothesis for the Possible 
Role of Zinc in the Immunological Pathways Related to COVID-19 Infection. Front Immunol 
2020; 11: 1736. 
328 Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With 
Early COVID-19. Ann Intern Med 2020; published online July 16. DOI:10.7326/m20-4207. 
329 Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin 
in Mild-to-Moderate Covid-19. N Engl J Med 2020; published online July 23. 
DOI:10.1056/nejmoa2019014. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
53 
 
330 Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as 
Postexposure Prophylaxis for Covid-19. N Engl J Med 2020; 383: 517–25. 
331 Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding W-Q. Chloroquine is a zinc ionophore. PLoS 
One 2014; 9: e109180. 
332 Derwand R, Scholz M. Does zinc supplementation enhance the clinical efficacy of 
chloroquine/hydroxychloroquine to win today’s battle against COVID-19? Med Hypotheses 
2020; 142: 109815. 
333 Shittu MO, Afolami OI. Improving the efficacy of Chloroquine and Hydroxychloroquine 
against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical 
trials. Le Infez Med 2020; 28: 192–7. 
334 Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J. Hydroxychloroquine and 
azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in 
hospitalized COVID-19 patients. medRxiv 2020; published online May 8. 
DOI:10.1101/2020.05.02.20080036. 
335 Morgan MJ, Liu Z-G. Reactive oxygen species in TNFα-induced signaling and cell death. Mol 
Cells 2010; 30: 1–12. 
336 Salzano S, Checconi P, Hanschmann E-M, et al. Linkage of inflammation and oxidative stress 
via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc Natl Acad 
Sci 2014; 111: 12157–62. 
337 Lenz A-G, Jorens PG, Meyer B, et al. Oxidatively modified proteins in bronchoalveolar lavage 
fluid of patients with ARDS and patients at‐risk for ARDS. Eur Respir J 1999; 13: 169. 
338 Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med 
2020; 217. DOI:10.1084/jem.20200678. 
339 Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic 
syndrome. Semin Immunopathol 2018; 40: 215–24. 
340 Steven S, Frenis K, Oelze M, et al. Vascular Inflammation and Oxidative Stress: Major Triggers 
for Cardiovascular Disease. Oxid Med Cell Longev 2019; 2019: 1–26. 
341 Schmidt HHHW, Stocker R, Vollbracht C, et al. Antioxidants in Translational Medicine. 
Antioxid Redox Signal 2015; 23: 1130–43. 
342 Zhang Y, Ding S, Li C, Wang Y, Chen Z, Wang Z. Effects of N-acetylcysteine treatment in acute 
respiratory distress syndrome: A meta-analysis. Exp Ther Med 2017; 14: 2863–8. 
343 Åkerlund B, Jarstrand C, Lindeke B, Sönnerborg A, Åkerblad A-C, Rasool O. Effect of N -
acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur 
J Clin Pharmacol 1996; 50: 457–61. 
344 Sotelo N, de los Ángeles Durazo M, Gonzalez A, Dhanakotti N. Early treatment with N-
acetylcysteine in children with acute liver failure secondary to hepatitis A. Ann Hepatol 2009; 
8: 353–8. 
345 De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement 
of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 
1535–41. 
346 Abeysekera R, Illangasekera U, Jayalath T, Sandeepana A, Kularatne S. Successful use of 
intravenous N-acetylcysteine in dengue haemorrhagic fever with acute liver failure. Ceylon 
Med J 2013; 57: 166. 
347 Kumarasena RS, Mananjala Senanayake S, Sivaraman K, et al. Intravenous N-acetylcysteine in 
dengue-associated acute liver failure. Hepatol Int 2010; 4: 533–4. 
348 Senanayake M, Jayamanne M, Kankananarachchi I. N-acetylcysteine in children with acute 
liver failure complicating dengue viral infection. Ceylon Med J 2013; 58: 80. 
349 Guerrero CA, Torres DP, García LL, Guerrero RA, Acosta O. N -Acetylcysteine Treatment of 
Rotavirus-Associated Diarrhea in Children. Pharmacother J Hum Pharmacol Drug Ther 2014; 
34: e333–40. 
350 Martindale R, Patel JJ, Taylor B, Arabi YM, Warren M, McClave SA. Nutrition Therapy in 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
54 
 
Critically Ill Patients With Coronavirus Disease 2019. J Parenter Enter Nutr 2020; 44: 1174–84. 
351 Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 
2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. J Med 
Virol 2020; 92: 568–76. 
352 WHO, Aylward, Bruce (WHO); Liang W (PRC). Report of the WHO-China Joint Mission on 
Coronavirus Disease 2019 (COVID-19). 2020 https://www.who.int/docs/default-
source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. 
353 Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass: Post-viral 
syndrome post COVID-19. Med Hypotheses 2020; 144: 110055. 
354 Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive 
care unit. Clin Nutr 2019; 38: 48–79. 
355 Romano L, Bilotta F, Dauri M, et al. Short Report - Medical nutrition therapy for critically ill 
patients with COVID-19. Eur Rev Med Pharmacol Sci 2020; 24: 4035–9. 
356 Cena H, Maffoni S, Braschi V, et al. Position paper of the Italian association of medical 
specialists in dietetics and clinical nutrition (ANSISA) on nutritional management of patients 
with COVID-19 disease. Med J Nutrition Metab 2020; 13: 113–7. 
357 Naja F, Hamadeh R. Nutrition amid the COVID-19 pandemic: a multi-level framework for 
action. Eur J Clin Nutr 2020; 74: 1117–21. 
358 Brugliera L, Spina A, Castellazzi P, et al. Nutritional management of COVID-19 patients in a 
rehabilitation unit. Eur J Clin Nutr 2020; 74: 860–3. 
359 Anderson L. Providing nutritional support for the patient with COVID-19. Br J Nurs 2020; 29: 
458–9. 
360 Wang H, Zeng T, Wu X, Sun H. Holistic care for patients with severe coronavirus disease 2019: 
An expert consensus. Int J Nurs Sci 2020; 7: 128–34. 
361 Frajkova Z, Tedla M, Tedlova E, Suchankova M, Geneid A. Postintubation Dysphagia During 
COVID-19 Outbreak-Contemporary Review. Dysphagia 2020; 35: 549–57. 
362 Horby P, Mafham M, Linsell L, et al. Hydroxychloroquine for COVID-19-Preliminary Report 
Effect of Hydroxychloroquine in Hospitalized Patients. medRxiv 2020; published online July 
15. DOI:10.1101/2020.07.15.20151852. 
363 James P, Friis H, Woodd S, et al. Minimal impact of an iron-fortified lipid-based nutrient 
supplement on Hb and iron status: a randomised controlled trial in malnourished HIV-positive 
African adults starting antiretroviral therapy. Br J Nutr 2015; 114: 1–11. 
364 Sochas L, Channon AA, Nam S. Counting indirect crisis-related deaths in the context of a low-
resilience health system: the case of maternal and neonatal health during the Ebola epidemic 
in Sierra Leone. Health Policy Plan 2017; 32: iii32–9. 
365 Roberton T, Carter ED, Chou VB, et al. Early estimates of the indirect effects of the COVID-19 
pandemic on maternal and child mortality in low-income and middle-income countries: a 
modelling study. Lancet Glob Heal 2020; 8: e901–8. 
366 Fore HH, Dongyu Q, Beasley DM, Ghebreyesus TA. Child malnutrition and COVID-19: the time 
to act is now. Lancet 2020; 396: 517–8. 
 
Next two pages: 
 
Figure 1: Overview flowchart of articles considered in narrative synthesis 
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Supplementary Material 1: Search Strategy 
This review looks at how malnutrition in all its forms (undernutrition, micronutrient deficiencies and 
overnutrition) may influence both susceptibility to, and progression of, COVID-19. We synthesise 
information on the following 13 nutrition-related components and their potential interactions with 
COVID-19:  
i) Protein-energy malnutrition 
ii) Overweight, obesity and diabetes 
iii) Anaemia 
iv) Iron 
v) Vitamin A 
vi) Vitamin C 
vii) Vitamin D 
viii) Vitamin E 




xiii) Nutritional support 
Each section follows the following structure: 
1. Landscape review of other pertinent evidence 
This section does not require a systematic search. Coverage is limited to: a) very brief description of 
nutrient/condition vis-à-vis infection/immunity; b) evidence of any role in other viral infections 
(especially of respiratory tract); c) possible mechanisms; d) possible utility in treatment. 
2. Systematic review of published literature and pre-prints 
 
a) PUBMED – see example search string in Supplementary Material 2 
b) EMBASE - see example search string below Supplementary Material 2  
c) Pre-print servers: see search terms in Supplementary Material 2 
i. WHO Global literature on coronavirus disease: https://search.bvsalud.org/global-
literature-on-novel-coronavirus-2019-ncov/ 
ii. The Lancet COVID-19 Resource Centre: https://www.thelancet.com/coronavirus  
iii. The JAMA network Coronavirus Resource site: 
https://jamanetwork.com/collections/46099/coronavirus-covid19  
iv. The New England Journal of Medicine Coronavirus Resource site: 
https://www.nejm.org/coronavirus  
v. The bioRxiv preprint server: https://www.biorxiv.org  
vi. The medRxiv preprint server: https://www.medrxiv.org  
vii. The ChinaXiv preprint server: http://chinaxiv.org/home.htm  
viii. The ChemRxiv preprint server: https://chemrxiv.org/  
ix. The Preprints server: https://www.preprints.org  
x. The Research Square preprint site: https://www.researchsquare.com  
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xi. The LitCovid hub: https://www.ncbi.nlm.nih.gov/research/coronavirus/  
xii. The WHO Global research database: 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-
research-on-novel-coronavirus-2019-ncov  
xiii. The Cell Press Coronavirus Resource Hub: https://www.cell.com/2019-nCOV  
xiv. The Nature Research Coronavirus collection: 
https://www.nature.com/collections/hajgidghjb 
xv. Science Coronavirus collection: 
https://www.sciencemag.org/collections/coronavirus 
xvi. The COVID-19 Primer: https://covid19primer.com/dashboard  
Inclusion criteria 
- Human studies 
- PubMed & EMBASE: related to COVID-19, MERS-CoV or SARS-CoV AND disease 
susceptibility / progression AND nutrient exposure of interest.  
- Pre-print servers: related to COVID-19 AND disease susceptibility / progression AND 
nutrient exposure of interest. 
- All original studies of any design 
- Systematic reviews (to check bibliography) 
- Published in English language 
Exclusion criteria 
- Comments, letters, opinions, non-systematic reviews 
 
3. Systematic review of the following clinical trial registers: 
a) ClinicalTrials.gov: https://clinicaltrials.gov/  
b) ISRCTN Registry: https://www.isrctn.com/ 
c) EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ 
d) Pan African Clinical Trials Registry: https://pactr.samrc.ac.za/  
e) India Clinical Trials Registry: http://ctri.nic.in/Clinicaltrials/login.php 
f) Chinese Clinical Trial Registry: http://www.chictr.org.cn/enIndex.aspx 
Inclusion criteria: trials related to COVID-19 AND nutrient exposure of interest, human trials, 
protocols in English language.  
See Supplementary Material 2 for simplified search terms.  
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Supplementary Material 2: Search terms 
Search terms for PubMed and EMBASE databases  
  Concept 1 AND  (Concept 2 OR  Concept 3) AND Concept 4 





Terms specific to sub-section 
Free text terms  
 
coronavir* OR 
“coronavirus infections” OR 
covid* OR ncov*OR 2019-ncov 
OR 2019ncov OR “2019-novel 
CoV” OR HCoV* OR cov2 OR 
“cov 2” OR OC43 OR NL63 OR 
229E OR HKU1 OR “sars 
coronavirus 2” OR “sars-like 
coronavirus” OR 
 
“Severe Acute Respiratory  
Syndrome” OR SARS OR sars-
cov* OR sarscov* OR 
 
“Middle East Respiratory 





“adaptive immunity” OR 
“acquired immunity” OR 
“innate immunity” OR 
“cell-mediated immunity” OR 
“humoral immunity” OR 
“antibody formation” OR 
immunosuppression OR 
immunodepression OR 
“immunity impairment” OR 
“immune dysfunction” OR 
“lymphocyte function” OR 
“macrophage activity” OR 
“oxidative stress” OR 
“host defence” OR 
“immune response” OR 
inflammation OR 
“immune pathology” OR 
immunopathology OR 
"Macrophage activation 
syndrome” OR  




“viral load” OR 
“viral pathogen*” OR 
“viral replication” OR 
“viral mutation” OR 
“viral transmission” OR 






pneumonia OR bronchitis OR 
bronchiolitis OR “asthma 
exacerbation*” OR seizure* 
OR diarrhoea OR diarrhea OR 
“acute gastroenteritis” or 
dehydration or “electrolyte 
imbalance” OR “renal failure” 
OR “kidney failure” OR “multi-
organ failure*” OR “multiple 
organ failure*” OR 
encephalomyelitis OR 
“Kawasaki disease” OR 
“Kawasaki syndrome” OR 
“Mucocutaneous Lymph Node 
Syndrome” OR coagulopathy 
OR death OR mortality 
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  Concept 1 AND  (Concept 2 OR  Concept 3) AND Concept 4 
 











"Severe Acute Respiratory 
Syndrome"[Mesh] OR 
"severe acute respiratory 
syndrome coronavirus 2" 
[Supplementary Concept] OR 










"Oxidative Stress"[Mesh] OR 
"Macrophage Activation 
Syndrome"[Mesh] 














Imbalance"[Mesh] OR "Kidney 
Failure, Chronic"[Mesh] OR 
"Shock"[Mesh] OR 
"Encephalomyelitis"[Mesh] OR 
"Mucocutaneous Lymph Node 












exp Coronavirus/  
exp Coronaviridae infection/ 
exp severe acute respiratory 
syndrome/  
exp SARS coronavirus/  
exp Middle East respiratory 
syndrome coronavirus/ 
exp immune system/ 
exp T lymphocyte/ 
exp inflammation/ 
exp immune deficiency/ 
exp oxidative stress/ 
exp macrophage activation/ 
exp cytokine storm/ 
exp virus load/ 
exp virus transmission/ 
exp virus shedding/  
exp virus virulence/  
exp virus characterization/  
exp virus immunity/  
exp virus infection/   
exp virus cell interaction/  
exp virus transcription/  
exp virus inhibition/ 
exp respiratory tract infection/ 
exp ascorbic acid/ 
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  Concept 1 AND  (Concept 2 OR  Concept 3) AND Concept 4 
exp gastrointestinal infection/ 
exp pneumonia/  
exp virus pneumonia/ 
exp bronchitis/ 
exp bronchiolitis/  




exp gastroenteritis/  
exp viral gastroenteritis/ 
exp dehydration/ 
exp electrolyte disturbance/ 
exp kidney failure/ 
exp multiple organ failure/ 
exp encephalomyelitis/ 
exp mucocutaneous lymph 
node syndrome/ 
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Vitamin C example 
Example search string in PubMed 
(coronavir* OR “coronavirus infections” OR covid* OR ncov* OR “2019-ncov” OR “2019ncov” OR “2019-novel CoV” OR HCoV* OR cov2 OR “cov 2” OR OC43 
OR NL63 OR 229E OR HKU1 OR “sars coronavirus 2” OR “sars-like coronavirus” OR “Severe Acute Respiratory Syndrome” OR SARS OR sars-cov* OR sarscov* 
OR “Middle East Respiratory Syndrome” OR MERS OR “MERS-CoV” OR "Coronavirus Infections"[Mesh] OR “Coronavirus”[Mesh] OR “COVID-
19"[Supplementary Concept] OR "Severe Acute Respiratory Syndrome"[Mesh] OR "severe acute respiratory syndrome coronavirus 2"[Supplementary 
Concept] OR "Middle East Respiratory Syndrome Coronavirus"[Mesh]) 
AND 
((“adaptive immunity” OR “acquired immunity” OR “innate immunity” OR “cell-mediated immunity” OR “humoral immunity” OR “antibody formation” OR 
immunosuppression OR immunodepression OR “immunity impairment” OR “immune dysfunction” OR “lymphocyte function” OR “macrophage activity” OR 
“oxidative stress” OR “host defence” OR “immune response” OR inflammation OR “immune pathology” OR immunopathology OR "Macrophage activation 
syndrome” OR “MAS” OR “cytokine storm” OR "Immune System Phenomena"[Mesh] OR "T-Lymphocytes, Regulatory"[Mesh] OR "Inflammation"[Mesh] OR 
"Immunosuppression"[Mesh] OR "Oxidative Stress"[Mesh] OR "Macrophage Activation Syndrome"[Mesh]) 
OR  
(“viral load” OR “viral pathogen*” OR “viral replication” OR “viral mutation” OR “viral transmission” OR “acute respiratory distress syndrome” OR “ARDS” 
OR “hemophagocytic lymphohistiocytosis” OR “HLH” OR “pneumonia” OR “bronchitis” OR “bronchiolitis” OR “asthma exacerbation*” OR “seizure*” OR 
“diarrhoea” OR “diarrhea” OR “acute gastroenteritis” or “dehydration” or “electrolyte imbalance” OR “renal failure” OR “kidney failure” OR “multi-organ 
failure*” OR “multiple organ failure*” OR “encephalomyelitis” OR “Kawasaki disease” OR “Kawasaki syndrome” OR “Mucocutaneous Lymph Node 
Syndrome” OR “coagulopathy” OR “death” OR “mortality” OR “Viral Load”[Mesh] OR “Virus Physiological Phenomena”[Mesh] OR "Respiratory Distress 
Syndrome, Adult"[Mesh] OR "Respiratory Tract Infections"[Mesh] OR "Gastrointestinal Diseases"[Mesh] OR "Gastroenteritis"[Mesh] OR "Seizures"[Mesh] 
OR "Diarrhea"[Mesh] OR "Dehydration"[Mesh] OR "Water-Electrolyte Imbalance"[Mesh] OR "Kidney Failure, Chronic"[Mesh] OR "Shock"[Mesh] OR 
"Encephalomyelitis"[Mesh] OR "Mucocutaneous Lymph Node Syndrome"[Mesh] OR "Blood Coagulation Disorders"[Mesh] OR "Mortality"[Mesh])) 
AND 
(“vitamin C” OR “ascorbic acid” OR "Ascorbic Acid"[Mesh]) 
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Example search string in EMBASE 
((coronavir* OR "coronavirus infections" OR covid* OR ncov* OR 2019-ncov OR 2019ncov OR "2019-novel CoV" OR HCoV* OR cov2 OR "cov 2" OR OC43 OR 
NL63 OR 229E OR HKU1 OR "sars coronavirus 2" OR "sars-like coronavirus" OR "Severe Acute Respiratory Syndrome" OR SARS OR sars-cov* OR sarscov* OR 
"Middle East Respiratory Syndrome" OR MERS OR MERS-CoV).ti,ab,kw. OR exp Coronavirus/ OR exp Coronaviridae infection/ OR exp severe acute 
respiratory syndrome/ OR exp SARS coronavirus/ OR exp Middle East respiratory syndrome coronavirus/) 
AND 
((("adaptive immunity" OR "acquired immunity" OR "innate immunity" OR "cell-mediated immunity" OR "humoral immunity" OR "antibody formation" OR 
immunosuppression OR immunodepression OR "immunity impairment" OR "immune dysfunction" OR "lymphocyte function" OR "macrophage activity" OR 
"oxidative stress" OR "host defence" OR "immune response" OR inflammation OR "immune pathology" OR immunopathology OR "Macrophage activation 
syndrome" OR MAS OR "cytokine storm").ti,ab,kw.  OR exp immune system/ OR exp T lymphocyte/ OR exp inflammation/ OR exp immune deficiency/ OR 
exp oxidative stress/ OR exp macrophage activation/ OR exp cytokine storm/) 
OR  
(("viral load" OR "viral pathogen*" OR "viral replication" OR "viral mutation" OR "viral transmission" OR "acute respiratory distress syndrome" OR ARDS OR 
"hemophagocytic lymphohistiocytosis" OR HLH OR pneumonia OR bronchitis  OR bronchiolitis OR "asthma exacerbation*" OR seizure* OR diarrhoea OR 
diarrhea OR "acute gastroenteritis" or dehydration or "electrolyte imbalance" OR "renal failure" OR "kidney failure" OR "multi-organ failure*" OR "multiple 
organ failure*" OR encephalomyelitis OR "Kawasaki disease" OR "Kawasaki syndrome" OR "Mucocutaneous Lymph Node Syndrome" OR coagulopathy OR 
death OR mortality).ti,ab,kw. OR exp virus load/ OR exp virus transmission/ OR exp virus shedding/ OR exp virus virulence/ OR exp virus characterization/ 
OR exp virus immunity/ OR exp virus infection/  OR exp virus cell interaction/ OR exp virus transcription/ OR exp virus inhibition/ OR exp respiratory tract 
infection/ OR exp gastrointestinal infection/ OR exp pneumonia/ OR exp virus pneumonia/ OR exp bronchitis/ OR exp bronchiolitis/ OR exp viral 
bronchiolitis/ OR exp asthma/ OR exp seizure/ OR exp diarrhea/ OR exp gastroenteritis/ OR exp viral gastroenteritis/ OR exp dehydration/ OR exp 
electrolyte disturbance/ OR exp kidney failure/ OR exp multiple organ failure/ OR exp encephalomyelitis/ OR exp mucocutaneous lymph node syndrome/ 
OR exp blood clotting disorder/ OR exp mortality/)) 
AND 
(("vitamin C" OR "ascorbic acid").ti,ab,kw. OR exp ascorbic acid/) 
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Search terms for specific sections (used in concept 4) 
Section PubMed search terms EMBASE search terms 
Protein-energy Malnutrition “protein energy malnutrition” OR “protein-energy 
malnutrition” OR “childhood undernutrition” OR “severe acute 
malnutrition” OR marasmus OR kwashiorkor OR “bilateral 
pitting oedema” OR “bilateral pitting edema” OR “elderly 
undernutrition” OR “low body mass index” OR “low BMI” OR 
sarcopenia OR (undernutrition AND elderly) OR “adult 
malnutrition” OR “adult undernutrition” OR "Protein-Energy 
Malnutrition"[Mesh] OR "Sarcopenia"[Mesh] OR "Severe 
Acute Malnutrition"[Mesh] 
("protein energy malnutrition" OR "protein-energy 
malnutrition" OR "childhood undernutrition" OR "severe acute 
malnutrition" OR marasmus OR kwashiorkor OR "bilateral 
pitting oedema" OR "bilateral pitting edema" OR "elderly 
undernutrition" OR "low body mass index" OR "low BMI" OR 
sarcopenia OR (undernutrition AND elderly) OR "adult 
malnutrition" OR "adult undernutrition").ti,ab,kw. OR exp 
malnutrition/ OR exp kwashiorkor/ OR exp marasmus/ OR exp 
muscle atrophy/ OR exp sarcopenia/ 
Overweight, obesity, diabetes overweight OR obes* OR “high body mass index” OR “high 
BMI” OR diabetes OR diabetic OR prediabetes OR 
"Obesity"[Mesh] OR "Overweight"[Mesh] OR "Diabetes 
Mellitus"[Mesh] 
(overweight OR obes* or "high body mass index" OR "high 
BMI" OR diabetes OR prediabetes).ti,ab,kw. OR exp obesity/ 
OR exp morbid obesity/ OR exp obesity management/ OR exp 
diet induced obesity/ OR exp abdominal obesity/ OR exp 
diabetic obesity/ OR exp maternal obesity/ OR exp diabetes 
mellitus/ OR exp impaired glucose tolerance/ 
Anaemia anaemia OR anemia OR "Anemia"[Mesh] (anaemia OR anemia).ti,ab,kw. OR exp megaloblastic anemia/ 
or exp microcytic anemia/ or exp iron deficiency anemia/ or 
exp normochromic normocytic anemia/ or exp sideroblastic 
anemia/ or exp hemolytic anemia/ or exp aplastic anemia/ or 
exp anemia/ or exp macrocytic anemia/ or exp pernicious 
anemia/ 
Vit A “vitamin A” OR retinol OR carotenoid* OR “xerophthalmia” OR 
"Vitamin A"[Mesh] OR "Vitamin A Deficiency"[Mesh] 
("vitamin A" OR retinol OR carotenoid* OR 
xerophthalmia).ti,ab,kw. OR exp retinol/ OR exp carotenoid/ 
OR exp retinol deficiency/ 
Vit C “vitamin C” OR “ascorbic acid” OR "Ascorbic Acid"[Mesh] ("vitamin C" OR "ascorbic acid").ti,ab,kw. OR exp ascorbic acid/ 
Vit D “Vitamin D” OR “vitamin D2” OR “vitamin D3” OR 
“cholecalciferol” OR “ergocalciferol” OR “25 hydroxyvitamin 
D” 
("vitamin D" OR "cholecalciferol" OR "ergocalciferol" OR "25 
hydroxyvitamin D").ti,ab,kw. OR exp vitamin D/ 
Vit E “Vitamin E” OR “alpha tocopherol” OR "Vitamin E"[Mesh] ("vitamin E" OR "alpha tocopherol").ti,ab,kw. OR exp alpha 
tocopherol/ 
PUFAs  “PUFA” OR “polyunsaturated fatty acid” OR "eicosapentaenoic 
acid" OR “EPA” OR “docosahexaenoic acid” OR “DHA” OR 
“gamma linolenic acid” OR “GLA” OR “fish oil”[Mesh] 
("PUFA" OR "polyunsaturated fatty acid" OR "eicosapentaenoic 
acid" OR "EPA" OR "docosahexaenoic acid" OR  "DHA" OR 
"gamma linolenic acid" OR "GLA" OR "fish oil").ti,ab,kw. OR 
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exp polyunsaturated fatty acid/ OR exp eicosapentaenoic acid/ 
OR exp docosahexaenoic acid/ OR exp gamma linolenic acid/ 
OR exp N-3 fatty acid/ 
Iron iron OR ferrous OR ferric OR hepcidin OR ferritin OR transferrin 
OR Tsat OR heme OR haem OR hypoferremia OR 
hemochromatosis OR (("Ferritins"[Mesh] OR 
"Transferrins"[Mesh]) OR "Hepcidins"[Mesh]) OR "Receptors, 
Transferrin"[Mesh] OR "Iron Metabolism Disorders"[Mesh] OR 
"Iron, Dietary"[Mesh] 
 
(iron OR ferrous OR ferric OR hepcidin OR ferritin OR 
transferrin OR Tsat OR heme OR haem OR hypoferremia OR 
hemochromatosis).ti,ab,kw. OR exp iron storage/ OR exp iron 
chelation/ OR exp iron/ OR exp iron overload/ OR exp iron 
metabolism disorder/ OR exp iron intake/ OR exp iron 
responsive element/ OR exp iron chelate/ OR exp iron 
deficiency anemia/ OR exp iron depletion/ OR exp iron 
therapy/ OR exp iron transport/ OR exp iron homeostasis/ OR 
exp iron chelating agent/ OR exp iron absorption/ OR exp iron 
deficiency/ OR exp iron metabolism/ OR exp iron binding 
capacity/ OR exp iron restriction/ OR exp iron balance/ OR exp 
iron blood level/ OR exp transferrin receptor/ OR exp 
transferrin receptor 2/ OR exp transferrin blood level/ OR exp 
transferrin/ OR exp hepcidin/ OR exp ferritin/ 
Selenium selenium OR "Selenium"[Mesh] (selenium).ti,ab,kw.  OR exp selenium/ 
Zinc zinc OR "Zinc"[Mesh] (zinc).ti,ab,kw.  OR exp zinc/ 
Anti-oxidants “anti-oxidant*” OR “anti oxidant*” OR hydroxytyrosol OR 
lycopene OR lutein OR carotene OR carotenoid* OR 
polyphenol* OR resveratrol OR "Antioxidants"[Mesh] OR 
"Resveratrol"[Mesh] OR "Carotenoids"[Mesh] 
 
("anti-oxidant*" OR "anti oxidant*" OR hydroxytyrosol OR 
lycopene OR lutein OR carotene OR carotenoid OR 
polyphenol* OR resveratrol).ti,ab,kw. OR exp antioxidant/ OR 
exp lycopene/ OR exp carotenoid/ OR exp polyphenol/ OR exp 
resveratrol/) 
Nutritional support “nutritional support” OR “enteral nutrition” OR “parenteral 
nutrition” OR "Nutritional Support"[Mesh] 
 
("nutritional support" OR "enteral nutrition" OR "parenteral 
nutrition").ti,ab,kw. OR exp nutritional support/ OR exp enteric 
feeding/ OR exp parenteral nutrition/ 
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Searches on clinical trial registries and pre-print servers are restricted to COVID-19 related studies, and use simplified search terms as below: 
Section Disease Nutritional exposure 
Protein-energy Malnutrition coronavirus AND “Protein-energy malnutrition” 
Undernutrition 
Sarcopenia 
“Severe acute malnutrition 




Anemia coronavirus AND Anemia 
Anaemia 
Vit A coronavirus AND “Vitamin A” 
Retinol 
Carotenoid 
Vit C coronavirus AND “Vitamin C” 
“Ascorbic Acid” 
Vit D coronavirus AND “Vitamin D” 
Cholecalciferol 
Ergocalciferol 
“25 hydroxyvitamin D” 
Vit E coronavirus AND “Vitamin E” 
Tocopherol 








Selenium coronavirus AND Selenium 
Zinc coronavirus AND Zinc 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 










Nutritional support coronavirus AND “nutritional support” 
“enteral nutrition” 
“Parenteral nutrition” 
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Supplementary Material 3: Detailed Search Results per section 












Pubmed and Embase searches 



























No. of hits 9 18 28 13 54 118 6 9 53 19 522 9 36 894 



























No. of hits 35 36 49 26 95 380 13 68 159 26 809 101 41 1838 
PUBMED + EMBASE hits 44 54 77 39 149 498 19 77 212 45 1331 110 77 2732 
No. of duplicates 5 11 18 9 39 91 7 8 69 8 384 0 12 661 
No. taken forwards to title / abstract 
screen 39 43 59 30 110 407 12 69 143 37 947 110 65 2071 
No. ineligible 36 39 50 24 65 398 10 63 99 32 832 87 48 1783 
No. taken to full text screen 3 4 9 6 45 9 2 6 44 5 115 23 17 288 
No. ineligible: not related to COVID-
19, SARS-CoV or MERS-CoV 1 0 3 0 10 0 0 0 9 0 1 8 3 35 
No. ineligible: not related to disease 
susceptibility or progression 0 0 0 0 1 0 0 3 7 0 12 10 1 34 
No. ineligible: not related to nutrient 
/ condition in your section 0 0 0 0 25 6 0 1 6 0 2 2 3 45 
No. ineligible: other reasons (e.g. not 
English, not human, reviews) 2 4 4 6 9 1 2 2 22 5 82 3 10 152 
FINAL included in review  0 0 2 0 0 2 0 0 0 0 18 0 0 22 
Clinical trial registries (searches 21-22/05/2020) 
clinicaltrials.gov 9 24 18 1 86 11 2 12 43 5 70 28 13 322 
ISRCTN Registry 0 0 0 0 3 0 0 0 0 0 26 1 0 30 
EU Clinical Trials Register 0 0 5 5 45 1 0 2 0 1 13 0 1 73 
Pan African Clinical Trials Registry 0 0 0 0 0 0 0 1 0 0 0 0 2 3 
India Clinical Trials Registry:  0 1 0 0 0 0 0 1 0 0 0 0 0 2 
Chinese Clinical Trial Registry:  0 2 1 0 0 0 0 0 0 0 0 0 0 3 
Total hits 9 27 24 6 134 12 2 16 43 6 109 29 16 433 
Total no. sent to author 9 27 24 6 134 12 2 16 43 6 109 29 16 433 
No. ineligible at author check 7 17 3 5 131 12 2 3 35 3 96 26 14 354 
Total included in review  2 10 21 1 3 0 0 13 8 3 13 3 2 79 
Pre-print servers (searches 25-28/05/2020) 
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WHO Global literature on coronavirus 
disease 1 14 34 1 37 18 4 19 4 2 431 5 26 596 
The Lancet COVID-19 Resource 
Centre 10 3 6 1 30 8 0 2 1 0 104 7 4 176 
The JAMA network Coronavirus 
Resource site 2 1 1 1 0 6 0 2 3 2 54 0 7 79 
The New England Journal of Medicine 
Coronavirus Resource site 0 0 0 0 2 2 0 0 0 0 22 0 1 27 
The bioRxiv preprint server 1 0 0 0 0 0 1 0 0 1 8 0 0 11 
The medRxiv preprint server 54 54 56 48 138 62 0 21 22 2 770 39 37 1303 
The ChinaXiv preprint server 14 4 1 1 0 0 0 1 1 3 0 7 1 33 
The ChemRxiv preprint server 4 0 9 3 1 0 1 2 2 0 1 0 0 23 
The Preprints server 9 11 9 8 0 0 0 2 7 4 5 22 3 80 
The Research Square preprint site 0 0 4 5 2 0 0 0 5 0 9 17 0 42 
The LitCovid hub 46 48 47 46 32 14 3 11 69 2 376 12 178 884 
The WHO Global research database 33 8 30 12 29 0 4 14 5 2 326 0 4 467 
The Cell Press Coronavirus Resource 
Hub 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
The Nature Research Coronavirus 
collection 15 10 6 9 29 8 1 15 15 1 99 9 13 230 
Science Coronavirus collection 2 2 2 1 3 0 0 7 2 1 27 3 0 50 
The COVID-19 Primer  0 0 0 0 68 4 0 0 1 0 89 0 0 162 
Total hits from pre-print servers 191 155 205 136 371 122 14 96 138 20 2321 121 274 4164 
No. ineligible from simple screen 190 138 152 132 330 118 6 83 132 19 2037 117 254 3708 
No. of duplicates across servers 0 4 15 0 17 0 4 3 0 0 130 0 5 178 
Total no. of citations sent to author  1 13 38 4 24 4 4 10 6 1 154 4 15 278 
No. ineligible at author check: not 
related to COVID-19 0 0 15 0 0 2 0 0 0 0 1 0 0 18 
No. ineligible at author check: not 
related to disease susceptibility or 
progression 0 0 0 0 0 0 0 0 0 0 14 0 0 14 
No. ineligible at author check: not 
related to nutrient / condition in your 
section 1 0 3 0 8 2 2 0 0 0 15 0 3 34 
No. ineligible at author check: other 
reason for exclusion (e.g. not in 
English), reviews 0 13 14 4 16 0 2 9 6 1 95 1 12 173 
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Total included in review (data 
extraction) 0 0 6 0 0 0 0 1 0 0 29 3 0 39 
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Supplementary Material 4: Results from Clinical Trial Registries Search 
Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 









gamma-linolenic acid and 
antioxidants (including 
2840 IU vitamin A)  
Isocaloric placebo Serum ferritin level, cytokine 
storm parameters 
(interleukin-6, Tumor necrosis 
factor-α, and monocyte 
chemoattractant protein 1), C-
reactive protein, total 
leukocyte count, differential 
lymphocytic count and 
neutrophil to lymphocyte 
ratio.  






Colchicine tablets -1.5 mg 
loading then 0.5 mg BID 
P.O 
Standard of care 
including daily 
(vitamin C 3grams, 
400 mg Thiamine, 
Selenium, Omega-3 
500 mg daily, Vit A, 
Vit D, Azithromycin, 
Ceftriaxone, Kaletra 
400 BID) 
Primary outcomes: 1. CRPxN/R 
ratio change. 2. Clinical 
deterioration by the WHO 
definition including change in 
fever or O2 Saturation. 3. PCR 
Viral Load change in RT-PCR. 
4. CT severity involvement 
index change in CT 
involvement. 











800mg on day 1 followed 
by 400mg on days 2-5. 
Vitamin D - IU1600 on 
day 1 and IU 800 on 
days 2-5 
COVID-19 status 








C, vit D, Zn 
VitC, vitD, Zn Prevention of COVID-19 
symptoms 












unknown dose of vit D, Zn 
No data Prevention of COVID-19 
symptoms 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 





control trial  
60 Positive cases 
admitted to 
hospital > 18y 
VitD (Videsil 100.000 UI) None Progression and clinical 
outcomes 
Vit D NCT04363840 USA non-blind, 
randomised, 
two-arm, no-





Group 1 - Aspirin (81mg 
once daily for 14 days) & 
group 2 aspirin  (81mg 
once daily for 14 days) + 
vitD (50,000 IU once 
weekly for 2 weeks) 
Observation only Hospitalization for COVID-19 








Colchicine (1.5 mg 
loading then 0.5 mg BID 
P.O) + std tx (vitamin C 
3grams daily, 400 mg 
Thiamine, Selenium, 
Omega-3 500 mg daily, 
Vit A, Vit D, Azithromycin, 
Ceftriaxone, Kaletra 400 
BID 10 days) 
Standard tx (vitamin C 
3grams daily, 400 mg 
Thiamine, Selenium, 
Omega-3 500 mg 
daily, Vit A, Vit D, 
Azithromycin, 
Ceftriaxone, Kaletra 
400 BID 10 days) 
CRP, clinical status, PCR viral 
load, CT severity involvement 
index 











azithromycin, vitC, vitD, 
Zn 
VitC, vitD, Zn Rate of recovery, reduction of 
symptomatic days 
Vit D NCT04399746 Mexico non-blind, 
non-
randomised, 
control trial  





Ivermectin 6mg once 
daily in day 0,1,7 and 8; 
Azithromycin 500mg once 
daily for 4 days; 
Cholecalciferol 400 IU 
twice daily for 30 days 
Observation only Viral clearance, symptoms 
duration, O2 sat 










dose) + vitD (Vitamin D3 
100,000 IU on day 1) 
VitD (Vitamin D3 
100,000 IU on day 1) 
Hospitalization for COVID-19 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 




260 Adults >=70y 
with COVID-
19 
High dose vitD 
(400,000IU) 
Low dose vitD 
(50,000IU) 
Number of deaths 








VitD (Calcifediol: 524µg 
on day 1; 266 µg on days 
3, 7, 14, 21 and 28) + best 
available tx (combination 
of drugs included in the 
current protocol of the 
Ministry of Health and/or 
complementary notes 
issued by the Spanish 
Agency of Medicines and 
Health Products (AEMPS)) 
Best available tx 
(combination of drugs 
included in the 
current protocol of 
the Ministry of Health 
and/or 
complementary notes 
issued by the Spanish 
Agency of Medicines 
and Health Products 
(AEMPS)) 
Admission to ICU, death 







Zinc: 15 mg x 2 per day 
during 2 months; 25-OH 
cholecalciferol (2000 IU) 
per day during 2 months 
Usual tx Survival rate 





64 17y+ with 
COVID-19 
High dose vitD (50,000IU) Low dose vitD 
(1000IU) 
Symptom recovery 








Single dose of 25000 UI 
VitD + usual tx (NSAIDs, 
ACE2 inhibitor, ARB or 
thiazolidinediones) 
Usual tx (NSAIDs, 
ACE2 inhibitor, ARB 
or thiazolidinediones) 
Mortality 











0,266 mg Calcifediol 
(unknown frequency) 
Placebo Progression and mortality 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 
Vit D NCT04395768 Australia Single-blind, 
randomized, 
control trial 
200 18y+ with 
active COVID-
19 
Vit C (inpatients: Vitamin 
C (Sodium Ascorbate) 
50mg/kg every 6hrs on 
day 1 followed by 
100mg/kg every 6hrs (4x 
per day; 400mg/kg/day) 
for 7 days (average 
28g/day; maximum dose 
of 50g/24hrs for those 
weighing more than 
125kg) & outpatients: 
200mg/kg x1 IV, then 1 
gram PO three times per 




400mg (2x200mg) PO for 
1 day, followed by 200mg 
PO per day for 6 days 
Azithromycin 500 mg PO 
on day 1 followed by 250 
mg PO once daily for 4 
days Zinc Citrate 30mg 
elemental zinc PO daily 
Vitamin D3 5,000iu PO 
daily for 14 days Vitamin 
B12 (Methylcobalamin) 





400mg (2x200mg) PO 
for 1 day, followed by 
200mg PO per day for 
6 days Azithromycin 
500 mg PO on day 1 
followed by 250 mg 
PO once daily for 4 
days Zinc Citrate 
30mg elemental zinc 
PO daily Vitamin D3 
5,000iu PO daily for 
14 days Vitamin B12 
(Methylcobalamin) 
500mcg PO daily for 
14 days 
Symptoms, duration of 
hospital stay, ventilation, 
mortality 






clinical trial  
1500 18-75y (1) 
diagnosed (2) 
prevention 
25 mcg of 25(OH)D3 once 
daily - for 2 months 
Placebo for 2 months Infection, severity, 
hospitalization, disease 
duration, death, O2 support 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 




100 Children and 
adults 
n/a - measure "exposure" 
is Vitamin D levels in 
positive COVID-19 
patients 
n/a Disease severity 















n/a - measured 
"exposure" is Vitamin D 
levels in positive COVID-
19 patients & Vitamin D 
levels in GP patients 
n/a Cross sectional: Death, O2 
therapy - Cohort: Infection 
with COVID 19 
Vit D NCT04370808 Portugal Prospective 
cohort study  
500 18y+ with 
active COVID-
19 
n/a - measured 
"exposure" is Vitamin D 
levels / genetic variants in 
vitamin D-related genes 





80 0.1 - 85 y 
males 
n/a - Measured 
"exposure" is Vitamin D 
deficiency 
n/a Progression, treatment 
outcome and prognosis of 
COVID-19   









Initial 1000 mg at 15 
mg.kg.hr (1g) 
Subsequent 500mg at 125 
mg.hr (0.5g) 
5% glucose 14d mortality 




















dose not stated 
Standard treatment 20d mortality  
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 
COVID-19, (3-
99 years) 

















(Favipiravir & Standard of 
Care) Favipiravir: Day 1 
1800mg twice per day, 
Days 2-10 800mg twice 
per day Intervention 2 
(Hydroxychloroquine, 
azithromycin, zinc & 
Standard of Care): 
Hydroxychloroquine: Day 
1 400mg twice per day, 
Days 2-10 200mg twice 
per day; Azithromycin: 
Day 1-3 250mg once per 
day; Zinc-sulphate: Days 
1-10 125mg twice per day  
Standard of care Outcome: Time to clinical 
improvement 




trial with 3 
arms 
660 Tunisia; 18 - 
65 y, COVID 
negative 
Active comparator: HCQ 
& zinc: 
Hydroxychloroquine 400 
mg at day 1 and day 2, 
then a weekly dose of 
400 mg up to 2 months. 
Zinc 15 mg at daily dose 
up to 2 months  
Double placebo of 
HCQ and zinc 
Primary outcome: Frequency 
of confirmed SARS CoV2 
infection 











and as such 
are at higher 
risk of 
infection 




Vitamin C, Vitamin D, 
Zinc.  
Vitamin C, Vitamin D, 
Zinc 
Primary outcome: Prevention 
of COVID symptoms over 24 
weeks 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
7 
 
Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 







600 USA; 18 y + 
with COVID 
diagnosis 
NB No information on 
dosing levels. 
Intervention: HCQ, 
Azithromycin, vit C, vit D, 
zinc  
Vit C, vit D, zinc. Primary outcome: Rate of 
recovery of mild or moderate 
COVID-19 













Intervention: will receive 




gamma-linolenic acid and 
antioxidants. The 
composition of one can (8 
fl oz) of the intervention-
ONS includes: 14.8 g 
protein, 22.2 g fat, 25 g 
carbohydrate, 355 kcal, 
1.1 g EPA, 450 mg DHA, 
950 mg GLA, 2840 IU 
vitamin A as 1.2 mg β-
carotene, 205 mg Vitamin 
C, 75 IU vitamin E, 18 ug 




product (by the same 
manufacture) and 
served in cans with 
the same colour and 
shape. 
Primary outcome: Nutrition 
risk screening and biochemical 
markers 
Zinc  NCT04342728 USA   Randomised 
open label 
trial 





Ascorbic acid: 8000 mg of 
ascorbic acid divided into 
2-3 doses/day with food. 
Zinc gluconate: 50 mg of 
zinc gluconate to be 
taken daily at bedtime 
Ascorbic acid & zinc 
gluconate: 8000 mg of 
ascorbic acid divided into 
2-3 doses/day with food 
and 50 mg of zinc 
Standard of care. Primary outcome: symptom 
reduction over 28 days 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 
gluconate to be taken 
daily at bedtime.  












mg twice a day on day 1, 
one 400 mg tablet on day 
2, 3, 4, and 5, followed by 
one 400 mg tablets every 
05 days until day 50th 
associated with 66 mg of 
zinc sulphate.  
No intervention 
(Control) Subjects 
who don't want not 
to receive the study 
drug, but agree to 
participate by signing 
the informed 
consent, will form the 
control group 
Primary outcome: proportion 
of participants in whom there 
was a clinical finding of 
COVID-19 or number of 
symptomatic COVID-19 
infections 
Zinc  EudraCT 










s > 65 y  
Demark Intervention: 
Hydoxychloroquine 
200mg, vit d & zinc (dose 
not found) 
  Outcome: severity of the 
disease, hospitalization rate, 











18 - 55 y 
Intervention 1. Kabasura 
Kudineer 60 ml bd for 14 
days  
Vitamin C - 60000IU 
OD for 14 days Zinc 
supplementation - 
100mg od for 14 days   
Outcome: Reduction in 
incidence of clinical symptoms 
of COVID 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 
Zinc  NCT04370782 USA Randomised, 
non-blinded 
two arm (no 
control) 
clinical trial 





Experimental Arm 1: 
Hydroxychloroquine, 
Azithromycin & zinc 
sulphate 
(Hydroxychloroquine 
400mg twice a day (BID) 
on day 1, followed by 
200mg BID for days 2-5; 
Azithromycin 500mg on 
day 1, followed by 250mg 
once daily for days 2-5, 
zinc sulphate 220mg once 
daily for 5 days). 
Experimental Arm 2: 
Hydroxychloroquine, 
Doxycycline & zinc 
sulphate 
(Hydroxychloroquine 
400mg twice a day (BID) 
on day 1, followed by 
200mg BID for days 2-5; 
Doxycycline 200mg once 
daily for days 2-5, zinc 
sulphate 220mg once 
daily for 5 days) 
NA Primary outcomes: 1. Time to 
resolution of symptoms (day 
5, 14 and 21), 2. number of 
participants hospitalized, 3. 
ICU Length of stay. 4. 











Patients > 18 





be given on 3 times daily 
(200mg - 200 mg - 200 
mg) during 6 days 
Azithromycin will be 
administered on a single 
daily dose: 500 mg the 
first day followed by 250 
mg from day2 to day 5 - 
Intervention 2. 
Hydroxychloroquine will 
be given on 2 times daily 
3. Control: Zinc (20mg 
/ d)  
Death at day 7, time to first 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 
(200mg - 200 mg) during 
6 days Azithromycin will 
be administered on a 
single daily dose: 500 mg 
the first day followed by 
250 mg from day2 to day 
5 
Zinc  NCT04351490 France Randomised 
open label 
3140 France; 60 y 
plus 
Experimental: Zinc 
gluconate capsule 15mg x 
2 per day during 2 
months + 25-OH 
cholecalciferol (2000 IU) 
per day during 2 months  
No intervention: 
Usual treatment 
Primary outcome: Survival 
rate in asymptomatic subjects 
at inclusion 









Australia > 18 
y active 
diagnosis 
Experimental: Vitamin C 
Participants will receive 
vitamin C in addition to 
active comparator 
treatment: Inpatients: IV 
Vitamin C (Sodium 
Ascorbate) 50mg/kg 
every 6hrs on day 1 
followed by 100mg/kg 
every 6hrs (4x per day; 
400mg/kg/day) for 7 days 
(average 28g/day; 
maximum dose of 
50g/24hrs for those 
weighing more than 
125kg). Can be converted 
to 1 gram three times per 
day PO on hospital 
discharge) Outpatients: 
Vitamin C Outpatient 
trial: 200mg/kg x1 IV, 
then 1-gram PO three 
times per day for 7 days 
 Hydroxychloroquine 
400mg PO twice a day 
for 1 day, followed by 
200mg PO two times 
a day for 6 days 
Azithromycin 500 mg 
PO on day 1 followed 
by 250 mg PO once 
daily for 4 days Zinc 
Citrate 30mg 
elemental zinc PO 
daily Vitamin D3 
5,000iu PO daily for 
14 days Vitamin B12 
(Methylcobalamin) 
500mcg PO daily for 
14 days 
Primary outcomes: 1. 
Symptoms 2. Length of 
hospital stay 3. Invasive 
mechanical ventilation 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 
Nutritional 
support 








N/A N/A Food intake at 1-month post 
discharge; weight variation 
during the infection; factors 
limiting food intake; 
implemented nutritional 





NCT04274322 China Prospective 
cohort 
117 ICU patients N/A N/A Validate the use of NUTRIC 
score nutritional risk 
assessment tool in Chinese 
ICU patients with covid-19; 28-
day all-cause mortality; all 
cause infection; rate of 
complications; length of ICU 
stay; duration of mechanical 
ventilation. 
Vitamin C NCT03680274 Canada Double-blind 
RCT 
800 Septic ICU (inc 
COVID) 
High dose intravenous 
vitamin C (HDIVC) 200 
mg.kg.d x 4d (56g) 
Dextrose 5% in water 
(D5W) or normal 
saline (0.9% NaCl). 
28-day mortality. 
Vitamin C NCT04264533 China Double-blind 
RCT 
140 Severe viral 
pneumonia 
HDIVC 340 mg.kg.d x 
7days (168g) 
50ml water for 
injection 
28-day ventilator free days 






Diet + IVC 140 mg.kg.d x 
1d (10g) 
N/A (Single group 
assignment). 
3-day mortality 




HDIVC 300 mg.kg.d x 3d 
(63g) 
Dextrose 5% Water 28-day ventilator free days 







HDIVC 200 mg.kg.d x 4d 
(56g) 
N/A (Single group 
assignment). 
Incidence of adverse events 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 





300/600/900 mg.kg.d x 
6d (126/252/378g) 
Routine care 3 day 'clinical improvement 
(50% reduction in the highest 
flow rate of oxygen during the 
72 hour period OR 50% 
reduction in the most 
frequent use of 
bronchodilators within a 12-
hour window within the 72-
hour period OR hospital 
discharge). 
Vitamin C NCT04395768 Australia Double-blind 
RCT 
200 ‘COVID-19’ 200 mg.kg.d x 1d + 400 
mg.kg.d x 7d (210g) 
No vitamin C 15 day symptoms since 
enrolment. 




HDIVC 200 mg.kg.d x 4d 
(56g) 
Normal saline (0.9% 
NaCl) or dextrose 5% 
in water (D5W) in a 
volume to match the 
vitamin C. 
28 day mortality or persistent 
organ dysfunction (POD). 
Vitamin C ChiCTR 
2000032716 
China RCT 12 Severe/critical 
COVID-19 
pneumonia 
HDIVC Dose Not stated Not stated C-Reactive protein, 
lymphocytes, CD4+ 
Vitamin C ChiCTR 
2000032717 
China RCT 60 Mild/severe 
COVID 
Bolus IVC 166 mg.kg.d x 
1d 












acid and antioxidants. 
1.1g eicosapentaenoic 
acid (EPA),  
450 mg docosahexaenoic 
acid (DHA),  
950 mg gamma linolenic 
acid (GLA),  
2840 IU vitamin A as 1.2 
mg β-carotene, 205 mg 
Vitamin C, 75 IU vitamin 
E,  
18 ug Selenium,  
5.7 mg Zinc 
Placebo 3 month change in score of 
Nutrition risk screening-2002 
(NRS-2002) at end. 
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Section  Registry ID Country  Trial design Sample 
size 













2g daily eicosapentaenoic 
acid free fatty acid. 
N/A (Single group 
assignment). 










risk of COVID 
Icosapent ethyl (IPE). 8g 
IPE days 1-3 
4g IPE days 4-60 
Placebo PCR or IgG positive for SARS-
CoV-2 by day 60. 
Overweight/obe
sity/diabetes 










age 45 to 
80years 
AT-527 at 550mg tablets 
on day 1 and twice 
everyday for 5 days. 
Placebo 14 day proportions (active vs. 












N/A N/A 3 month relationship between 









ICU with BMI> 
30 
N/A N/A The resting energy 
expenditure (in Kcal / 24h) 
measured by indirect 
calorimetry during the stay in 

















In-hospital mortality, 30 days. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted October 21, 2020. ; https://doi.org/10.1101/2020.10.19.20214395doi: medRxiv preprint 
14 
 
Section  Registry ID Country  Trial design Sample 
size 












NCT04390074 Sweden  Case-control 9905 ICU patients N/A Age- and sex-
matched controls are 
drawn from all 
residents of Sweden 
by Statistics Sweden. 
Odds of intensive care treated 
patients with COVID-19 having 
been diagnosed with diabetes 
type I, diabetes type II, obesity 






384 People living 




to a registry. 
N/A N/A Self-reported acute-diabetes 
complication. Severe 














in the study 
will be 
collected 
DMT2 COVID19 positive 
patients treated with 
Sitagliptin. 
DMT2 COVID19 
positive patients not 
treated with 
Sitagliptin 










Linagliptin 5 mg PO once 
daily 
Standard of care Time to clinical change (within 
28 days) 
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Section  Registry ID Country  Trial design Sample 
size 





NCT04365634 China Case-control 306 Hospitalised 
COVID-19 
patients with 
and without  
diabetes. 
N/A N/A The predictive factors 
associated with hospitalized 
death of patients with COVID-
19 (28 days). 
Overweight/obe
sity/diabetes 







from type 2 
diabetes. 
 Sitagliptin at an adjusted 
dosage for estimated 
glomerular filtrate: 100 
mg once daily (estimated 
glomerular filtration rate 
less than or equal to 45 
mL / min / 1.73 m2 ) or 
50 mg (estimated 
glomerular filtration rate 
30-45 mL / min / 1.73 
m2) in combination or 
not with insulin 
Standard of care Time to clinical improvement 
within 1 month. Clinical 
parameter of acute lung 
disease (1 month). 
Overweight/obe
sity/diabetes 





with type 2 
diabetes. 
5 mg Linagliptin 
administered by mouth 
once daily 
Standard of care Changes in glucose levels up 
to 2 weeks. 
Overweight/obe
sity/diabetes 












N/A N/A Assess the prevalence of 
severe forms among 
hospitalized patients with 









N/A N/A Time to improvement within 3 
weeks. 
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Section  Registry ID Country  Trial design Sample 
size 












Resveratrol QID x 15 days Placebo Hospitalisation 21 days from 
randomization. 
Antioxidants NCT04394208 Egypt Double-blind 
RCT 
50 Patients with 
COVID-19 
pneumonia 
420 mg/day Silymarin in 3 
divided doses 
Placebo Time to clinical improvement 
(7-28 days) 
Antioxidants NCT04382040 Israel Double-blind 
RCT 






6 mg Artemisinin, 20 mg 
Curcumin, 15 mg 
Frankincense and 60 mg 
vitamin C given daily in 
two divided doses, on 
Days 1 and 2. 
Placebo Time to clinical improvement, 
percent of patients with 
adverse events (24 hours). 
Antioxidants NCT04377789 Turkey Non-
randomised 
50 At moderate-







500 (prophylaxis group) 
or 1000mg (treatment 
group) Quercetin. Time of 
treatment unclear. 
Placebo Prevalence of COVID-19 
(prophylaxis group). Mortality 
rate (treatment group) 













N-acetylcysteine IV 6 
g/day 
None Arm A: number of patients 
who are successfully 
extubated and/or transferred 
out of critical care due to 
clinical improvement   Arm B: 
number of patients who are 
discharged from the hospital 
due to clinical improvement 
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Section  Registry ID Country  Trial design Sample 
size 
Population Intervention Comparator Outcomes 






Melatonin 2 mg/day for 
12 weeks 
Placebo SARS-CoV-2 infection rate up 
to 12 weeks. 





Methylene Blue (1 mg/kg) 
along with vitamin C 
(1500 mg/kg) and N-
acetyl Cysteine 
(1500 mg/kg) orally or 
intravenously 
Standard of care Proportion of patients 
remaining free of need for 
mechanical ventilation 
















N/A N/A Body Mass Index evolution 
from baseline at 1 and 3 
months 
PEM NCT04350073 USA 
 
120 US, Duke 
University 


















Standard of care Metabolic and nutritional 
needs of COVID-19 Patients; 
Cardiac Output and Cardiac 
Measures (non-invasive) in 
COVID-19 patients 
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Section  Registry ID Country  Trial design Sample 
size 





48 h receiving 
similar ICU 
standards of 
care at Duke 
PEM NCT04346212 Spain 
 








Hospital de St. 






N/A N/A Prevalence of oropharyngeal 
dysphagia according to a 
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